Cannabis Based Therapeutic and Method of Use

CROSS-REFERENCE

This application is a continuation of U.S. application Ser. No. 16/971,781, filed Aug. 21, 2020, which is a National Stage Application of International Application No. PCT/US2019/019465, filed Feb. 25, 2019, which claims the benefit of U.S. Provisional Application No. 62/634,547, filed Feb. 23, 2018, the disclosures of which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

There is a need in the art for methods and compositions to manage pain, e.g., chronic pain. There is also a need in the art for methods and compositions for treating opioid addiction.

SUMMARY OF THE INVENTION

Disclosed herein are pharmaceutical compositions comprising: tetrahydrocannabinol (THC) and cannabidiol (CBD) in a THC:CBD ratio of from 1:1.5 to 3:1 by weight; and one or more terpenes. In some embodiments, the THC:CBD ratio is from 1.5:1 to 2:1. In some embodiments, the THC:CBD ratio is about 1.5:1.

In some embodiments, the pharmaceutical composition comprises about 15-20 mg tetrahydrocannabinol (THC) per dose. In some embodiments, the pharmaceutical composition comprises 10-12 mg cannabidiol (CBD).

In some embodiments, the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, α-humulene, linalool, p-cymene, camphene, cis-nerolidol, terpinolene, isopulegol, caryophyllene oxide, δ-limonene, geraniol, guaiol, α-bisabolol, 3-carene, β-pinene, γ-terpinene, or a combination thereof. In some embodiments, rein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, and α-humulene.

In some embodiments, the one or more terpenes comprise β-myrcene, and wherein the pharmaceutical composition comprises 30-60 mg of β-myrcene per dose.

In some embodiments, the one or more terpenes comprise β-caryophyllene, and wherein the pharmaceutical composition comprises 2.5-5 mg of β-caryophyllene per dose.

In some embodiments, the one or more terpenes comprise ocimene, and wherein the pharmaceutical composition comprises 2.3-4.7 mg of ocimene per dose.

In some embodiments, the one or more terpenes comprise α-pinene, and wherein the pharmaceutical composition comprises 1.1-2.1 mg of α-pinene per dose.

In some embodiments, the one or more terpenes comprise α-humulene, and wherein the pharmaceutical composition comprises 0.8-1.6 mg of α-humulene per dose.

In some embodiments, the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, and α-humulene; and wherein the pharmaceutical composition comprises about 30-60 mg of the β-mycene, about 2.5-5 mg of the β-caryophyllene, about 2.3-4.7 mg of the ocimene, about 1.1-2.1 mg of the α-pinene, and about 0.8-1.6 mg of the α-humulene per dose.

In some embodiments, the pharmaceutical composition is formulated as a liquid, a pill, a gel capsule, a vaporizable liquid, a vaporizable solid, a transdermal ointment or salve, or a transdermal patch.

In some embodiments, the pharmaceutical composition is formulated as a liquid. In some embodiments, the liquid comprises citric acid, blue agave, glycerine, one or more lorann oils, food coloring, or a combination thereof.

In some embodiments, the liquid comprises: about 1% to 7% w/w citric acid; about 40% to 49% w/w blue agave; about 40% to 49% w/w glycerin; about 0.1% to 1.5% w/w lorann oils; about 0.01 to 0.4% food coloring; or a combination thereof. In some embodiments, the liquid comprises: about 3-5% w/w citric acid; about 45-49% w/w blue agave; about 45-49% w/w glycerin; about 0.7-0.9% w/w lorann oils; and about 0.1-0.3% food coloring.

In some embodiments, the pharmaceutical composition is for use in the treatment of opioid addiction.

In some embodiments, the pharmaceutical composition is for use in the treatment of pain.

In some embodiments, the pharmaceutical composition is for use in the treatment of chemotherapy-induced nausea and vomiting.

Also disclosed herein are methods of treating opioid addition, the methods comprising administering an effective amount of a pharmaceutical composition comprising one or more cannabinoids to a subject in need thereof. The pharmaceutical composition can be any pharmaceutical composition disclosed herein.

In some embodiments, the pharmaceutical composition is administered every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours.

In some embodiments, the pharmaceutical composition is administered every 6, 8 or 12 hours.

In some embodiments, the subjects opioid use decreases by at least 50% within 5 weeks of beginning treatment as determined by morphine equivalency of opioids used.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event that a term incorporated by reference conflicts with a term defined herein, this specification shall control.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIGS. 1 a & b illustrates weekly pill counts in chart form ( FIG. 1 a ) and graph form with regression analysis ( FIG. 1 b ).

FIGS. 2 a & b illustrates weekly pill counts in morphine equivalents in tabular form ( FIG. 2 a ) and graph form with regression analysis ( FIG. 2 b ).

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure relates to therapeutics, and more especially the use of cannabinoid-based therapeutics, for use in treating those known to have chronic pain. In some cases, the chronic pain may have been treated using opiates. The present disclosure also relates to cannabinoid-based therapeutics for use in treating opioid addiction.

INTRODUCTION

In the United States the estimated total annual cost of pain-related health is approximately $600 billion and perhaps this figure is even higher for the nations in European Union (EU). This estimate includes the actual costs related to the medical care as well as the economic losses which contribute to approximately one-half of these costs. Economic losses include claimed disability, loss of productivity and lost wages. Medical care including physician time, hospitalization, surgical procedures, diagnostic testing and prescription drugs all contribute to the costs associated with the treatment of pain, as well the costs associated with the adverse effects associated with their utilization. Unfortunately, one of the adverse effects associated with prescription painkillers is death. Overdose deaths secondary to prescription opioids were five times higher in 2016 than 1999 and sales of these prescription drugs have quadrupled. That being said, the number of deaths dues to prescription opioids has remained relative stable at approximately 14,000 to 16,000 deaths per year. Much of the increase in mortality related to opioid consumption is due the rapid rise in those associated with the use of synthetic opioids. In states with either medical marijuana or both medical and retail marijuana programs in place there was a 24.8% lower mean annual opioid overdose mortality rate (95% CI, −37.5% to −9.5%: P=0.003) compared with states without medical marijuana laws.

Addressing the opiate crisis in this country has led to a number of studies being conducted using cannabis -based therapy as an alternative means of managing chronic and cancer-related pain. Despite Nabiximols not appearing to be statistically superior when compared to placebo in controlling pain in cancer patients, there are other randomized placebo controlled trials demonstrating the efficacy of using cannabis for pain control. There is also significant evidence that a cannabis -opioid interaction exists that results in improved pain control. All of the studies to date have either used pain scales or patient interview results to determine the success or failure of the cannabis intervention.

A group of physicians in Nevada, licensed to cultivate, produce and sell cannabis -related products and have recently undertaken a two phase II trials ran using a guava-based syrup with a THC:CBD ratio of 2:1 and at a 1:1 ratio containing only the flavored guava-based syrup. Each dose of syrup contained either 10 mg/ml of both delta-9-tetracannabinol (THC) and cannabidiol (CBD) or 20 mg of THC and 10 mg of CBD. As a proof of concept 25 patients in each group with a history of at least 3 years of chronic opiate use were enrolled in a single arm study with the endpoint being a 30% reduction of opiate intake determined by weekly pill count. 23 of the 25 patients reduced their opiate intake by greater than 50%. This provides an objective basis to evaluate the potential of cannabis to reduce the opiate consumption across the US.

The claimed beneficial medicinal effects associated with cannabis consumption are quite diverse and of long-standing. In 1889, some of these benefits were first described in the medical literature by Dr. E. A. Birch. Of the claims made, the most studied are in patients with multiple sclerosis, where a beneficial effect on muscle spasticity and pain are well-documented, but not necessarily as consistently as one might like. Cannabis has also been shown to be effective in treating seizures, anorexia, chronic pain, and nausea and vomiting that is associated with chemotherapy. There is some evidence that cannabidiols have a therapeutic effect of inflammation, chronic pain, diabetes, cancer, and neurodegenerative diseases.

To understand the underlying basis for the use of cannabinoids in the treatment of chronic pain it is imperative to understand their likely mechanisms of action. Cannabis contains at least 63 cannabinoids but two are best understood studied. The first, delta-9 tetrahydrocannabinol (THC), is responsible for the psychoactive effects that is widely associated with cannabis . The other main active component, cannabidiol (CBD), has no psychoactive effect associated with its consumption but is thought to provide anti-neoplastic, analgesic and antineuroleptic effects per the literature. Even though both cannabinoids are present in every plant, the interactions with the cerebral endocannabinoid receptor system are quite different. CBD binds as an antagonist to the cannabinoid receptor CB1 but the bond between THC and the same receptor is at least 100 times stronger. CBD also antagonizes the action on the cannabinoid G protein-coupled receptor GPR55, which is thought to be responsible the different neuromodulatory actions as the CB1 receptor. Claims of the subjective effects associated with cannabis ingestion include improvement in mood; relaxation; and increased sensitivity. On the other hand THC ingestion has been associated with less than desirable adverse effects such as agitation; panic disorder; depression and even psychosis.

Cannabinoids have an effect on serotonergic systems, including increasing cerebral production of 5-hydroxytryptamine (5-HT), serotonin while decreasing its uptake at the synapse level. THC has been found to have dopaminergic antagonistic actions which may contribute to its beneficial profile regarding pain control.

Other phytocannabinoids such as cannabichromene (CBC), cannabigerol (CBG) as well as a number of terpenoids likely contribute its analgesic effect. CBC and CBG have significant anti-inflamatory and analgesic effects over and beyond that associated with THC. B-caryophyllene has been shown to be a selective CB2 agonist and other terpenes such as linalool and a-Pinene have analgesic and anti-inflamatory effects respectively. Myrcene other the other hand has been shown to have analgesic effects mediated through an opioid-like action. This is an important development as it helps explain another avenue as to how cannabis and it component parts may prevent opiate withdrawal and allow for the use of lesser amounts of opioids while preventing the development of tolerance. Used in combination with opioid pain medications, cannabis can lower opioid side effects, cravings, and withdrawal severity, as well as enhance the analgesic effects of opioids, thereby allowing for lower doses and less risk of overdose.

As explained above the actions of THC, CBD, associated terpenes are potentially complementary and there is substantial evidence to suggest benefit of using together for patients with chronic pain.

Embodiments of the Disclosure

An embodiment of the present disclosure is the therapeutic compound for the use in treating chronic pain and like disorders and preferably in liquid form compromising a formulation including cannabinoids, but not limited to delta-9—tetrahydrocannabinol and cannabidiol. The compound may optionally include any terpene or terpinoid present in a cannabis plant. A subject suffering from chronic pain is orally administered a therapeutically effective amount of the compound so as to alleviate, cure or prevent the symptoms associated with chronic pain.

Another embodiment of the present disclosure is the therapeutic compound for the use in treating chronic pain and like disorders and preferably in a pill form compromising a formulation including cannabinoids, but not limited to delta-9-tetrahydrocannabinol and cannabidiol. The compound may optionally include any terpene or terpinoid present in a cannabis plant. A subject suffering from chronic pain is orally administered a therapeutically effective amount of the compound so as to alleviate, cure or prevent the symptoms associated with chronic pain

Another embodiment of the present disclosure is the therapeutic compound for the use in treating chronic pain and like disorders and preferably in suppository form compromising a formulation including cannabinoids, but not limited to delta-9-tetrahydrocannabinol and cannabidiol. The compound may optionally include any terpene or terpinoid present in a cannabis plant. A subject suffering from chronic pain is orally administered a therapeutically effective amount of the compound so as to alleviate, cure or prevent the symptoms associated with chronic pain

Another embodiment of the present disclosure is the therapeutic compound for the use in treating chronic pain and like disorders and preferably in capsule form compromising a formulation including cannabinoids, but not limited to delta-9-tetrahydrocannabinol and cannabidiol. The compound may optionally include any terpene or terpinoid present in a cannabis plant. A subject suffering from chronic pain is orally administered a therapeutically effective amount of the compound so as to alleviate, cure or prevent the symptoms associated with chronic pain.

Another embodiment of the present disclosure is the therapeutic compound for the use in treating chronic pain and like disorders and preferably in a transdermal form compromising a formulation including cannabinoids, but not limited to delta-9-tetrahydrocannabinol and cannabidiol. The compound may optionally include any terpene or terpinoid present in a cannabis plant. A subject suffering from chronic pain is transdermally administered a therapeutically effective amount of the compound so as to alleviate, cure or prevent the symptoms associated with chronic pain.

Another embodiment of the present disclosure is the therapeutic compound for the use in treating chronic pain and like disorders and preferably in an inhalable/nebulized form compromising a formulation including cannabinoids, but not limited to delta-9-tetrahydrocannabinol and cannabidiol. The compound may optionally include any terpene or terpinoid present in a cannabis plant. A subject suffering from chronic pain is inhaled in a therapeutically effective amount of the compound so as to alleviate, cure or prevent the symptoms associated with chronic pain

It shall be noted that the cannabinoid disclosed herein may include any of the identified cannabinoids, but not limited to THC (Tetrahydrocannabinol); THCA (Tetrahydrocannabinolic acid); CBD (Cannabidiol); CBDA (Cannabidiolic Acid); CBN (Cannabinol); CBG (Cannabigerol); CBC (Cannabichromene); CBL (Cannabicyclol); CBV (Cannabivarin); THCV (Tetrahydrocannabivarin); CBDV (Cannabidivarin); CBCV (Cannabichromevarin); CBGV (Cannabigerovarin); CBGM (Cannabigerol Monomethyl Ether); CBE (Cannabielsoin); CBT (Cannabicitran); (OTHC) 10-Oxo-delta-6a-tetrahydrocannabinol; (CBCF) Cannabichromanon; (CBF) Cannabifuran; Cannabiglendol; (CBR) Cannabiripsol; (CBT)Cannbicitran; (DCBF) Dehydrocannabifuran; (cis-THC) Delta-9-cis-tetrahydrocannabinol; (triOH-THC) Tryhydroxy-delta-9-tetrahydrocannabinol; and OH-iso-HHCV.

It shall also be noted that the terpene disclosed herein may, but is not limited to, any single or combination of the terpenes listed in table 1.

TABLE 1

List of exemplary terpenes

RI

No. chemical name (DB1) formula MW

1 Fusicocca-3,5-diene 1850 C20H32 272

2 9-epi-Sclarene 1896 C20H32 272

3 Laurenene 1903 C20H32 272

4 Rimuene 1907 C20H32 272

5 Isopimara-8,15-diene 1922 C20H32 272

6 Cembrene 1938 C20H32 272

7 Pimara-8,15-diene 1942 C20H32 272

8 Sclarene 1943 C20H32 272

9 Isohibaene 1944 C20H32 272

10 Rosa-5,15-diene 1945 C20H32 272

11 (E)-2,6-Dimethyl-10-(p-tolyl)- 1945 C20H30 270

undeca-2,6-diene

12 Isocembrene 1951 C20H32 272

13 Beyerene 1951 C20H32 272

14 Pimara-8(14),15-diene 1955 C20H32 272

15 Cembrene A 1962 C20H32 272

16 Labda-7,13,14-triene 1978 C20H32 272

17 Isopimara-8(14),15-diene 1981 C20H32 272

18 Isophyllocladene 1982 C20H32 272

19 Dolabella-6,10,15-triene 1984 C20H32 272

20 (Z)-Biformene 1988 C20H32 272

21 Manool oxide 2007 C20H34O 290

22 Geranyllinalool 2008 C20H32 272

23 Isopimara-7,15-diene 2010 C20H32 272

24 15-Kaurene 2011 C20H32 272

25 Isopimara-8,15-diene 2016 C20H32 272

26 Dolabradiene 2017 C20H32 272

27 Trachylobane 2022 C20H32 272

28 (E)-Biformene 2017 C20H32 272

29 Cembrene C 2023 C20H32 272

30 13-epi-Manoyl oxide 2023 C20H34O 290

31 (E)-Labda-7,12,14-triene 2036 C20H32 272

32 Phyllocladene 2042 C20H32 272

33 Abietatriene 2046 C20H30 270

34 16-Atisirene 2051 C20H32 272

35 16-Kaurene 2056 C20H32 272

36 Manool 2070 C20H32 272

37 Aphidicol-15-ene 2073 C20H32 272

38 Valpara-2,15-diene 2073 C20H32 272

39 Abieta-7,13-diene 2084 C20H32 272

40 Labda-7,14-dien-13-ol 2096 C20H34O 290

41 Aphidicol-16-ene 2102 C20H32 272

42 Isoabienol 2124 C20H34O 290

43 Abieta-8(14),13(15)-diene 2152 C20H32 272

44 (8a,12Z)-Abienol 2146 C20H34O 290

45 Incensole 2193 C20H34O2 306

46 Sclareol 2231 C20H36O2 308

47 Labda-8(17),14-dien-6,13-diol 2248 C20H34O2 306

48 Incensol acetate 2220 C22H36O3 348

49 Verticilla-4(20),7,11-triene 2040 C20H32 272

50 m-Camphorene 1947 C20H32 272

51 p-Camphorene 1980 C20H32 272

52 Cembrenol 2131 C20H34O 290

53 Sterna-13-ene 2025 C20H32 272

54 2-Allyl-4-methylphenol 1262 C10H12O 148

55 8,9-Dehydrothymol acetate 1360 C12H14O2 190

56 3,5,5-Trimethyl-4- 1200 C10H14O 150

methylenecyclohex-2-enone

57 Cabreuva oxide D 1467 C15H24O 220

58 p-Isopropylbenzaldehyd 1220 C10H12O 148

59 3-Methyl-4-(2,6,6- 1471 C14H22O 206

trimethylcyclohex-2-enyl)-but-3-en-

2-one

60 2,6,6-Trimethyl-3-oxocyclohex-1- 1110 C10H14O2 166

ene-1-carbaldehyde

61 Isophorone 1100 C9H14O 138

62 3,5,5-Trimethylcyclohex-3-enone 1027 C9H14O 138

63 trans-Sabinyl acetate 1278 C12H16O2 192

64 Nerol 1210 C10H18O 154

65 3a-Hydroxy-1,8-cineol 1217 C10H18O2 170

66 Carvone 1214 C10H14O 150

67 Thymol methyl ether 1215 C11H16O 164

68 Pulegone 1215 C10H16O 152

69 Neral 1215 C10H16O 152

70 p-Anisaldehyde 1218 C8H8O2 136

71 Chavicol 1219 C9H10O 134

72 2,3-Dehydro-1,4-cineol 1219 C10H16O 152

73 trans-Isopulegone 1161 C10H16O 152

74 Piperitone 1226 C10H16O 152

75 1,4-Dimethoxy-2-methylbenzene 1226 C9H12O2 152

76 Carvacrol methyl ether 1226 C11H16O 164

77 Isobornyl formate 1228 C11H18O2 182

78 2-Phenylethyl acetate 1230 C10H12O2 164

79 (E)-Cinnamaldehyde 1234 C9H8O 132

80 2,3-Dehydro-1,8-cineol 993 C10H16O 152

81 2-Hydroxypinan-3-one 1235 C10H16O2 168

82 Geraniol 1235 C10H18O 154

83 Pseudodiosphenol 1245 C10H16O2 168

84 cis-Chrysanthenyl acetate 1253 C12H18O2 194

85 trans-Carvone epoxide 1243 C10H14O2 166

86 cis-Sabinene hydrat acetate 1248 C12H20O2 196

87 cis-Ethyl chrysanthemate 1251 C12H20O2 196

88 trans-Sabinen hydrate acetate 1254 C12H20O2 196

89 Citronellyl formate 1259 C11H20O2 184

90 Perilla aldehyde 1260 C10H14O 150

91 trans-Ethyl chrysanthemate 1260 C12H20O2 196

92 trans-Anethol 1262 C10H12O 148

93 Nonanoic acid 1263 C9H18O2 158

94 Isopulegol acetate (Isomer 1) 1263 C12H20O2 196

95 Methyl nerolate 1265 C11H18O2 182

96 Safrol 1265 C10H10O2 162

97 cis-Thiorose oxide 1265 C10H18S 170

98 cis-Verbenyl acetate 1266 C12H18O2 194

99 Thymol 1267 C10H14O 150

100 Bornyl acetate 1270 C12H20O2 196

101 Neomenthyl acetate 1263 C12H22O2 198

102 Deca-2,4-dienal 1270 C10H16O 152

103 Isopulegol acetate (Isomer 2) 1271 C12H20O2 196

104 2-Undecanone 1273 C10H16O 152

105 4,8-Dimethylnonanol 1276 C11H24O 172

106 Diosphenol 1276 C10H16O2 168

107 Isobornyl acetate 1276 C12H20O2 196

108 Carvacrol 1278 C10H14O 150

109 Thujopsadiene 1470 C15H22 202

110 Sesamol 1280 C7H6O3 138

111 Menthyl acetate 1280 C12H22O2 198

112 Geranial 1244 C10H16O 152

113 Geranyl formate 1284 C11H18O2 182

114 trans-Thiorose oxide 1284 C10H18S 170

115 2-Undecanol 1284 C11H24O 172

116 p-Isopropylbenzyl alcohol 1285 C10H14O 150

117 Sencyunolide 1672 C12H16O2 192

118 trans-Pinocarvyl acetate 1287 C12H18O2 194

119 2,3,6-Trimethylbenzaldehyde 1287 C10H12O 148

120 Terpinen-4-ol acetate 1289 C12H20O2 196

121 Chrysanthenone epoxide 1290 C10H14O2 166

122 (E,E)-Deca-2,4-dienal 1291 C10H16O 152

123 Puleganolide (Isomer 1) 1292 C10H16O2 168

124 Dihydrocarveol acetate (Isomer 2) 1295 C12H20O2 196

125 Isoascaridol 1295 C10H16O2 168

126 Theaspirane (Isomer 1) 1299 C13H22O 194

127 cis-Pinocarvyl acetate 1300 C12H18O2 194

128 Dihydronaginata ketone 1300 C10H14O2 166

129 Naginata ketone alcohol 1306 C10H14O3 182

130 Puleganolide (Isomer 2) 1305 C10H16O2 168

131 Methyl geranate 1306 C11H18O2 182

132 Vinylguaiacol 1311 C9H10O2 150

133 5-Acetoxylinalool 1303 C12H20O3 212

134 Theaspirane (Isomer 2) 1313 C13H22O 194

135 Chavicol acetate 1313 C11H12O2 176

136 Myrtenyl acetate 1313 C12H18O2 194

137 Dihydrocarveol acetate (Isomer 2) 1314 C12H20O2 196

138 Apiol 1649 C12H14O4 222

139 trans-Carvyl acetate 1318 C12H18O2 194

140 Thymol acetate 1329 C12H16O2 192

141 Menthothiophene 1330 C10H14S 166

142 2,3,4-Trimethylbenzaldehyde 1331 C10H12O 148

143 Eugenol 1331 C10H12O2 164

144 cis-Dihydrocarvone epoxide 1333 C10H16O2 168

145 Ethyl nerolat 1335 C12H20O2 196

146 Fragranol 1201 C12H20O2 196

147 7,8-Dihydro-b-ionone 1422 C13H22O 194

148 8-Hydroxylinalool 1336 C10H18O2 170

149 3,4-Dimethoxystyrene 1337 C10H12O2 164

150 Citronellyl acetate 1337 C12H22O2 198

151 trans-8-Mercapto-p-menthan-3-one 1340 C10H18OS 186

152 Anhydroencecalinol 1640 C14H16O2 216

153 Neryl acetate 1342 C12H20O2 196

154 Dihydrocarveol acetate (Isomer 2) 1342 C12H20O2 196

155 exo-Isocamphanyl acetate 1345 C12H20O2 196

156 cis-Carvyl acetate 1345 C12H18O2 194

157 (Z)-Ethyl cinnamate 1344 C11H12O2 176

158 Chavibetol (m-Eugenol) 1346 C10H12O2 164

159 4-Methoxyphenylethanol 1347 C9H12O2 152

160 (E)-Anethol epoxide 1347 C10H12O2 164

161 trans-Dihydrocarvone epoxide 1352 C10H16O2 168

162 endo-Isocamphanyl acetate 1352 C12H20O2 196

163 (E)-Methyl cinnamate 1354 C10H10O2 162

164 cis-8-Mercapto-p-menthan-3-one 1356 C10H18OS 186

165 Dihydrojasmone 1361 C10H14O2 166

166 (E)-b-Damascenone 1363 C13H18O 190

167 3-Allyl-1,4-dimethoxybenzene 1370 C11H14O2 178

168 (Z)-Jasmone 1371 C11H16O 164

169 Isobornyl propionate 1375 C13H22O2 210

170 Ethyl geranate 1377 C12H20O2 196

171 Methyl perillate 1381 C11H16O2 180

172 (Z)-Isoeugenol 1381 C10H12O2 164

173 Osmorhizol 1383 C11H14O2 178

174 2-Dodecanol 1387 C12H26O 186

175 1-Tetradecene 1387 C14H28 196

176 Davanafuran 1394 C14H20O2 220

177 Methyl 4-methoxyphenylacetate 1398 C10H12O3 180

178 (E)-b-Damascone 1398 C13H20O 192

179 trans-Carvyl propionate 1402 C13H20O2 208

180 2,6-Dimethoxycymene 1402 C12H18O2 194

181 Nerylacetone 1412 C13H22O 194

182 2-Hydroxy-1,2-dihydrolavandulyl 1416 C12H22O3 214

acetate

183 (Z)-1,2-Dimethoxy-4- 1419 C11H14O2 178

propenylbenzene

184 (E)-Cinnamyl acetate 1420 C11H12O2 176

185 Isobornyl isobutyrate 1424 C14H24O2 224

186 Citronellyl propionate 1427 C13H24O2 212

187 3,4-Dimethoxybenzaldehyde 1428 C9H10O3 166

188 (E)-Isoeugenol 1429 C10H12O2 164

189 cis-Carvyl propionate 1436 C13H20O2 208

190 Massoialactone 1439 C10H16O2 168

191 d-Undecanolide 1565 C11H20O2 184

192 Nordavanone 1451 C11H18O2 182

193 8-Dehydrothymol isobutyrate 1458 C14H18O2 218

194 (E)-1,2-Dimethoxy-4- 1460 C11H14O2 178

propenylbenzene

195 Thymol isobutyrate 1462 C14H20O2 220

196 Isobornyl butyrate 1462 C14H24O2 224

197 3,4-Dimethoxybenzyl alcohol 1464 C9H12O3 168

198 Sarisane 1466 C11H12O3 192

199 2-Tridecanone 1477 C13H26O 198

200 2-Tridecanol 1490 C13H28O 200

201 Davana ether 1489 C15H22O2 234

202 a-Campholenyl formate 1240 C11H18O2 182

203 Chavibetyl acetate 1488 C12H14O3 206

204 Homovanilline alcohol 1494 C9H12O3 168

205 Davana ether (Isomer) 1507 C15H22O2 234

206 Isobornyl isovalerate 1516 C15H26O2 238

207 Citronellyl butyrate 1516 C14H26O2 226

208 Elemicine 1522 C12H16O3 208

209 Flavesone 1526 C14H20O4 252

210 allo-Davanone 1539 C15H24O2 236

211 Isodavanone 1545 C15H24O2 236

212 Eupatoriochromene 1726 C13H16O3 220

213 cis-Davanone 1557 C15H24O2 236

214 Geranyl crotonate 1555 C14H22O2 222

215 Diethylphthalate 1555 C12H14O4 222

216 cis-8-Acetylthio-p-menthan-3-one 1559 C12H20O2S 228

217 4-Allyl-2,6-dimethoxyphenol 1561 C11H14O3 194

218 Sandela 1568 C16H28O 236

219 trans-8-Acetylthio-p-mentan-3-one 1570 C12H20O2S 228

220 (Z)-Asarone 1584 C12H16O3 208

221 (Z)-3-Hexenyl benzoate 1545 C13H16O2 204

222 Geranyl 2-methylbutyrate 1591 C15H26O2 238

223 1,2-Diacetoxy-4-allylbenzene 1602 C13H14O4 234

224 Leptospermone 1611 C15H22O4 266

225 (Z)-Ethyl p-methoxycinnamate 1614 C12H14O3 206

226 Butylphthalide 1616 C12H14O2 190

227 (E)-Asarone 1636 C12H16O3 208

228 (Z)-Butylidenphthalide 1644 C12H12O2 188

229 6-Methoxythymol isobutyrate 1658 C15H22O3 250

230 2-Pentadecanone 1688 C15H30O 226

231 (E)-Ethyl p-methoxycinnamate 1711 C12H14O3 206

232 (Z)-Ligustilide 1732 C12H14O2 190

233 Heyderiol 2374 C22H30O4 358

234 (E)-Ligustilide 1782 C12H14O2 190

235 7,11-Dimethylheptadecane 1792 C19H40 268

236 Avocadynofuran 1796 C17H26O 246

237 Galaxolide 1838 C18H26O 258

238 Traseolide 1840 C18H26O 258

239 Tonalide 1850 C18H26O 258

240 1-Nonadecene 1875 C19H38 266

241 Nonadecane 1900 C19H40 268

242 Falcarinol 2028 C17H24O 244

243 Trichocoleine 1875 C14H18O4 250

244 Ambrettolide 1905 C16H28O2 252

245 Methyl 4-Hydroxy-3-methoxy-5- 1833 C14H18O4 250

(1,1-dimethylprop-2-enyl)-benzoate

246 (E)-Benzyl cinnamate 2023 C16H14O2 238

247 trans-Pinocarvyl formate 1228 C11H16O2 180

248 Hex-5-en-1-ol 820 C6H12O 100

249 Hex-5-en-3-ol 832 C6H12O 100

250 1-Hexanol 837 C6H14O 102

251 (Z)-Hex-3-en-1-ol 851 C6H12O 100

252 (E)-Hex-3-en-1-ol 851 C6H12O 100

253 (Z)-Hex-2-en-1-ol 861 C6H12O 100

254 2-Heptanone 871 C7H14O 114

255 2-Heptanol 880 C7H16O 116

256 3-Heptanol 877 C7H16O 116

257 n-Heptanal 882 C7H14O 114

258 Santene 884 C9H14 122

259 2-Methyl-1-hexanol 917 C7H16O 116

260 Tricyclene 927 C10H16 136

261 a-Pinene 936 C10H16 136

262 Benzaldehyde 941 C7H6O 106

263 a-Fenchene 941 C10H16 136

264 Thuja-2,4(10)-diene 946 C10H14 134

265 6-Methyl-2-heptanol 950 C8H18O 130

266 Camphene 950 C10H16 136

267 1-Octen-3-ol 962 C8H16O 128

268 3-Octanone 969 C8H16O 128

269 4-Octanol 973 C8H18O 130

270 2-Octanol 981 C8H18O 130

271 3-Octanol 981 C8H18O 130

272 2-Pentylfuran 981 C9H14O 138

273 Yomogialcohol 991 C10H18O 154

274 3,6-Dimethyl-3-heptanol 990 C9H20O 144

275 D 2-Carene 1000 C10H16 136

276 a-Phellandrene 1002 C10H16 136

277 (Z)-Hex-3-enyl acetate 1002 C8H14O2 142

278 p-Methylanisol 1004 C8H10O 122

279 Benzyl alcohol 1006 C7H8O 108

280 D 3-Carene 1010 C10H16 136

281 Phenylacetaldehyde 1012 C8H8O 120

282 m-Cymene 1013 C10H14 134

283 p-Cymene 1015 C10H14 134

284 Salicylaldehyde 1020 C7H6O2 122

285 Limonene 1025 C10H16 136

286 1,8-Cineol 1024 C10H18O 154

287 (Z)-b-Ocimene 1029 C10H16 136

288 (E)-2-Octenal 1034 C8H14O 126

289 5,5-Dimethylbut-3-enolide 916 C6H8O2 112

290 Methyl 3-methylfuroate 1038 C7H8O3 140

291 (E)-b-Ocimene 1041 C10H16 136

292 Oct-3-en-1-ol (Isomer 1) 1044 C8H16O 128

293 Artemisia ketone 1044 C10H16O 152

294 cis-Dihydroroseoxide 1047 C10H20O 156

295 d-Terpineol 1155 C10H16O 152

296 g-Terpinene 1051 C10H16 136

297 trans-Sabinene hydrate 1053 C10H18O 154

298 Dihydromyrcenol 1058 C10H20O 156

299 Non-1-en-3-ol 1058 C9H18O 142

300 trans-Linalooloxide (furanoid) 1058 C10H20O2 172

301 p-Mentha-3,8-diene 1059 C10H16 136

302 Benzyl formate 1060 C8H8O2 136

303 m-Cresol 1061 C7H8O 108

304 p-Cresol 1062 C7H8O 108

305 1-Octanol 1063 C8H18O 130

306 Fenchone 1069 C10H16O 152

307 o-Guiacol 1072 C7H8O2 124

308 Methyl benzoate 1072 C8H8O2 136

309 cis-Linalool oxide (furanoid) 1072 C10H18O2 170

310 Artemisia alcohol 1073 C10H18O 154

311 Dehydrolinalool 1073 C10H16O 152

312 trans-Dihydroroseoxide 1075 C10H20O 156

313 4-Nonanol 1076 C9H20O 144

314 Terpinolene 1082 C10H16 136

315 cis-Sabinene hydrate 1082 C10H18O 154

316 2-Nonanol 1085 C9H20O 144

317 Linalool 1086 C10H18O 154

318 Photocitral B 1086 C10H16O 152

319 a-Thujone 1089 C10H16O 152

320 2,2′,5,6-Tetramethylcyclohexanone 1092 C10H18O 154

(Isomer 1)

321 1-Oct-3-enyl acetate 1093 C10H18O2 170

322 4,8-Dimethyl-1,3,7-nonatriene 1096 C11H18 150

(Isomer 1)

323 a-Pinene epoxide (Isomer 1) 1096 C10H16O 152

324 a-Fenchol 1099 C10H18O 154

325 cis-Rose oxide 1100 C10H18O 154

326 Isochrysanthenone 1086 C10H14O 150

327 b-Thujone 1103 C10H16O 152

328 a-Campholenal 1105 C10H16O 152

329 2,2′,5,6-Tetramethylcyclohexanone 1106 C10H18O 154

(Isomer 2)

330 2-Methyl-5-propionylfuran 1108 C8H10O2 138

331 cis-p-Menth-2-en-1-ol 1108 C10H18O 154

332 (Z)-Ocimenoxide 1115 C10H16O 152

333 4,8-Dimethylnona-1,3,7-triene 1115 C11H18 150

(Isomer 2)

334 a-Pinene epoxide (Isomer 2) 1116 C10H16O 152

335 trans-Rose oxide 1116 C10H18O 154

336 Dihydrolinalool 1118 C10H20O 156

337 Ipsdienol 1123 C10H16O 152

338 Camphor 1123 C10H16O 152

339 trans-p-Menth-2-en-1-ol 1123 C10H18O 154

340 (E)-Ocimenoxide 1125 C10H16O 152

341 p-Mentha-1,5-diene-8-ol 1127 C10H16O 152

342 trans-Pinocarveol 1126 C10H16O 152

343 cis-Limonene oxide 1126 C10H16O 152

344 Photocitral A 1127 C10H16O 152

345 o-Cymenene 1076 C10H12 132

346 (E)-Tagetone 1128 C10H16O 152

347 (Z)-Tagetone 1136 C10H16O 152

348 trans-Limonene oxide 1130 C10H16O 152

349 Isopulegol 1132 C10H18O 154

350 1,3-Dimethoxybenzene 1136 C8H10O2 138

351 Menthone 1136 C10H18O 154

352 Pinocarvone 1137 C10H14O 150

353 b-Terpineol 1137 C10H18O 154

354 (E)-Non-2-enal 1139 C9H16O 140

355 Isoneral 1140 C10H16O 152

356 cis-b-Terpineol 1141 C10H18O 154

357 Isoborneol 1142 C10H18O 154

358 Karahanaenone 1142 C10H16O 152

359 cis- or trans-Linalool oxide 1144 C10H18O2 170

(pyranoid)

360 Isomenthone 1146 C10H18O 154

361 cis-Chrysanthenol 1147 C10H16O 152

362 2-Hydroxyethyl-4-methylbenzene 1147 C9H12O 136

363 4-Isopropylcyclohexanone 1148 C9H16O 140

364 cis- or trans-Linalool oxide 1148 C10H18O2 170

(pyranoid)

365 cis-Isopulegone 1148 C10H16O 152

366 Methyl phenylacetate 1148 C9H10O2 150

367 cis-Thujol 1149 C10H18O 154

368 b-Pinene epoxide 1149 C10H16O 152

369 Ethyl benzoate 1150 C9H10O2 150

370 Borneol 1150 C10H18O 154

371 Lavandulol 1150 C10H18O 154

372 Umbellulone 1152 C10H14O 150

373 trans-Chrysanthemol 1153 C10H18O 154

374 Neomenthol 1156 C10H20O 156

375 Viridene 1159 C10H12O 148

376 Isogeranial 1156 C10H16O 152

377 cis-Chrysanthemol 1157 C10H18O 154

378 Benzoic acid 1160 C7H6O2 122

379 3-Thujene-10-al 1158 C10H14O 150

380 Cryptone 1160 C9H14O 138

381 Terpinen-4-ol 1164 C10H18O 154

382 b-Pinene epoxide (Isomer) 1170 C10H16O 152

383 Nona-2,4-dienal 1170 C9H14O 138

384 Methyl salicylate 1171 C8H8O3 152

385 2-Methyl-2-borneol 1175 C11H20O 168

386 2-Allylphenol 1174 C9H10O 134

387 Thujopsa-3-one 1645 C15H24O 220

388 7-Hydroxyhotrienol 1177 C10H18O2 170

389 Myrtenol 1178 C10H16O 152

390 cis-Piperitol 1181 C10H18O 154

391 Safranal 1182 C10H14O 150

392 Estragol (Methylchavicol) 1175 C10H12O 148

393 2-Decanol 1188 C10H22O 158

394 g-Terpineol 1188 C10H18O 154

395 (E,E)-Nona-2,4-dienal 1188 C9H14O 138

396 Methyl a-cyclogeranate 1190 C11H18O2 182

397 trans-Piperitol 1193 C10H18O 154

398 Chrysanthenone 1110 C10H14O 150

399 Fenchyl acetate 1205 C12H20O2 196

400 Benzylacetone 1207 C10H12O 148

401 2-epi-Thujopsa-3-one 1634 C15H24O 220

402 Carvotanacetone 1220 C10H16O 152

403 Menthol 1172 C10H20O 156

404 Isomenthol 1176 C10H20O 156

405 a-Terpinyl acetate 1335 C10H16 136

406 Octyl acetate 1188 C10H20O2 172

407 Dillether 1170 C10H16O 152

408 (E)-Ethyl cinnamate 1439 C11H12O2 176

409 b-Ionone 1468 C13H20O 192

410 Piperonal 1294 C8H6O3 150

411 Vanilline 1355 C8H8O3 152

412 Coumarin 1392 C9H6O2 146

413 (Z)-2-Hexylcinnamic aldehyde 1725 C15H20O 216

414 1-Phenylethyl acetate 1166 C10H12O2 164

415 (Z)-2-Pentylcinnamaldehyde 1632 C14H18O 202

416 Benzyl salicylate 1847 C14H12O3 228

417 Menthofuran 1150 C10H14O 150

418 a-Campholenol 1190 C10H18O 154

419 Methyl jasmonate 1611 C13H20O3 224

420 Isophytol 1949 C20H40O 296

421 Phytol 2114 C20H40O 296

422 (E)-Anyl 2-methylbutyrate 1651 C14H18O2 218

423 (E)-4-4Propenylphenol tiglate 1765 C14H16O2 216

424 trans-Epoxypseudoisoeugenyl-2- 1871 C15H20O4 264

methylbutyrate

425 (E)-Pseudoisoeugenyl tiglate 1895 C15H18O3 246

426 trans-Epoxypseudoisoeugenol tiglate 1942 C15H18O4 262

427 Dictyotene 1155 C11H18 150

428 Desmarestene 1168 C11H14 146

429 Dictyopterene A 1099 C11H18 150

430 Ectocarpene 1136 C11H16 148

431 (E)-Ectocarpene 1147 C11H16 148

432 cis-Hormosirene 1152 C11H16 148

433 trans-Hormosirene 1160 C11H16 148

434 (Z)-Multifidene 1040 C11H16 148

435 (E)-Multifidene 1047 C11H16 148

436 (E)-Aucantene 1062 C11H16 148

437 (E)-Aucantene 1077 C11H16 148

438 cis-Dihydromultifidene 1052 C11H18 150

439 trans-Dihydromultifidene 1058 C11H18 150

440 Neothujol 1136 C10H16O 152

441 (Z)-Methyl cinnamate 1270 C10H10O2 162

442 Isothujol 1121 C10H16O 152

443 Neoisothujol 1132 C10H16O 152

444 Citronellal 1129 C10H18O 154

445 2-Methyl-2-pentanol 944 C6H14O 102

446 6-Acetoxy-p-mentha-1(7),8-diene 1312 C12H18O2 194

(Isomer 1)

447 n-Nonanal 1076 C9H18O 142

448 5,7-Dimethylocta-1,6-diene 911 C10H18 138

449 Dec-9-en-1-ol 1240 C10H20O 156

450 Elsholtzia ketone 1175 C10H14O2 166

451 a-Dehydroelsholtzia ketone 1188 C10H12O2 164

452 Dehydroelsholtzia ketone 1277 C10H12O2 164

453 4-Methyl-3-heptanol 956 C8H18O 130

454 6-Methylhept-5-en-2-ol (Sulcatol) 981 C8H16O 128

455 b-Helmiscapene 1446 C15H24 204

456 2,2-Dimethyl-4-oxocyclohexane-1- 1132 C9H14O2 154

carbaldehyde

457 Menth-1-en-9-ol 1283 C10H18O 154

458 cis-Dihydrocarvone 1172 C10H16O 152

459 trans-Dihydrocarvone 1177 C10H16O 152

460 Limonen-10-ol 1272 C10H16O 152

461 Tuberolactone 1437 C10H14O2 166

462 trans-Carveol 1200 C10H16O 152

463 Dihydrocarveol (Isomer 1) 1176 C10H18O 154

464 Dihydrocarveol (Isomer 2) 1193 C10H18O 154

465 Dihydrocarveol (Isomer 3) 1205 C10H18O 154

466 cis-Carveol 1210 C10H16O 152

467 4-Methoxyphenylacetone 1343 C10H12O2 164

468 4-Methoxypropiophenone 1415 C10H12O2 164

469 Grandisol 1200 C10H18O 154

470 Hotrienol 1083 C10H16O 152

471 Isopinocampheol 1168 C10H16O 152

472 (E)-Pseudoisoeugenyl-2-methyl 1823 C15H20O3 248

butyrate

473 Falcarinone 1990 C17H22O 242

474 Ethyl salicylate 1245 C9H10O3 166

475 1,2-Dihydro-1,1,6-trimethyl- 1339 C13H16 172

naphthalene

476 g-Hexanolide 1006 C6H10O2 114

477 g-Heptanolide 1103 C7H12O2 128

478 g-Octanolide 1208 C8H14O2 142

479 g-Nonanolide 1318 C9H16O2 156

480 g-Decanolide 1433 C10H18O2 170

481 g-Undecanolide 1547 C11H20O2 184

482 g-Dodecanolide 1656 C12H22O2 198

483 g-Tetradecanolide 1866 C14H26O2 226

484 d-Nonanolide 1348 C9H16O2 156

485 d-Octanolide 1240 C8H14O2 142

486 d-Heptanolide 1156 C7H12O2 128

487 d-Decanolide 1461 C10H18O2 170

488 (E)-a-Damascone 1375 C13H20O 192

489 4-Methyl-3-heptanone 918 C8H16O 128

490 a-Ionone 1409 C13H20O 192

491 p-Methylacetophenone 1156 C9H10O 134

492 b-Cyclocitral 1195 C10H16O 152

493 cis-a-Irone 1520 C14H22O 206

494 cis-g-Irone 1525 C14H22O 206

495 Dodecanal 1389 C12H24O 184

496 Methyl linolenate 2102 C19H32O2 292

497 Geranylacetone 1430 C13H22O 194

498 trans-Isolimonene 975 C10H16 136

499 cis-Myrtanol 1238 C10H18O 154

500 n-Octanal 981 C8H16O 128

501 p-Menth-1-ene 1017 C15H18 198

502 (E)-Jasmone 1356 C11H16O 164

503 trans-Myrtanol 1240 C10H18O 154

504 allo-Ocimene 1113 C10H16 136

505 (4E,6Z)-allo-Ocimene 1126 C10H16 136

506 Dodecanol 1472 C12H26O 186

507 6-Acetoxy-p-menta-1,8-diene 1341 C12H18O2 194

508 b-Citronellene 943 C15H18 198

509 n-Nonanol 1149 C9H20O 144

510 trans-Sabinol 1120 C10H16O 152

511 3,5-Dimethoxytoluene 1231 C9H12O2 152

512 Phantolide 1712 C17H24O 244

513 Perilla alcohol 1280 C10H16O 152

514 b-Phellandrene 1023 C10H16 136

515 b-Phenylethanol 1085 C8H10O 122

516 Citronellol 1213 C10H20O 156

517 Methyleugenol 1369 C11H14O2 178

518 2-Nonanone 1074 C9H18O 142

519 2-Decanone 1176 C10H20O 156

520 2-Dodecanone 1381 C12H24O 184

521 4-Isopropylcyclohexanol (Isomer 2) 1130 C9H18O 142

522 Moskachane B 1794 C13H16O3 220

523 Moskachane D 2001 C15H20O3 248

524 cis-Verbenol 1132 C10H16O 152

525 (Z)-Salvene 849 C9H16 124

526 (E)-Salvene 859 C9H16 124

527 Santolinatriene 909 C10H16 136

528 a-Thujene 932 C10H16 136

529 Sabinene 973 C10H16 136

530 a-Terpinene 1013 C10H16 136

531 trans-Verbenol 1136 C10H14O 150

532 Verbenone 1183 C10H14O 150

533 Z-Cinnamaldehyde 1185 C9H8O 132

534 3-Phenylpropanol 1201 C9H12O 136

535 (E)-Cinnamyl alcohol 1275 C9H10O 134

536 b-Irone 1566 C14H22O 206

537 Benzyl acetate 1134 C9H10O2 150

538 Indole 1257 C8H7N 117

539 d-Jasmolactone 1450 C10H16O2 168

540 N-Acetyl methyl anthranilate 1565 C10H11O3N 193

541 Benzyl benzoate 1730 C14H12O2 212

542 6-Methylhept-5-en-2-one 978 C8H14O 126

543 Rosefuran 1091 C10H14O 150

544 Rosefuran epoxide 1161 C10H14O2 166

545 b-Pinene 978 C10H16 136

546 Myrcene 987 C10H16 136

547 Oct-3-en-1-ol (Isomer 2) 1049 C8H16O 128

548 6-Acetoxy-p-mentha-1(7),8-diene 1343 C12H18O2 194

(Isomer 2)

549 (E)-4-Propenylphenol angelate 1751 C14H16O2 216

550 cis-Epoxypseudoisoeugenyl-2- 1870 C15H20O4 264

methyl butyrate

551 Myrtenal 1172 C10H14O 150

552 (E)-Ocimenone 1219 C10H14O 150

553 (Z)-Ocimenone 1209 C10H14O 150

554 Isomenthyl acetate 1298 C12H22O2 198

555 Thymoquinone 1215 C10H12O2 164

556 Cymen-9-ol 1157 C10H14O 150

557 8,9-Dehydrothymol 1190 C10H12O 148

558 (Z)-Methyl p-hydroxycinnamate 1603 C10H10O3 178

559 b-Thujaplicine 1449 C10H12O2 164

560 n-Undecane 1100 C11H24 156

561 n-Nonane 906 C9H20 128

562 Pinocamphone 1139 C10H16O 152

563 Isopinocamphone 1151 C10H16O 152

564 Methyl 2-methylbutyrate 954 C6H12O2 116

565 6-Methylhept-5-enal 985 C8H14O 126

566 Furomyrcenol 1256 C10H14O2 166

567 a-Ionone epoxide (Isomer 1) 1516 C13H20O2 208

568 o-Cresol 1037 C7H8O 108

569 (E)-2-Hexenal 832 C6H10O 98

570 Ethyl 2-methylbutyrate 843 C7H14O2 130

571 p-Mentha-2,4(8)-diene 1077 C10H16 136

572 p-Mentha-1,3,8-triene 1101 C10H16 136

573 Neroloxide 1137 C10H16O 152

574 Neoisopulegol 1150 C10H18O 154

575 (E,E)-Nona-3,6-dien-1-ol 1145 C9H16O 140

576 n-Pentylbenzene 1150 C11H16 148

577 (Z)-Ethyl oct-5-enoate 1174 C10H18O2 170

578 a-Terpineol 1176 C10H18O 154

579 2a-Hydroxy-1,8-cineol 1196 C10H18O2 170

580 cis-Pulegol 1215 C10H18O 154

581 3b-Hydroxy-1,8-cineol 1229 C10H18O2 170

582 Linalyl acetate 1239 C12H20O2 196

583 Isopiperitenone 1240 C10H14O 150

584 Piperitenone 1318 C10H14O 150

585 Piperitenone oxide 1335 C10H14O2 166

586 Geranyl acetate 1362 C12H20O2 196

587 2-Methylbutyl benzoate 1419 C12H16O2 192

588 Myristicine 1489 C11H12O3 192

589 Acetophenone 1036 C8H8O 120

590 Dihydrotagetone 1047 C10H18O 154

591 p-Cymenene 1075 C10H12 132

592 Piperiton epoxid 1232 C10H16O2 168

593 Nepetalacton (Isomer 2) 1360 C10H14O2 166

594 3,4-Dimethyl-5-pentyl-5H-furan-2- 1481 C11H18O2 182

one

595 Methyl p-methoxybenzoate 1338 C9H10O3 166

596 (E)-o-Methoxycinnamyl alcohol 1488 C10H12O2 164

597 (E)-m-Methoxycinnamyl alcohol 1511 C10H12O2 164

598 (E)-p-Methoxycinnamyl alcohol 1523 C10H12O2 164

599 Perillene 1090 C10H14O 150

600 Methyl anthranilate 1308 C8H9O2N 151

601 1-(3-Methoxyphenyl)-2- 1735 C15H16O 212

phenylethane

602 1-Phenyl-2-(3,5-dimethoxyphenyl)- 1962 C16H18O2 242

ethane

603 1-(3-Methoxyphenyl)-2-(4- 1988 C16H18O2 242

methoxyphenyl)-ethane

604 Neryl isobutyrate 1468 C14H24O2 224

605 Zingiberenol 1596 C14H24O 208

606 Encecalin 1813 C14H16O3 232

607 Ethyl p-methoxybenzoate 1415 C10H12O3 180

608 Albanone 1389 C12H18O 178

609 7,10-Anhydro-11,12- 1449 C15H24O 220

dihydrochiloscypholone

610 1(11)-Africanen-8-ol 1486 C15H24O 220

611 Atractylone 1497 C15H20O 216

612 Conocephalenol 1497 C15H26O 222

613 Cubebol 1514 C15H26O 222

614 Photosantalol 1511 C15H24O 220

615 Cyperene epoxide 1524 C15H24O 220

616 Isoafricanol 1529 C15H26O 222

617 cis-Cadina-4,6-dien-11-ol 1531 C15H24O 220

618 Elema-1,3-dien-7-ol 1531 C15H24O 220

619 Tamariscol 1535 C15H26O 222

620 Pacifigorgiol 1539 C15H26O 222

621 (E,E)-Methyl 10-oxofarnesoate 1896 C16H26O3 266

622 b-Caryophyllene oxide 1546 C15H24O 220

623 Africanone 1547 C15H22O 218

624 1,8-Oxidocadin-4-ene 1551 C15H24O 220

625 4bH,5aH-cis-Eudesm-6-en-11-ol 1555 C15H26O 222

626 Dactylol 1556 C15H26O 222

627 cis-Sesquisabinenhydrate 1558 C15H26O 222

628 11,12-Dihydrochiloscyphone 1558 C15H24O 220

629 Aromadendran-5-ol 1562 C15H26O 222

630 Oxidohimachalene 1557 C15H22O 218

631 (+)-Marsupellol 1564 C15H24O 220

632 b-Himachalol 1638 C15H26O 222

633 Maaliol 1565 C15H26O 222

634 Deoxopinguisone 1563 C15H22O 218

635 Palustrol 1569 C15H26O 222

636 4a-Hydroxygermacra-1(10),5-diene 1571 C15H26O 222

637 Spathulenol 1572 C15H24O 220

638 4-Dehydroviridiflorol 1572 C15H24O 220

639 Caryophyllene oxide 1578 C15H24O 220

640 7-Acetoxyelema-1,3,8-triene 1584 C17H26O2 262

641 Globulol 1589 C15H26O 222

642 Cubeban-11-ol 1591 C15H26O 222

643 Salvial-4(14)-en-1-one 1592 C15H24O 220

644 Bisabola-2,10-diene 1,9-oxide 1592 C15H24O 220

645 b-Oplopenone 1595 C15H24O 220

646 Longiborneol 1597 C15H26O 222

647 Rosifoliol 1599 C15H26O 222

648 Ledol 1600 C15H26O 222

649 2-Methyl-1-(octahydro-7,7a- 1601 C15H26O 222

dimethyl-1H-inden-1-yl)-propan-1-

one

650 Eudesm-4-en-7-ol 1604 C15H26O 222

651 Rearrangement product from 1608 C15H22O 218

Grimaldone

652 Maalian-5-ol 1607 C15H26O 222

653 10-epi-g-Eudesmol 1609 C15H26O 222

654 ar-Curcumen-7-ol 1610 C15H22O 218

655 Amorpha-4,7-dien-11-ol 1610 C15H24O 220

656 5-Guaiene-11-ol 1619 C15H26O 222

657 g-Eudesmol 1618 C15H26O 222

658 Alismol 1619 C15H24O 220

659 Gymnomitrone 1620 C15H22O 218

660 Isospathulenol 1625 C15H24O 220

661 Isogymnomitrol 1625 C15H24O 220

662 Furanoeudesm-1,3-diene 1630 C15H18O 214

663 Amorpha-4-en-7-ol 1629 C15H26O 222

664 Eudesm-3,11-dien-5-ol 1632 C15H24O 220

665 Hinesol 1632 C15H26O 222

666 T-Muurolol 1633 C15H26O 222

667 (E,E)-Germacradiene-11-ol 1633 C15H26O 222

668 T-Cadinol 1633 C15H26O 222

669 Gymnomitr-3(15)-en-4-one 1635 C15H22O 218

670 1(10)-Spirovetivene-7b-ol 1636 C15H26O 222

671 Muurola-3,7(11)-dien-1-ol 1637 C15H24O 220

672 6-Himachalen-9b-ol 1638 C15H26O 222

673 Gymnomitran-4-one 1639 C15H24O 220

674 b-Eudesmol 1641 C15H26O 222

675 Furanoeremophilene 1642 C15H22O 218

676 2-Himachalen-7b-ol 1642 C15H26O 222

677 a-Cadinol 1643 C15H26O 222

678 Eudesm-4(15)-en-7-ol 1643 C15H24O 220

679 2-Methyl-1-(octahydro-7,7a- 1645 C15H28O 224

dimethyl-1H-inden-1-yl)-propan-1-

ol

680 Eudesm-11-en-4a-ol 1649 C15H26O 222

681 1(10)-Valencen-7b-ol 1646 C15H26O 222

682 Valerianol 1647 C15H26O 222

683 Eudesm-3-en-7-ol 1650 C15H26O 222

684 10-epi-trans-Dracunculifoliol 1591 C15H26O 222

685 7-epi-a-Eudesmol 1653 C15H26O 222

686 Acorenol B 1654 C15H26O 222

687 Bisabolol oxide B 1654 C15H26O2 238

688 Aromadendran-12-ol 1654 C15H24O 220

689 Grimaldone 1656 C15H22O 218

690 Gymnomitrol 1657 C15H24O 220

691 Eudesm-4(15)-en-6-ol 1656 C15H26O 222

692 Saccogynol 1660 C15H22O 218

693 Valeranone 1664 C15H26O 222

694 4-epi-Acorenone 1664 C15H24O 220

695 Gymnomitr-3(15)-en-4a-ol 1665 C15H24O 220

696 Acorenol 1667 C15H26O 222

697 epi-Cyclosantalal 1668 C15H24O 220

698 (Z)-g-Atlantone 1669 C15H22O 218

699 a-Alasken-6-ol 1674 C15H24O 220

700 Bisabolone oxide A 1675 C15H24O2 236

701 Amorpha-4,7(11)-dien-8-one 1679 C15H22O 218

702 Amorpha-4,9-dien-2-ol 1679 C15H24O 220

703 Amorpha-4,9-dien-14-al 1685 C15H22O 218

704 Eudesm-3-en-6-ol 1679 C15H26O 222

705 Khusiol 1680 C15H26O 222

706 (E)-g-Atlantone 1681 C15H22O 218

707 Acorenone 1681 C15H24O 220

708 Cadina-1(10),4-dien-8a-ol 1682 C15H24O 220

709 Bicyclogermacren-14-al 1684 C15H22O 218

710 Cyperotundone 1684 C15H22O 218

711 (Z)-a-Atlantone 1689 C15H22O 218

712 Lanceol oxide 1695 C15H24O 220

713 Farnesol (Isomer 1) 1694 C15H26O 222

714 6a-Hydroxygermacra-1(10),4-diene 1687 C15H26O 222

715 Acora-7(11),9-dien-2-one 1706 C15H22O 218

716 Valerenal 1706 C15H22O 218

717 a-Herbertenol 1711 C15H22O 218

718 Dihydrochiloscypholone 1711 C15H26O2 238

719 Italicen-4-one 1717 C15H22O 218

720 Farnesol (Isomer 2) 1718 C15H26O 222

721 10-epi-1,8-Oxidocadina-4-ene 1539 C15H24O 220

722 Neopetasone 1733 C15H22O 218

723 7,14-Anhydroamorpha-4,9-diene 1733 C15H22O 218

724 Lepidozenal 1744 C15H22O 218

725 7-Acetoxyelema-1,3-dien-8-ol 1793 C17H28O3 280

726 Naviculol 1734 C15H26O 222

727 Bisabolol oxide A 1740 C15H26O2 238

728 a-Cyperone 1741 C15H22O 218

729 Cyclocolorenone 1745 C15H22O 218

730 Gymnomitrol acetate 1751 C17H26O2 262

731 b-Herbertenol 1751 C15H22O 218

732 (E)-a-Atlantone 1754 C15H22O 218

733 (Z)-Lanceol 1755 C15H24O 220

734 Cuparophenol 1763 C15H22O 218

735 Cedryl acetate 1764 C17H28O2 264

736 14-Oxocalamenene 1768 C15H20O 216

737 Isovalencenol 1779 C15H24O 220

738 Drimenol 1750 C15H26O 222

739 cis-5-Hydroxycalamenene 1790 C15H22O 218

740 Khusienol acetate 1789 C17H26O2 262

741 Fukinanolide 1798 C15H22O2 234

742 Bisabola-2,7(Z),10(Z)-triene-13-ol 1806 C15H24O 220

743 Cyperadione 1820 C15H24O2 236

744 cis-Spiroether 1850 C13H12O2 200

745 trans-Spiroether 1853 C13H12O2 200

746 trans-4,8a-Dimethyl-4a,5- 1350 C12H20O 180

epoxydecaline

747 Peculiaroxide 1416 C15H26O 222

748 Furanoelemene 1485 C15H20O 216

749 Guaioxide 1487 C15H26O 222

750 Elemol 1541 C15H26O 222

751 Lemnalol 1579 C15H24O 220

752 Fokienol 1582 C15H24O 220

753 Thujopsane-2b-ol 1593 C15H26O 222

754 a-Alasken-8-ol 1600 C15H24O 220

755 6-epi-Cubenol 1602 C15H26O 222

756 Widdrol 1601 C15H26O 222

757 Marsupellone 1604 C15H22O 218

758 Axinyssene 1860 C20H32 272

759 Selina-1,3,7(11)-trien-8-one 1616 C15H20O 216

760 Myliol 1617 C15H22O 218

761 a-Acorenol 1623 C15H26O 222

762 Furanogermacrene 1624 C15H20O 216

763 Acora-3,7(11)-dien-6-ol 1626 C15H24O 220

764 b-Acorenol 1626 C15H26O 222

765 a-Alaskene-8-ol 1632 C15H24O 220

766 Microbiotol 1632 C15H26O 222

767 Isopinguisanine 1638 C15H20O2 232

768 Gymnomitr-3(15)-en-4b-ol 1653 C15H24O 220

769 a-Eudesmol 1653 C15H26O 222

770 Isorotundenol 1659 C15H26O 222

771 Bulnesol 1665 C15H26O 222

772 Bicyclohumulenone 1668 C15H24O 220

773 Selina-4(15),11-dien-8-ol 1670 C15H24O 220

774 Smyrnicordifuran 1673 C15H18O2 230

775 b-Sinensal 1675 C15H22O 218

776 Isocyperol 1676 C15H24O 220

777 a-Cuparenone 1681 C15H20O 216

778 Cyperol 1681 C15H24O 220

779 Gymnomitr-3-en-15-ol 1688 C15H24O 220

780 Pinguisanine 1706 C15H20O2 232

781 Acora-3,7(11)-dien-8-one 1709 C15H22O 218

782 Vetiselinol 1709 C15H24O 220

783 10,11-Dihydro-a-cuparenone 1712 C15H22O 218

784 Oxidoselina-1,3,7(11)-trien-8-one 1725 C15H20O2 232

785 a-Sinensal 1726 C15H22O 218

786 Plagiochilide 1729 C15H20O2 232

787 (E,E)-Methyl 10,11-epoxyfarnesoate 1875 C16H26O3 266

788 Eudesma-3,11-dien-2-one 1776 C15H22O 218

789 Zizaenic acid 1791 C15H22O2 234

790 Acutifolene B 1806 C15H20O3 248

791 a-Vetivone 1821 C15H22O 218

792 (E,E)-Farnesylacetate 1822 C17H28O2 264

793 Acutifolene A 1833 C16H22O3 262

794 Furanoeremophilone 1855 C15H20O2 232

795 2-Acetoxyfuranoelemene 1876 C17H22O3 274

796 Guaia-3,10(14)-dien-6,12-olide 1938 C15H20O2 232

797 Guaia-3,7(11),10(14)-trien-6,12- 1950 C15H18O2 230

olide

798 1b-Acetoxyfurano-4(15)-eudesmene 1964 C17H22O3 274

799 1b-Acetoxyfurano-3-eudesmene 1978 C17H22O3 274

800 Maalioxide 1508 C15H26O 222

801 Kessane 1533 C15H26O 222

802 Humulene epoxide 3 1626 C15H24O 220

803 8-Hydroxybicyclogermacrene 1661 C15H24O 220

804 Lactarovioline 2068 C15H14O 210

805 5-epi-Pinguisenol 1764 C15H26O 222

806 b-Santalol acetate 1800 C17H26O2 262

807 Bisacumol (Isomer 1) 1596 C15H22O 218

808 Bisacumol (Isomer 2) 1619 C15H22O 218

809 Bisabola-1,3(15),10-trien-9-ol 1666 C15H24O 220

(Isomer 1)

810 Bisabola-1,3(15),10-trien-9-ol 1678 C15H24O 220

(Isomer 2)

811 trans-Sesquisabinen hydrate 1564 C15H26O 222

812 1bH-Presilphiperfolane-9a-ol 1510 C15H26O 222

813 1aH-Presilphiperfolan-9b-ol 1499 C15H26O 222

814 Presilphiperfolane-9a-ol 1519 C15H26O 222

815 ar-Curcumen-15-al 1681 C15H20O 216

816 Sesquicineol 1507 C15H26O 222

817 Italicen-13-al 1671 C15H22O 218

818 a-Copaen-8-ol 1551 C15H24O 220

819 Khusimol 1720 C15H24O 220

820 Zizanol 1656 C15H24O 220

821 Oxidocadalene 1644 C15H18O 214

822 Eremoligenol 1614 C15H26O 222

823 Isohumbertiol D (Isomer 2) 1519 C15H24O 220

824 Isohumbertiol D (Isomer 1) 1490 C15H24O 220

825 Brachylaenalone B 1824 C15H20O2 232

826 Khusien-12-al 1580 C15H22O 218

827 Eudesma-4(15),7(11)-dien-8-one 1713 C15H22O 218

828 Elemenone 1589 C15H22O 218

829 b-Cedrene epoxide 1610 C15H24O 220

830 b-Panasinsen-5a-ol 1621 C15H24O 220

831 Eudesm-7(11)-en-4a-ol 1676 C15H26O 222

832 5,8-Cyclocaryophyllan-4-ol 1514 C15H26O 222

833 Khusol 1769 C15H24O 220

834 cis-10-Hydroxycalamenene 1643 C15H22O 218

835 trans-10-Hydroxycalamenene 1635 C15H22O 218

836 Bryopterine A 1735 C16H20O3 260

837 Isoitalicene epoxide 1501 C15H24O 220

838 Italicene epoxide 1535 C15H24O 220

839 a-Agarofuran 1537 C15H24O 220

840 Longipin-3-en-10-ol 1560 C15H24O 220

841 Dihydrosesquicineol 1467 C15H28O 224

842 Dehydrosesquicineol 1466 C15H24O 220

843 Longicamphenilone 1549 C14H22O 206

844 Longicamphenilol 1578 C14H24O 208

845 Isobutyl angelate 1027 C9H16O2 156

846 Isoacorone 1774 C15H24O2 236

847 Dehydrosesquicineyl-12-ol 1707 C15H24O2 236

848 Dihydrobryopterine A 1763 C16H22O3 262

849 (E)-Nuciferal 1705 C15H20O 216

850 (Z)-Nuciferal 1695 C15H20O 216

851 Pinguisanene 1544 C15H20O 216

852 (E)-Methyl 10-hydroxy-3,7,11- 1930 C16H26O3 266

trimethyldodeca-2,6,11-trienoate

853 Dihydroagarofuran 1500 C15H26O 222

854 Isolongifolol 1717 C15H26O 222

855 (Z)-Nerolidol 1522 C15H26O 222

856 (E)-Nerolidol 1553 C15H26O 222

857 a-Cedrene oxide 1571 C15H24O 220

858 Caryolan-1-ol 1567 C15H26O 222

859 Thujopsan-2a-ol 1584 C15H26O 222

860 Curcerenone 1588 C15H18O2 230

861 a-Guaiol 1593 C15H26O 222

862 Viridiflorol 1592 C15H26O 222

863 Epicurcerenone 1593 C15H18O2 230

864 Carotol 1594 C15H26O 222

865 Cedrol 1603 C15H26O 222

866 12-epi-Cedrol 1620 C15H26O 222

867 1-epi-Cubenol 1623 C15H26O 222

868 ar-Turmerone 1643 C15H20O 216

869 3(15)-Cedren-4-ol 1647 C15H24O 220

870 a-Turmerone 1649 C15H22O 218

871 Patchouli alcohol 1661 C15H26O 222

872 (Z)-a-Santalol 1669 C14H22O 206

873 a-Bisabolol 1673 C15H26O 222

874 Acorenone B 1679 C15H24O 220

875 Germacrone 1684 C15H22O 218

876 Curcuphenol 1693 C15H22O 218

877 2-Butylfuran 869 C8H12O 124

878 Pinguisone 1705 C15H20O2 232

879 (Z)-b-Santalol 1702 C15H24O 220

880 Xanthorhizol 1732 C15H22O 218

881 cis-2-Hydroxycalamenene 1762 C15H22O 218

882 Furanogermenone 1770 C15H20O2 232

883 Alantolactone 1873 C15H20O2 232

884 Dihydroisoalantolactone 1875 C15H22O2 234

885 Frullanolide 1900 C15H20O2 232

886 Isoalantolactone 1912 C15H20O2 232

887 ent-Diplophyllolide 1937 C15H20O2 232

888 Guaia-6,9-dien-4b-ol 1565 C15H24O 220

889 Guaia-6,10(14)-diene-4b-ol 1610 C15H24O 220

890 Cedrenone 1722 C15H22O 218

891 8bH-Cedran-9-one 1608 C15H24O 220

892 Deodarone 1676 C15H24O2 236

893 Pogostol 1647 C15H26O 222

894 Dihydro-ar-turmerone 1570 C15H22O 218

895 Norpatchoulenol 1551 C14H22O 206

896 Caryophyllan-2,6-a-oxide 1412 C15H26O 222

897 Caryophyllen-2,6-b-oxide 1422 C15H26O 222

898 b-Atlantol (Isomer 1) 1436 C15H24O 220

899 b-Atlantol (Isomer 2) 1443 C15H24O 220

900 1,11-Oxidocalamenene 1474 C15H20O 216

901 Furopelargone A 1517 C15H22O2 234

902 Isohumbertiol B 1522 C15H24O 220

903 Silphiperfolene-5-ol 1549 C15H24O 220

904 b-Funebrene epoxide 1591 C15H24O 220

905 b-Himachalene epoxide 1594 C15H24O 220

906 Copaborneol 1595 C15H26O 222

907 10-epi-Italicen-4-one 1615 C15H22O 218

908 ar-Bisabolol 1619 C15H22O 218

909 allo-Aromadendrene epoxide 1623 C15H24O 220

910 Amorph-4-en-10a-ol 1634 C15H26O 222

911 alio-Himachalol 1648 C15H26O 222

912 Farnesal (Isomer 1) 1655 C15H24O 220

913 b-Sesquiphellandrone 1677 C15H22O 218

914 Aromadendran-14-ol 1679 C15H26O 222

915 Farnesal (Isomer 2) 1683 C15H24O 220

916 Farnesal (Isomer 3) 1707 C15H24O 220

917 Longifolol 1707 C15H26O 222

918 Sesquichamaenol 1744 C15H22O2 234

919 (E,E)-Methyl farnesoate 1765 C16H26O2 250

920 trans-2-Hydroxycalamenene 1753 C15H22O 218

921 a-Santalol acetate 1756 C17H26O2 262

922 8-Acetoxyelemol 1759 C17H26O2 262

923 Nootkatone 1782 C15H22O 218

924 Striatol 1550 C15H26O 222

925 Eremophila-1(10),11-dien-9b-ol 1552 C15H24O 220

926 Longipinanol 1559 C15H26O 222

927 Brachyl oxide 1599 C15H24O 220

928 Humulene epoxide 2 1602 C15H24O 220

929 Copaen-15-ol 1661 C15H24O 220

930 Isonaviculol 1743 C15H26O 222

931 Cyperenal 1741 C15H22O 218

932 g-Curcumen-15-al 1744 C15H22O 218

933 Brachylaenalone A 1802 C15H20O2 232

934 Muurola-4,10(14)-dien-8a-ol 1594 C15H24O 220

935 Cadina-1(10),4-dien-8a-ol 1637 C15H24O 220

936 Hexyl acetate 1006 C8H16O2 144

937 Muurola-4,10(14)-dien-8b-ol 1675 C15H24O 220

938 (Z)-Nuciferol 1695 C15H22O 218

939 (Z)-g-Curcumen-12-ol 1701 C15H24O 220

940 (E)-Nuciferol 1715 C15H22O 218

941 (Z)-g-Curcumyl acetate 1767 C17H26O2 262

942 (Z)-Nuciferyl acetate 1793 C17H24O2 260

943 (Z)-Nuciferyl isobutyrate 1916 C19H28O2 288

944 (Z)-g-Curcumenyl isobutyrate 1920 C19H30O2 290

945 (Z)-Nuciferyl 2-methylbutyrate 2003 C20H30O2 302

946 (Z)-g-Curcumyl 2-methylbutyrate 2011 C20H32O2 304

947 Drim-8-en-7-one 1778 C15H24O 220

948 1-Oxo-a-longipinene 1639 C15H22O 218

949 g-Bicyclohomofarnesal 1784 C16H26O 234

950 Geosmin 1392 C12H22O 182

951 Muurol-4-en-6a-ol 1609 C15H26O 222

952 Veticadine oxide 1482 C15H24O 220

953 Cubenol 1630 C15H26O 222

954 4-epi-Cubebol 1490 C15H26O 222

955 Muurol-4-en-3,8-dione 1753 C15H22O2 234

956 3-Acetoxyamorpha-4,7(11)-dien-8- 1950 C17H24O3 276

one

957 (E)-4,8-Dimethylnona-1,3,7-triene 1103 C11H18 150

958 Geijerene 1139 C12H18 162

959 Albene 1154 C12H18 162

960 Trinoranastreptene 1197 C12H16 160

961 1,4a-Dimethyl-1,2,3,4,4a,5,6,7- 1233 C12H20 164

octahydro-naphthalene

962 Pregeijerene 1288 C12H18 162

963 (Z)-2,6,10-Trimethylundeca-2,6- 1305 C14H26 194

diene

964 Isocyclobazzanene 1319 C15H24 204

965 8,9-Didehydrocycloisolongifolene 1320 C15H22 202

966 (E)-2,6,10-Trimethylundeca-2,6- 1321 C14H26 194

diene

967 Cyprotene 1322 C14H24 192

968 Presilphiperfol-1-ene 1325 C15H24 204

969 7aH-Silphiperfol-5-ene 1329 C15H24 204

970 Brasila-5,10-diene 1335 C15H24 204

971 Bicycloax-4(15)-ene 1336 C15H24 204

972 Bicycloelemene 1338 C15H24 204

973 d-Elemene 1340 C15H24 204

974 3,10-Dihydro-1,4-dimethylazulene 1342 C12H14 158

975 Presilphiperfol-7-ene 1342 C15H24 204

976 Pentalenene 1343 C15H24 204

977 African-5-ene 1350 C15H24 204

978 African-2(6)-ene 1350 C15H24 204

979 Maali-1,3-diene 1347 C15H22 202

980 Silphin-1-ene 1350 C15H24 204

981 7bH-Silphiperfol-5-ene 1352 C15H24 204

982 a-Cubebene 1355 C15H24 204

983 Tamariscene 1355 C15H24 204

984 Africa-1,5-diene 1355 C15H22 202

985 African-1-ene 1356 C15H24 204

986 Bicycloax-3-ene 1357 C15H24 204

987 Silphiperfola-5,7(14)-diene 1360 C15H22 202

988 a-Longipinene 1360 C15H24 204

989 Clovene 1365 C15H24 204

990 Cyperadiene 1365 C15H22 202

991 Cyclomyltaylane 1366 C15H24 204

992 1-epi-a-Pinguisene 1367 C15H24 204

993 Brasila-5(10),6-diene 1370 C15H24 204

994 Anastreptene 1373 C15H22 202

995 Capnell-9(12)-ene 1372 C15H24 204

996 a-Ylangene 1376 C15H24 204

997 Isopatchoula-3,5-diene 1377 C15H22 202

998 Cyclosativene 1378 C15H24 204

999 Hirsutene 1378 C15H24 204

1000 a-Copaene 1379 C15H24 204

1001 a-Bourbonene 1378 C15H24 204

1002 Daucene 1380 C15H24 204

1003 Silphiperfol-6-ene 1378 C15H24 204

1004 Bourbon-7-ene 1381 C15H24 204

1005 a-Elemene 1381 C15H24 204

1006 Isodauca-4,7(14)-diene 1381 C15H24 204

1007 Isoledene 1382 C15H24 204

1008 Protoillud-6-ene 1382 C15H24 204

1009 Longicyclene 1382 C15H24 204

1010 Modhephene 1383 C15H24 204

1011 Pacifigorgia-1(9),10-diene 1384 C15H24 204

1012 3-epi-African-5-ene 1384 C15H24 204

1013 10-epi-Italicene 1384 C15H24 204

1014 Asterisca-3(15),6-diene 1385 C15H24 204

1015 a-Funebrene 1385 C15H24 204

1016 b-Panasinsene 1385 C15H24 204

1017 Bicycloopposit-4-ene 1386 C15H24 204

1018 b-Bourbonene 1386 C15H24 204

1019 Isodauca-4,6-diene 1385 C15H24 204

1020 African-2-ene 1387 C15H24 204

1021 7-epi-Sesquithujene 1387 C15H24 204

1022 b-Patchoulene 1388 C15H24 204

1023 a-Duprezianene 1388 C15H24 204

1024 b-Elemene 1389 C15H24 204

1025 a-Isocomene 1389 C15H24 204

1026 1,5-di-epi-a-Bourbonene 1389 C15H24 204

1027 b-Cubebene 1390 C15H24 204

1028 1,5-di-epi-b-Bourbonene 1390 C15H24 204

1029 African-3-ene 1391 C15H24 204

1030 Bicyclo-4(15)-oppositene 1391 C15H24 204

1031 Isolongifolene 1393 C15H24 204

1032 Isodauca-6,9-diene 1393 C15H24 204

1033 Sativene 1394 C15H24 204

1034 Pacifigorgia-1,10-diene 1400 C15H24 204

1035 Petasitene 1398 C15H24 204

1036 Sesquithujene 1399 C15H24 204

1037 African-3(15)-ene 1400 C15H24 204

1038 Cyperene 1402 C15H24 204

1039 b-Longipinene 1403 C15H24 204

1040 7-epi-a-Cedrene 1404 C15H24 204

1041 Helifolene 1406 C15H24 204

1042 7-epi-Helifolene 1406 C15H24 204

1043 Italicene 1408 C15H24 204

1044 Isocaryophyllene 1409 C15H24 204

1045 b-Isocomene 1411 C15H24 204

1046 Longifolene 1411 C15H24 204

1047 Ylanga-2,4(15)-diene 1411 C15H22 202

1048 cis-a-Bergamotene 1411 C15H24 204

1049 allo-Isolongifolene 1412 C15H24 204

1050 Cycloseychellene 1413 C15H24 204

1051 a-Gurjunene 1413 C15H24 204

1052 a-Barbatene 1414 C15H24 204

1053 b-Funebrene 1418 C15H24 204

1054 b-Maaliene 1414 C15H24 204

1055 Pacifigorgia-1(6),10-diene 1414 C15H24 204

1056 Cascarilladiene 1416 C15H24 204

1057 Isosativene 1416 C15H24 204

1058 Tritomarene 1416 C15H24 204

1059 a-Microbiotene 1414 C15H24 204

1060 Aristolene 1423 C15H24 204

1061 a-Cedrene 1418 C15H24 204

1062 Pacifigorgia-2,10-diene 1422 C15H24 204

1063 b-Ylangene 1420 C15H24 204

1064 (Z)-b-Farnesene 1420 C15H24 204

1065 Acora-3,5-diene 1421 C15H24 204

1066 (E)-b-Caryophyllene 1421 C15H24 204

1067 a-Santalene 1422 C15H24 204

1068 Spirovetiva-1(10),6-diene 1422 C15H24 204

1069 b-Duprezianene 1423 C15H24 204

1070 Opposita-4(15),7-diene 1423 C15H24 204

1071 b-Cedrene 1424 C15H24 204

1072 Opposita-4(15),11-diene 1424 C15H24 204

1073 Selina-3,6-diene 1424 C15H24 204

1074 Bourbon-11-ene 1424 C15H24 204

1075 Dauca-3,8-diene 1428 C15H24 204

1076 Elema-1,3,7(11),8-tetraene 1428 C15H22 202

1077 g-Elemene 1429 C15H24 204

1078 Isobarbatene 1428 C15H24 204

1079 g-Maaliene 1428 C15H24 204

1080 Aristola-1(10),8-diene 1429 C15H22 202

1081 Chenopodene 1430 C15H24 204

1082 b-Copaene 1430 C15H24 204

1083 Thujopsene 1434 C15H24 204

1084 Selina-4(15),5-diene 1433 C15H24 204

1085 Pacifigorgia-2(10),11-diene 1435 C15H24 204

1086 trans-a-Bergamotene 1434 C15H24 204

1087 a-Pinguisene 1436 C15H24 204

1088 b-Sesquifenchene 1437 C15H24 204

1089 Sesquisabinene A 1435 C15H24 204

1090 Calarene 1437 C15H24 204

1091 Cubeb-11-ene 1445 C15H24 204

1092 b-Gorgonene 1440 C15H24 204

1093 a-Maalinene 1440 C15H24 204

1094 Cyclofarnesa-5(14),8,10-triene 1441 C15H24 204

1095 a-Guaiene 1440 C15H24 204

1096 Acora-3,9-diene 1442 C15H24 204

1097 Aromadendrene 1443 C15H24 204

1098 Brasila-1(6),5(10)-diene 1442 C15H24 204

1099 Isobazzanene 1442 C15H24 204

1100 Guaia-6,9-diene 1443 C15H24 204

1101 Nardosina-7,9,11-triene 1444 C15H22 202

1102 4aH,10aH-Guaia-1(5),6-diene 1445 C15H24 204

1103 Isogermacrene D 1445 C15H24 204

1104 Selina-5,11-diene 1444 C15H24 204

1105 Eremophila-1(10),6-diene 1445 C15H24 204

1106 b-Barbatene 1445 C15H24 204

1107 Cadina-4,11-diene 1458 C15H24 204

1108 Erythrodiene 1446 C15H24 204

1109 epi-b-Santalene 1446 C15H24 204

1110 Sesquisabinene B 1446 C15H24 204

1111 Seychellene 1447 C15H24 204

1112 Cadina-3,5-diene 1448 C15H24 204

1113 (E)-b-Farnesene 1446 C15H24 204

1114 4bH,10aH-Guaia-1(5),6-diene 1448 C15H24 204

1115 Selina-4(15),6-diene 1450 C15H24 204

1116 a-Himachalene 1450 C15H24 204

1117 Prezizaene 1452 C15H24 204

1118 Bourbon-7(11)-ene 1454 C15H24 204

1119 a-Humulene 1455 C15H24 204

1120 e-Muurolene 1455 C15H24 204

1121 a-Panasinsene 1455 C15H24 204

1122 Zizaene 1456 C15H24 204

1123 a-Neoclovene 1456 C15H24 204

1124 Valerena-4,7(11)-diene 1456 C15H24 204

1125 Acora-3,10(14)-diene 1457 C15H24 204

1126 Selina-4(15),7-diene 1457 C15H24 204

1127 b-Spathulene 1457 C15H22 202

1128 Muurola-4,11-diene 1458 C15H24 204

1129 Selina-2,4-diene 1462 C15H24 204

1130 (Z,Z)-a-Farnesene 1460 C15H24 204

1131 b-Santalene 1460 C15H24 204

1132 7bH,10bH-Cadina-1(6),4-diene 1460 C15H24 204

1133 Rotundene 1461 C15H24 204

1134 Selina-3,7-diene 1460 C15H24 204

1135 Striatene 1458 C15H24 204

1136 allo-Aromadendrene 1462 C15H24 204

1137 Aromadendr-9-ene 1463 C15H24 204

1138 a-Patchoulene 1467 C15H24 204

1139 a-Acoradiene 1464 C15H24 204

1140 Carota-5,8-diene 1465 C15H24 204

1141 b-Acoradiene 1465 C15H24 204

1142 4,5-di-epi-Aristolochene 1470 C15H24 204

1143 Selina-4,7-diene 1469 C15H24 204

1144 2-epi-(E)-b-Caryophyllene 1467 C15H24 204

1145 g-Muurolene 1474 C15H24 204

1146 Amorpha-4,11-diene 1472 C15H24 204

1147 7aH,10bH-Cadina-1(6),4-diene 1472 C15H24 204

1148 ar-Curcumene 1473 C15H22 202

1149 Eudesma-1,4(15),11-triene 1472 C15H22 202

1150 Eudesma-2,4,11-triene 1471 C15H22 202

1151 g-Gurjunene 1472 C15H24 204

1152 Ishwarane 1468 C15H24 204

1153 Valenca-2,9,11-trIene 1473 C15H22 202

1154 b-Chamigrene 1474 C15H24 204

1155 (3E,6Z)-a-Farnesene 1475 C15H24 204

1156 Selina-4,11-diene 1475 C15H24 204

1157 b-Microbiotene 1473 C15H24 204

1158 a-Amorphene 1477 C15H24 204

1159 g-Curcumene 1475 C15H24 204

1160 Herbertene 1476 C15H22 202

1161 Zierene 1476 C15H22 202

1162 a-Neocallitropsene 1475 C15H24 204

1163 Amorpha-4,7(11)-diene 1476 C15H24 204

1164 5-epi-Aristolochene 1477 C15H24 204

1165 Isobicyclogermacrene 1477 C15H24 204

1166 b-Neoclovene 1475 C15H24 204

1167 trans-b-Bergamotene 1480 C15H24 204

1168 g-Himachalene 1479 C15H24 204

1169 Laurene 1483 C15H20 200

1170 Germacrene D 1479 C15H24 204

1171 (3Z,6E)-a-Farnesene 1480 C15H24 204

1172 a-Vetispirene 1481 C15H22 202

1173 e-Cadinene 1483 C15H24 204

1174 g-Humulene 1483 C15H24 204

1175 Isolepidozene 1483 C15H24 204

1176 cis-Eudesma-6,11-diene 1484 C15H24 204

1177 Nardosina-9,11-diene 1484 C15H24 204

1178 Nardosina-1(10),11-diene 1484 C15H24 204

1179 Eudesma-3,5,11-triene 1485 C15H22 202

1180 Aristolochene 1486 C15H24 204

1181 Eremophilene 1486 C15H24 204

1182 d-Selinene 1490 C15H24 204

1183 b-Vetispirene 1486 C15H22 202

1184 Bicyclosesquiphellandrene 1487 C15H24 204

1185 b-Selinene 1486 C15H24 204

1186 g-Amorphene 1492 C15H24 204

1187 allo-Aromadendr-9-ene 1489 C15H24 204

1188 Eremophila-1(10),7-diene 1488 C15H24 204

1189 Selina-3,5-diene 1486 C15H24 204

1190 Zingiberene 1489 C15H24 204

1191 b-Alaskene 1495 C15H24 204

1192 Ledene 1491 C15H24 204

1193 Drim-8(12)-ene 1497 C15H26 206

1194 Valencene 1494 C15H24 204

1195 epi-Zonarene 1494 C15H24 204

1196 (Z)-a-Bisabolene 1494 C15H24 204

1197 a-Selinene 1494 C15H24 204

1198 Bicyclogermacrene 1494 C15H24 204

1199 Caparratriene 1493 C15H26 206

1200 Eudesma-2,4(15),11-triene 1495 C15H22 202

1201 Hinesene 1495 C15H24 204

1202 a-Muurolene 1496 C15H24 204

1203 Aciphyllene 1495 C15H24 204

1204 a-Cuprenene 1497 C15H24 204

1205 Cuparene 1498 C15H22 202

1206 g-Patchoulene 1497 C15H24 204

1207 e-Amorphene 1498 C15H24 204

1208 g-Guaiene 1499 C15H24 204

1209 b-Pinguisene 1500 C15H24 204

1210 d-Amorphene 1499 C15H24 204

1211 (E,E)-a-Farnesene 1498 C15H24 204

1212 1aH,10aH-Guaia-4,6-diene 1500 C15H24 204

1213 b-Himachalene 1500 C15H24 204

1214 D7(14)-ar-Himachalene 1501 C15H20 200

1215 b-Bisabolene 1503 C15H24 204

1216 a-Chamigrene 1503 C15H24 204

1217 Eremophila-1(10),8,11-triene 1504 C15H22 202

1218 Germacrene A 1503 C15H24 204

1219 Isorotundene 1503 C15H24 204

1220 a-Bulnesene 1503 C15H24 204

1221 b-Curcumene 1503 C15H24 204

1222 Drimenene 1503 C15H24 204

1223 Pseudowiddrene 1503 C15H24 204

1224 a-Alaskene 1512 C15H24 204

1225 (Z)-g-Bisabolene 1505 C15H24 204

1226 g-Cadinene 1507 C15H24 204

1227 Nootkatene 1512 C15H22 202

1228 Cyclobazzanene 1514 C15H24 204

1229 cis-Calamenene 1517 C15H22 202

1230 b-Sesquiphellandrene 1516 C15H24 204

1231 D7,8-ar-Himachalene 1518 C15H20 200

1232 7-epi-a-Selinene 1519 C15H24 204

1233 b-Bazzanene 1519 C15H24 204

1234 d-Cadinene 1520 C15H24 204

1235 (E)-g-Bisabolene 1521 C15H24 204

1236 trans-Calamenene 1517 C15H22 202

1237 Zonarene 1521 C15H24 204

1238 b-Cadinene 1526 C15H24 204

1239 g-Cuprenene 1523 C15H24 204

1240 Spirovetiva-1(10),7(11)-diene 1523 C15H24 204

1241 g-Vetivenene 1525 C15H22 202

1242 Cadina-1,4-diene 1523 C15H24 204

1243 w-Cadinene 1526 C15H24 204

1244 a-Calacorene 1527 C15H20 200

1245 Eremophila-1(10),7(11)-diene 1527 C15H24 204

1246 ar-Himachalene 1528 C15H22 202

1247 (E)-a-Bisabolene 1530 C15H24 204

1248 5-epi-Laurene 1531 C15H20 200

1249 1,4-Dimethylazulene 1532 C12H12 156

1250 Selina-4(15),7(11)-diene 1534 C15H24 204

1251 a-Cadinene 1534 C15H24 204

1252 w-Amorphene 1540 C15H24 204

1253 d-Cuprenene 1546 C15H24 204

1254 (1(10)E,4Z)-Germacrene B 1543 C15H24 204

1255 Selina-3,7(11)-diene 1542 C15H24 204

1256 Germacrene B 1552 C15H24 204

1257 b-Vetivenene 1552 C15H22 202

1258 g-Calacorene 1554 C15H20 200

1259 (3E,7E)-4,8,12-Trimethyltrideca- 1565 C16H26 218

1,3,7,11-tetraene

1260 Cadalene 1659 C15H18 198

1261 Daucalene 1671 C15H18 198

1262 Chamazulene 1719 C14H16 184

1263 Guaiazulene 1761 C15H18 198

1264 6-epi-b-Cubebene 1449 C15H24 204

1265 e-Cuprenene 1524 C15H24 204

1266 Gymnomitra-3(15),4-diene 1413 C15H22 202

1267 Tenuifolene 1570 C15H22 202

1268 ar-Tenuifolene 1528 C15H20 200

1269 trans-Eudesma-3,5-diene 1490 C15H24 204

1270 Pethybrene 1440 C15H24 204

1271 Premnaspirodiene 1516 C15H24 204

1272 Spirolepechinene 1450 C15H24 204

1273 trans-Dauca-4(11),7-diene 1554 C15H24 204

1274 trans-Dauca-4(11),8-diene 1529 C15H24 204

1275 Cadina-1(10),3,7(11)-triene 1575 C15H22 202

1276 7,8-Dehydro-a-acoradiene 1450 C15H22 202

1277 cis-Muurola-4(15),5-diene 1462 C15H24 204

1278 Patchoula-2,4(15)-diene 1434 C15H22 202

1279 Norrotundene 1421 C14H22 190

1280 cis-b-Guaiene 1488 C15H24 204

1281 Bisaboia-1,3,5,11-tetraene 1461 C15H24 204

1282 4-epi-b-Patchoulene 1376 C15H24 204

1283 d-Patchoulene 1466 C15H24 204

1284 e-Patchoulene 1473 C15H24 204

1285 10-epi-Muurola-4,11-diene 1458 C15H24 204

1286 Dauca-8,11-diene 1431 C15H24 204

1287 Neotrifaradiene 1365 C15H24 204

1288 Sandvicene 1399 C15H24 204

1289 Trifara-9,14-diene 1403 C15H24 204

1290 cis-Muurola-3,5-diene 1447 C15H24 204

1291 Pacifigorgia-6,10-diene 1429 C15H24 204

1292 b-Bulnesene 1558 C15H24 204

1293 Isocalamenene 1527 C15H22 202

1294 Myltayl-4(12)-ene 1452 C15H24 204

1295 3,7-di-epi-Trifara-9,14-diene 1399 C15H24 204

1296 6-epi-a-Cubebene 1418 C15H24 204

1297 2-Sterpurene 1351 C15H24 204

1298 a-Corocalen 1602 C15H20 200

1299 Lactarazulene 1796 C15H16 196

1300 Prenyllimonene (Isomer 1) 1436 C15H24 204

1301 Prenyllimonene (Isomer 2) 1450 C15H24 204

1302 Cadina-1(10),7(11)-diene 1538 C15H24 204

1303 Elema-1,3,7-triene 1346 C15H24 204

1304 7-epi-Cadina-1(10),11-diene 1525 C15H24 204

1305 Cadina-1(10),11-diene 1480 C15H24 204

1306 Vetivazulene 1790 C15H18 198

1307 Mintsulphide 1734 C15H24S 236

1308 Brasila-1,10-diene 1307 C15H24 204

1309 Drim-8-ene 1442 C15H26 206

1310 Selina-4(15),7,11-triene 1469 C15H22 202

1311 5,6-Dehydroalaskene 1371 C15H22 202

1312 (all-Z)-6,9,12,15-Heneicosatetraene 2048 C21H36 288

1313 Isoperillene 1073 C10H14O 150

1314 (E)-Cinnamyl isovalerate 1641 C14H18O2 218

1315 (E)-Cinnamyl isobutyrate 1543 C13H16O2 204

1316 (E)-Cinnamyl propionate 1500 C12H14O2 190

1317 (Z)-Isobutyl cinnamate 1593 C13H16O2 204

1318 Phenylethyl tiglate 1547 C13H16O2 204

1319 7-epi-Eremophila-1(10),8,11-triene 1508 C15H22 202

1320 5-Hydroxymarsupellyl acetate 1814 C17H26O3 278

1321 Marsupellyl acetate 1681 C17H26O2 262

1322 4-epi-Marsupellyl acetate 1733 C17H26O2 262

1323 (E)-Methyl p-methoxycinnamate 1625 C11H12O3 192

1324 (Z)-Methyl p-methoxycinnamate 1543 C11H12O3 192

1325 4-epi-Marsupellol 1614 C15H24O 220

1326 (Z)-Cinnamyl propionate 1552 C12H14O2 190

1327 (E)-Isobutyl cinnamate 1633 C13H16O2 204

1328 Methyl 4-methoxymandelate 1511 C10H12O4 196

1329 (E)-Isoamyl cinnamate 1697 C14H18O2 218

1330 Pentadecanoic acid 1823 C15H30O2 242

1331 Methyl o-methoxybenzoate 1300 C9H10O3 166

1332 Patchenol 1305 C11H18O 166

1333 Syringa aldehyde 1599 C9H10O4 182

1334 Methyl 3-methylorsellinate 1674 C10H12O4 196

1335 Dihydroactinidiolide 1487 C11H16O2 180

1336 b-Ionone epoxide 1460 C13H20O2 208

1337 Oxoisophorone 1111 C9H12O2 152

1338 Sabina ketone 1132 C9H14O 138

1339 2,6-Di-tert-butyl-4-methylphenol 1492 C15H24O 220

1340 Cadin-1(10)-ene 5,11-oxide 1574 C15H24O 220

1341 6,11-Epoxyisodaucane 1463 C15H26O 222

1342 3-Acetoxy-b-ionone 1752 C15H22O3 250

1343 Nardosina-7,9-dien-11-ol 1596 C15H24O 220

1344 Porosadienol 1627 C15H24O 220

1345 a-Ionone epoxide (Isomer 2) 1512 C13H20O2 208

1346 Cabreuva oxide A 1437 C15H24O 220

1347 Cabreuva oxide B 1452 C15H24O 220

1348 Cabreuva oxide C 1456 C15H24O 220

1349 (E)-o-Methoxycinnamaldehyde 1477 C10H10O2 162

1350 (Z)-o-Methoxycinnamaldehyde 1408 C10H10O2 162

1351 Hydrocinnamyl acetate 1336 C11H14O2 178

1352 N-Methyl methyl anthranilate 1372 C9H11O2N 165

1353 Abietal 2261 C20H30O 286

1354 trans-Totarol 2241 C20H30O 286

1355 Dehydrogeosmin 1362 C12H20O 180

1356 1bH,5aH,7bH-Guaia-3,10(14)-dien- 1646 C15H24O 220

11-ol

1357 9a,11-Epoxy-1bH,5aH,7bH,9bH- 1587 C15H22O 218

guaia-3,10(14)-diene

1358 4-(4-Hydroxyphenyl)-2-butanone 1508 C10H12O2 164

1359 15-Norlabdan-8-ol 1943 C19H36O 280

1360 Oxoisoambrox 1819 C16H26O2 250

1361 Sclareolide 2022 C16H24O3 264

1362 1-Decanol 1264 C10H22O 158

1363 Amberone 1810 C17H26O 246

1364 Methyl arachidonate 2217 C21H34O2 318

1365 Cyclomyltaylan-15-ol 1641 C15H24O 220

1366 Tridenson 1633 C15H26O 222

1367 Tridensenal 1617 C15H26O 222

1368 6b-Acetoxyeudesm-4(15)-en-7b-ol 1898 C18H30O2 278

1369 Tridensenone 1815 C15H20O 216

1370 2,6,6-Trimethylcyclohexanone 1023 C9H16O 140

1371 2,6,6-Trimethylcyclohex-2-enone 1045 C9H14O 138

1372 Acetoxycedren-13-ol 1782 C17H26O2 262

1373 4-Isopropylcyclohexanol (Isomer 1) 1126 C9H18O 142

1374 3-Hydroxy-4-methoxybenzyl 1421 C8H10O3 154

alcohol

1375 a-Ambrinol (Isomer 1) 1382 C13H22O 194

1376 a-Ambrinol (Isomer 2) 1410 C13H22O 194

1377 Thymohydroquinone 1509 C10H14O2 166

1378 Oreodaphnenol 1484 C15H24O 220

1379 Ambrox 1747 C16H28O 236

1380 4-Isopropylphenol 1201 C9H12O 136

1381 Scopoletine 1888 C10H8O4 192

1382 2,5-Dimethoxy-4-isopropyltoluene 1400 C12H18O2 194

1383 Silphiperfol-5-en-3-one 1533 C15H22O 218

1384 Clovenol 1575 C15H24O 220

1385 trans-6-Hydroxyisocalamenene 1782 C15H22O 218

1386 1,4-trans-6-Methoxyisocalamenene 1722 C16H24O 232

1387 Non-1-ene 837 C9H18 126

1388 Mintoxide 1565 C15H24O 220

1389 6-Methylheptan-2,4-dione 975 C8H14O2 142

1390 5-Methylheptan-2,4-dione 966 C8H14O2 142

1391 2,2-Dimethyl-7-isobutyl-2H,5H- 1770 C14H18O3 234

pyrano[4.3-b]pyran-5-one

1392 2,2-Dimethyl-7-secbutyl-2H,5H- 1764 C14H18O3 234

pyrano[4.3-b]pyran-5-one

1393 Cyclo-b-ionone 1329 C13H20O 192

1394 Germacra-4(15),5,10(14)-trien-1a-ol 1680 C15H24O 220

1395 Eudesma-4(15),7-dien-1b-ol 1671 C15H24O 220

1396 Cadina-4,10(14)-dien-1a-ol 1662 C15H24O 220

1397 b-Calacorene 1541 C15H20 200

1398 1a,10a-Epoxyamorph-4-ene 1569 C15H24O 220

1399 Muurola-4,10(14)-dien-1-ol 1626 C15H24O 220

1400 Caryophylla-3(15),7(14)-dien-6-ol 1635 C15H24O 220

1401 4(15)-Dehydroglobulol 1597 C15H24O 220

1402 trans-Bisabola-1(6),10-dien-2,3-diol 1758 C15H26O2 238

1403 6,10-Epoxybisabol-2-en-12-al 1664 C15H24O2 236

1404 6,10-Epoxybisabol-3-en-12-al 1677 C15H24O2 236

1405 11-epi-6,10-Epoxybisabol-3-en-12- 1649 C15H24O2 236

al

1406 Acora-3,5-dien-11-ol 1574 C15H24O 220

1407 Acora-2,4(15)-dien-11-ol 1616 C15H24O 220

1408 7-epi-Bisabol-1-one 1718 C15H24O 220

1409 (E)-trans-a-Bergamota-2,10-dien-12- 1679 C15H22O 218

al

1410 Helifolen-12-al (syn-syn-syn) 1611 C16H24O 232

1411 Italicene ether 1531 C15H24O 220

1412 7-epi-b-Bisabolol 1657 C15H26O 222

1413 Bisabol-1-one 1712 C15H24O 220

1414 Humulene epoxide 1 1593 C14H22O 206

1415 10-epi-Italicene ether 1511 C15H24O 220

1416 3-Hydroxybisabola-1(6),10-dien-2- 1748 C15H24O2 236

one

1417 b-Bisabolol 1659 C15H26O 222

1418 10-epi-Junenol 1581 C15H26O 222

1419 Junenol 1617 C15H26O 222

1420 1,10-di-epi-Cubenol 1615 C15H26O 222

1421 Carquejyl acetate 1284 C12H16O2 192

1422 (E)-Dendrolasin 1566 C15H22O 218

1423 Artemisyl acetate 1164 C12H20O2 196

1424 Artedouglasia oxide C 1507 C15H22O3 250

1425 Artedouglasia oxide A 1517 C15H22O3 250

1426 1-Undecanol 1363 C11H24O 172

1427 Laciniata furanone H 1530 C15H22O3 250

1428 Lanciniata furanone F 1514 C15H22O3 250

1429 Artedouglasia oxide B 1561 C15H22O3 250

1430 Artedouglasia oxide D 1542 C15H22O3 250

1431 Cymen-8-ol 1169 C10H14O 150

1432 2,2,9-Trimethyl-1,6- 1079 C10H14O2 166

dioxaspiro[4.4]nona-3,8-diene

1433 Menthyl formate 1230 C11H20O2 184

1434 Folifolone 1090 C10H14O 150

1435 Santolina alcohol 1029 C10H18O 154

1436 cis-p-Mentha-1(7),8-dien-2-ol 1217 C10H16O 152

1437 trans-p-Mentha-1(7),8-dien-2-ol 1176 C10H16O 152

1438 trans-p-Menth-2-en-1-ol 1116 C10H18O 154

1439 cis-p-Mentha-2,8-dien-1-ol 1125 C10H16O 152

1440 trans-p-Mentha-2,8-dien-1-ol 1113 C10H16O 152

1441 Dehydrosabinaketone 1100 C9H12O 136

1442 4-Hydroxy-4-methylcyclohex-2- 1089 C7H10O2 126

enone

1443 2-(1-Hydroxyethyl)-5-methyl-5- 1054 C9H16O2 156

vinyltetrahydrofuran

1444 trans-Arbusculone 1036 C9H14O2 154

1445 Lavender lactone 1006 C7H10O2 126

1446 Pulegone epoxide 1238 C10H16O2 168

1447 3-Methylcyclohexanone 928 C7H12O 112

1448 trans-Linalool oxide acetate 1274 C12H20O3 212

1449 Fragranyl acetate 1331 C11H18O2 182

1450 6-Methyl-6-(3-methylphenyl)-2- 1609 C15H22O 218

heptanone

1451 3-exo-Acetoxybornyl acetate 1520 C14H22O4 254

1452 3-exo-Acetoxyborneol 1402 C12H20O3 212

1453 3-exo-Hydroxybornyl acetate 1393 C12H20O3 212

1454 Lavandulyl acetate 1275 C12H20O2 196

1455 5-Hydroxymarsupellol 1776 C15H24O2 236

1456 b-Isolongibornene 1440 C15H24 204

1457 Geranyl propionate 1486 C13H22O2 210

1458 (E)-Isosafrol 1356 C10H10O2 162

1459 2,3-Dihydrofarnesol 1674 C15H28O 224

1460 Methyl 4-hydroxymandelate 1572 C9H10O4 182

1461 Methyl 3-(4-methoxyphenyl)- 1494 C11H14O3 194

propionate

1462 Methyl 3,5-dimethoxyphenylacetate 1603 C11H14O4 210

1463 2a-Hydroxyamorpha-4,7(11)-diene 1678 C15H24O 220

1464 l-Hepten-3-one 956 C7H12O 112

1465 Ferulyl angelate 1682 C15H20O3 248

1466 Undecanal 1290 C11H22O 170

1467 n-Hexadecanoic acid 1951 C16H32O2 256

1468 n-Tetradecanoic acid 1748 C14H28O2 228

1469 n-Dodecanoic acid 1554 C12H24O2 200

1470 n-Decanal 1180 C10H20O 156

1471 Axenol (Gleenol) 1574 C15H26O 222

1472 epi-Methyl jasmonate 1637 C13H20O3 224

1473 5-Ethylcyclopent-1-enecarbaldehyde 1010 C8H12O 124

1474 Methyl hexanoate 905 C7H14O2 130

1475 Methyl undecanoate 1400 C12H24O2 200

1476 Methyl dodecanoate 1500 C13H26O2 214

1477 Methyl tridecanoate 1600 C14H28O2 228

1478 Methyl myristoleate 1683 C15H28O2 240

1479 (Z)-Methyl pentadec-10-enoate 1786 C16H30O2 254

1480 Methyl palmitoleate 1877 C17H32O2 268

1481 (Z)-Methyl Heptadec-10-enoate 1978 C18H34O2 282

1482 Methyl heptadecanoate 2001 C17H34O2 270

1483 Methyl oleate 2082 C19H36O2 296

1484 Dihydroedulan 1290 C13H22O 194

1485 2-Methylbenzofuran 1149 C9H8O 132

1486 (all-Z)-Methyl Docosa- 2395 C23H34O2 342

4,7,10,13,16,19-hexaenoate

1487 (Z,Z)-Methyl docosa-13,16-dienoate 2433 C23H42O2 350

1488 Methyl erucate 2440 C23H44O2 352

1489 Methyl behenate 2459 C23H46O2 354

1490 Methyl tricosanoate 2558 C24H48O2 368

1491 Methyl nervonate 2650 C25H48O2 380

1492 (Z)-Methyl eicosa-11-enoate 2248 C21H40O2 324

1493 Methyl lignocerate 2695 C25H50O2 382

1494 Methyl arachidate 2306 C21H42O2 326

1495 Methyl heneicosanoate (C-21) 2412 C22H44O2 340

1496 Methyl stearate 2104 C19H38O2 298

1497 (all-Z)-Methyl eicosa-11,14-dienoate 2243 C22H40O2 336

1498 Methyl elaidate 2084 C19H36O2 296

1499 Methyl linolenate 2036 C19H32O2 292

1500 Methyl linoleate 2046 C19H34O2 294

1501 Methyl palmitate 1901 C17H34O2 270

1502 Methyl pentadecanoate 1796 C16H32O2 256

1503 Methyl myristate 1700 C15H30O2 242

1504 Methyl octanoate 1100 C91H8O2 158

1505 Methyl nonanoate 1208 C10H20O2 172

1506 Methyl decanoate 1300 C11H22O2 186

1507 (3Z,9E)-Isoligustilide 1824 C12H14O2 190

1508 (Z)-3-Butyliden-4,5,6,7- 1697 C12H16O2 192

tetrahydrophthalide

1509 Neophytadiene (Isomer 1) 1807 C20H38 278

1510 Neophytadiene (Isomer 2) 1830 C20H38 278

1511 Neophytadiene (Isomer 3) 1849 C20H38 278

1512 Eudesm-3-ene 6,7-oxide 1787 C15H24O 220

1513 Eudesma-3,7(11)-dien-8-one 1745 C15H22O 218

1514 5-Methylfurfural 941 C6H6O2 110

1515 g-Costol 1732 C15H24O 220

1516 a-Costol 1761 C15H24O 220

1517 b-Costol 1754 C15H24O 220

1518 Dehydrocostunolide 1956 C15H18O2 230

1519 Dihydrodehydrocostus lactone 1903 C15H20O2 232

1520 Eudesma-4(15),11-dien-8-one 1643 C15H22O 218

1521 (E)-15,16-Bisnorlabda-8(17),12- 2051 C18H28O 260

dien-14-al

1522 (E)-15,16-Bisnorlabda-8(17),11- 1958 C18H28O 260

dien-13-one

1523 Albicanol 1736 C16H28O 236

1524 g-Bicyclofarnesal 1656 C15H24O 220

1525 trans-6,6,10-Trimethyl-2-decalone 1505 C13H22O 194

1526 Coronarin E 2095 C20H28O 284

1527 10-Hydroxy-4-oplopanone 1708 C15H26O2 238

1528 Valerenic acid 1843 C15H22O2 234

1529 Vulgarone A 1580 C15H22O 218

1530 Artemisiatriene 923 C10H16 136

1531 2-Methylbutyl octanoate 1427 C13H26O2 214

1532 Hexyl hexanoate 1363 C12H24O2 200

1533 (E)-2-Decenal 1240 C10H18O 154

1534 2-methylbutyl hexanoate 1235 C11H22O2 186

1535 n-Hexyl 2-methylbutanoate 1220 C11H22O2 186

1536 n-Hexyl butanoate 1176 C10H20O2 172

1537 (E)-2-Heptenal 942 C7H12O 112

1538 Fenchyl acetate (Isomer) 1224 C12H20O2 196

1539 11-Nordrim-8-en-12-al 1609 C14H22O 206

1540 Undecanoic acid 1452 C11H22O2 186

1541 Allyl-2,4-di-acetoxybenzene 1592 C13H14O4 234

1542 n-Decane 993 C10H22 142

1543 n-Dodecane 1200 C12H26 170

1544 n-Tridecane 1300 C13H28 184

1545 n-Tetradecane 1392 C14H30 198

1546 n-Pentadecane 1500 C15H32 212

1547 n-Hexadecane 1600 C16H34 226

1548 n-Heptadecane 1700 C17H36 240

1549 n-Octadecane 1792 C18H38 254

1550 n-Eicosane (C-20) 2000 C20H42 282

1551 n-Heneicosane (C-21) 2100 C21H44 296

1552 n-Docosane (C-22) 2200 C22H46 310

1553 n-Tricosane (C-23) 2301 C23H48 324

1554 n-Tetracosane (C-24) 2400 C24H50 338

1555 n-Pentacosane (C-25) 2498 C25H52 352

1556 n-Hexacosane (C-26) 2598 C26H54 366

1557 Verbenene 982 C10H14 134

1558 trans-Chrysanthenyl acetate 1214 C12H18O2 194

1559 trans-Chrysanthenol 1096 C10H16O 152

1560 (Z)-2,6-Dimethylocta-1,5,7-trien-3- 1048 C10H16O 152

ol

1561 (E)-2,6-Dimethylocta-1,5,7-trien-3- 1058 C10H16O 152

ol

1562 Dihydrodiplophylline 1896 C15H22O2 234

1563 Diplophylline 1965 C15H20O2 232

1564 Ginsensene 1353 C15H24 204

1565 2-Methyl-2,5-divinyltetrahydrofuran 900 C9H14O 138

1566 5-Ethyl-2-methyl-2- 893 C9H16O 140

vinyltetrahydrofuran

1567 (all-E)-1,7-Dimethylcyclodeca- 1274 C12H18 162

1,4,7-triene

1568 Salviadienol 1545 C15H24O 220

1569 Torilenol 1599 C13H20O 192

1570 Betaer-13-ene 2040 C20H32 272

1571 Ethylbenzene 843 C8H10 106

1572 4-epi-11-Noraristola-9,11-diene 1399 C14H20 188

1573 4-epi-11-Noraristola-1,9,11-triene 1419 C14H18 186

1574 4-epi-11-Noraristola-1(10),11-diene 1409 C14H20 188

1575 4-Ethylguiacol 1257 C9H12O2 152

1576 2-Hydroxy-4-methoxyacetophenone 1294 C9H10O3 166

1577 4-Vinylanisol 1134 C9H10O 134

1578 p-Ethylanisol 1099 C9H12O 136

1579 1-Acetoxy-4-ethylbenzene 1238 C10H12O2 164

1580 Tetradecanal 1596 C14H28O 212

1581 4-Ethylphenol 1139 C8H10O 122

1582 Dehydropinguisenol 1800 C15H20O2 232

1583 Fusicocca-2,5-diene 2020 C20H32 272

1584 Crispatanolide 1760 C15H22O2 234

1585 (+)-Himachala-2,4-diene 1433 C15H24 204

1586 Polygodial 1839 C15H22O2 234

1587 9-epi-Polygodial 1960 C15H22O2 234

1588 Dihydrofrullanolide 1874 C15H22O2 234

1589 Eudesma-3,11-dien-8-one 1666 C15H22O 218

1590 5,8a-Dimethyl-3,4,4a,7,8,8a- 1464 C12H18O 178

hexahydro-1H-naphthalen-2-one

1591 8a-Hydroxyeudesma-3,11-diene 1668 C15H24O 220

1592 6,11-Epoxyeudesmane 1521 C15H26O 222

1593 Eudesma-5,7(11)-diene 1543 C15H24 204

1594 6b-Hydroxyeudesm-11-ene 1643 C15H26O 222

1595 6a-Hydroxyeudesm-11-ene 1598 C15H26O 222

1596 6,7-seco-Eudesm-7(11)-en-6-al 1615 C15H26O 222

1597 Ipsenol 1083 C10H18O 154

1598 Phytane 1808 C20H42 282

1599 Farnesane 1375 C15H32 212

1600 b-n-Octyl-g-butanolide 1655 C12H22O2 198

1601 Crocetane 1810 C20H42 282

1602 Pristane 1706 C19H40 268

1603 cis-Eudesma-4,11-dien-8-ol 1648 C15H24O 220

1604 Bisabola-1(6),2,10Z-trien-12-al 1733 C15H22O 218

1605 8,9-Epoxyselina-4,11-diene 1597 C15H22O 218

1606 Eudesma-4(15),11-dien-5-ol 1629 C15H24O 220

1607 cis-Eudesma-4(15),11-dien-5-ol 1623 C15H24O 220

1608 Pentadecanal 1702 C15H30O 226

1609 3-Methylbutanolide 909 C5H8O2 100

1610 2-n-Propyl-g-butanolide 1100 C7H12O2 128

1611 2-n-Pentyl-g-butanolide 1311 C9H16O2 156

1612 2-Ethylbutanolide 1000 C6H10O2 114

1613 2-Methylbutanolide 902 C5H8O2 100

1614 4-Allyl-g-butanolide 1090 C7H10O2 126

1615 d-Tetradecalactone 1893 C14H26O2 226

1616 d-Tridecanolide 1786 C13H24O2 212

1617 d-Dodecanolide 1675 C12H22O2 198

1618 g-n-Tetradecyl-g-butanolide 2720 C18H34O2 282

1619 d-Hexaolide 1044 C6H10O2 114

1620 N-2-[(4-Hydroxyphenyl)-ethyl]- 2325 C13H17O2N 219

tiglamide

1621 4-Hydroxy-b-ionone 1628 C13H20O2 208

1622 (E)-Megastigm-7-en-3,9-dione (t) 1572 C13H20O2 208

1623 a-Helmiscapene 1447 C15H24 204

1624 Methyl 2-(2-methylbutyroxy)-3- 1339 C12H22O4 230

methylpentanoate

1625 7,8-Dihydro-b-ionol 1431 C13H24O 196

1626 Dodecyl acetate 1585 C14H28O2 228

1627 (Z)-Heptadec-8-ene 1666 C17H34 238

1628 cis-Dracunculifolione 1500 C15H24O 220

1629 Italicen-13-ol 1670 C15H24O 220

1630 10-epi-cis-Dracunculifoliol 1533 C15H26O 222

1631 cis-Dracunculifoliol 1534 C15H26O 222

1632 trans-Dracunculifoliol 1581 C15H26O 222

1633 3-Hydroxy-b-ionone 1647 C13H20O2 208

1634 3-Hydroxy-5,6-dihydro-b-ionone 1609 C13H22O2 210

1635 (E)-b-Santalol 1680 C15H24O 220

1636 o-Cymene 976 C10H14 134

1637 Methyl 11-methyltridecanoate 1668 C15H30O2 242

1638 Libocedrol 2326 C22H30O4 358

1639 Aristol-1(10)-en-12-ol 1712 C15H24O 220

1640 Costunolide 1914 C15H20O2 232

1641 7-Hydroxyeudesm-4-en-6-one 1703 C15H24O2 236

1642 Aristol-1(10)-en-12-al 1704 C15H22O 218

1643 Methyl 10-methyldodecanoate 1575 C14H28O2 228

1644 Dotriacontane 3200 C32H66 450

1645 Eudesma-4(15),7(11),9-trien-12- 1971 C15H18O2 230

olide

1646 Isogermafurenolide 1867 C15H20O2 232

1647 Chloranthalactone A 1941 C15H16O2 228

1648 Ethyl decanoate 1375 C12H24O2 200

1649 Ethyl palmitate 1954 C18H36O2 284

1650 7,11-Epoxymegastigm-5-en-9-one 1551 C13H20O2 208

1651 Neoiso-isopulegol 1164 C10H18O 154

1652 b-Ionol 1400 C13H22O 194

1653 8-Hydroxylinalyl tiglate 1760 C15H24O3 252

1654 (Z)-Methyl 4-(geranyloxy)- 2334 C20H26O3 314

cinnamate

1655 (E)-Methyl 4-(geranyloxy)- 2461 C20H26O3 314

cinnamate

1656 Tetradecyl acetate 1775 C16H32O2 256

1657 Benzyl 3-methylbutyrate 1366 C12H16O2 192

1658 Benzyl 2-methylbutyrate 1360 C12H16O2 192

1659 Decanoic acid 1347 C10H20O2 172

1660 n-Octanoic acid 1156 C8H16O2 144

1661 Dihydromayurone 1591 C14H22O 206

1662 Ethyl hexadecanoate 1990 C18H36O2 284

1663 8-Hydroxylinalyl propionate 1551 C13H22O3 226

1664 4-Acetoxy-3-methoxyacetophenone 1434 C11H12O4 208

1665 o-Anisaldehyde 1202 C8H8O2 136

1666 2-Octanone 964 C8H16O 128

1667 (E)-trans-Bergamotol 1680 C15H24O 220

1668 Methyl 3-methylpentanoate 853 C7H14O2 130

1669 Methyl 3,7-dimethyloctanoate 1207 C11H22O2 186

1670 Methyl 4-methylhexanoate 974 C8H16O2 144

1671 Muurolan-4,7-oxide 1480 C15H26O 222

1672 cis-Totarol 2252 C20H30O 286

1673 4-Butyl-3-methyl-g-butanolide 1252 C9H16O2 156

1674 Isosaccogynol 1740 C15H22O 218

1675 Isosaccogynone 1744 C15H20O 216

1676 Taylorione 1617 C15H22O 218

1677 2-a-Acetoxy-11-methoxyamorpha- 1846 C18H28O3 292

4,7-diene

1678 2-a-Acetoxyamorpha-4,7(11)-dien- 1963 C17H24O3 276

8-one

1679 Neryl formate 1265 C11H18O2 182

1680 Geranyl butyrate 1534 C15H26O2 238

1681 Nerylpropionate 1451 C14H24O2 224

1682 Geranyl tiglate 1670 C15H24O2 236

1683 2-Methylbutyl angelate 1130 C10H18O2 170

1684 3-Methylbutyl angelate 1125 C10H18O2 170

1685 Methallyl angelate 1040 C9H14O2 154

1686 3-Methylbutyl methacrylate 1018 C9H16O2 156

1687 3-Methylbutyl isobutyrate 994 C9H18O2 158

1688 3-Methylpentyl isobutyrate 1095 C10H20O2 172

1689 3-Methylpentyl angelate 1230 C11H20O2 184

1690 Butyl angelate 1065 C9H16O2 156

1691 10-Acetoxy-4-oplopanone 1874 C17H28O3 280

1692 Butyl benzoate 1556 C11H14O2 178

1693 Propyl benzoate 1347 C10H12O2 164

1694 Phenylacetonitrile 1085 C8H7N 117

1695 Hexadecyl acetate 1847 C18H36O2 284

1696 Octadecyl acetate 2084 C20H40O2 312

1697 Octadecanal 2012 C18H36O 268

1698 Hexadecanal 1782 C16H32O 240

1699 Heptacosane 2700 C27H56 380

1700 Docosanal 2338 C22H44O 324

1701 cis-b-Elemene 1381 C15H24 204

1702 Eicosanal 2170 C20H40O 296

1703 1-Methyl-3-(2-oxopropyl)-4-(1- 1409 C13H20O 192

methylethenyl)-cyclohexene

1704 Ginsenol 1621 C15H26O 222

1705 4-n-Propylanisol 1254 C10H14O 150

1706 n-Decyl acetate 1390 C12H24O2 200

1707 Dimethyl-tetrasulfide 1181 C2H6S4 158

1708 Dimethyl trisulfide 942 C2H6S3 126

1709 S,S-Dimethyl dithiocarbonate 935 C3H6OS2 122

1710 2,5-Diethyltetrahydrofuran 875 C8H16O 128

1711 Neoiso-isopulegol acetate 1366 C12H20O2 196

1712 Methyl 2-hydroxy-4-methoxy-6- 1555 C10H12O4 196

methylbenzoate

1713 1-Octen-3-yl 3-methylbutyrate 1315 C13H24O2 212

1714 1-Octen-3-yl 2-methylbutyrate 1310 C13H24O2 212

1715 Oct-1-en-3-yl butyrate 1266 C12H22O2 198

1716 1-Octen-3-yl isobutyrate 1223 C12H22O2 198

1717 l-Octen-3-yl propanoate 1181 C11H20O2 184

1718 14-Hydroxy-4,5-dihydro-b- 1692 C15H26O 222

caryophyllene

1719 14-Hydroxy-b-caryophyllene 1656 C15H24O 220

1720 4,5-Dihydro-b-caryophyllen-14-al 1610 C15H24O 220

(Isomer 1)

1721 4,5-Dihydro-b-caryophyllen-14-al 1621 C15H24O 220

(Isomer 2)

1722 4-Desmethylcaryophyll-8(14)-en-5- 1521 C14H22O 206

one

1723 Isocaryophyllen-14-al (b-Betulenal) 1630 C15H22O 218

1724 1-Angeloyloxyverbenone 1694 C15H20O3 248

1725 4-Hydroxy-2-methylacetophenone 1254 C9H10O2 150

1726 7-epi-1,2-Dehydrosesquicineole 1460 C15H24O 220

1727 1,2-Dimethoxybenzene (Veratrol) 1117 C8H10O2 138

1728 (E)-Isoelemicin 1614 C12H16O3 208

1729 (Z)-Isoelemicin 1559 C12H16O3 208

1730 1,2,4-Trimethoxybenzene 1330 C9H12O3 168

1731 p-Menth-1-en-9-al (Isomer 1) 1188 C10H16O 152

1732 p-Menth-1-en-9-al (Isomer 2) 1190 C10H16O 152

1733 (Methoxymethyl)-benzene 964 C8H10O 122

1734 1,4-Dimethoxybenzene 1132 C8H10O2 138

1735 6,10,14-Trimethylpentadecan-2-one 1817 C18H36O 268

1736 (Z)-a-Damascone 1343 C13H20O 192

1737 Lilac alcohol (2R,2′R,5′S) 1210 C10H18O2 170

1738 Lilac alcohol (2R,2′S,5′S)) 1196 C10H18O2 170

1739 Lilac alcohol (2S,2′S,5′S) 1185 C10H18O2 170

1740 Lilac aldehyde (2R,2′R,5′S) 1146 C10H16O2 168

1741 Lilac aldehyde (2R,2′S,5′S) 1133 C10H16O2 168

1742 Lilac aldehyde (2S,2′S,5′S) 1124 C10H16O2 168

1743 Methyl citronellate 1245 C11H20O2 184

1744 Myli-4(15)-ene 1418 C15H22 202

1745 Maali-4(15)-en-1-ol 1624 C15H24O 220

1746 (E)-Taylopyran 1530 C15H22O 218

1747 7-epi-Bourbon-3-ene 5,11-oxide 1473 C15H22O 218

1748 Mylian-3-one 1593 C15H22O 218

1749 Myli-4(15)-en-3-one 1610 C15H20O 216

1750 5,5-Dimethyl-1-vinylbicyclo- 931 C10H16 136

[2.1.1] hexane

1751 Cara-2,4-diene 900 C10H14 134

1752 Eudesm-4(15)en-6-one 1616 C15H24O 220

1753 Eudesm-4-en-6-one 1605 C15H24O 220

1754 Guaia-3,9-diene 5,11-oxide 1519 C15H22O 218

1755 Guaia-3,10(14)-diene 5,11-oxide 1555 C15H22O 218

1756 3-Ethylacetophenone 1260 C10H12O 148

1757 4-Ethylacetophenone 1240 C10H12O 148

1758 (6Z,8E)-Megastigma-4,6,8-trien-3- 1553 C13H18O 190

one

1759 (E,E)-Megastigma-4,6,8-trien-3-one 1598 C13H18O 190

1760 Aromadendra-1(10),4(15)-diene 1506 C15H22 202

1761 Perfora-1,7-diene 1543 C15H24 204

1762 Guaia-1(10),11-diene 1516 C15H24 204

1763 Guaia-9,11-diene 1522 C15H24 204

1764 Norpinguisone 1600 C14H18O2 218

1765 Methyl norpinguisonate 1776 C15H18O4 262

1766 Bisabola-1,3,5,7(14)-tetraene 1484 C15H22 202

1767 Lemnalone 1611 C15H22O 218

1768 Methyl 2,4-Dimethoxy-6- 1588 C11H14O4 210

methylbenzoate

1769 Methyl 6-Methoxy-2-methyl-3,4- 1661 C11H12O5 224

methylendioxybenzoate

1770 Methyl 6-Hydroxy-2-methyl-3,4- 1640 C10H10O5 210

methylendioxybenzoate

1771 Methyl 3,4,6-trimethoxy-2- 1705 C12H16O5 240

methylbenzoate

1772 4-Methoxyphenylacetaldehyde 1255 C9H10O2 150

1773 Aromadendra-4,9-diene 1534 C15H22 202

1774 Aromadendra-1(10),4-diene 1462 C15H22 202

1775 Aromadendra-4,10(14)-diene 1440 C15H22 202

1776 5,6-Dihydro-1,4-dimethylazulene 1428 C12H14 158

1777 3,4,5,6-Tetrahydro-1,4- 1246 C12H16 160

dimethylazulene

1778 2,3,3a,4,5,6-Hexahydro-1,4- 1447 C12H18O 178

dimethylazulen-3-ol

1779 3a-Acetoxyamorpha-4,7(11)-diene 1780 C17H26O2 262

1780 Amorpha-2,4,7(11)-triene 1449 C15H22 202

1781 Amorpha-4,7(11)-dien-2-one 1645 C15H22O 218

1782 2a-Acetoxyamorpha-4,7(11)-diene 1796 C17H26O2 262

1783 2b-Acetoxyamorpha-4,7(11)-diene 1722 C17H26O2 262

1784 9a-Hydroxyamorpha-4,7(11)-diene 1680 C15H24O 220

1785 7b-Hydroxyamorpha-4,11-diene 1615 C15H24O 220

1786 3a-Hydroxyamorpha-4,7(11)-diene 1665 C15H24O 220

1787 Amorpha-4,7(11)-dien-3-one 1677 C15H22O 218

1788 Eudesma-4,11-dien-9-one 1649 C15H22O 218

1789 2,8-Epoxyamorpha-4,7(11)-diene 1597 C15H22O 218

1790 5,9-Epoxyamorpha-3,7(11)-diene 1594 C15H22O 218

1791 n-Tridecanal 1493 C13H26O 198

1792 (E)-Non-2-en-4-one 306 1098 C9H16O 140

1793 (E)-3-Methylnon-2-en-4-one 1190 C10H18O 154

1794 Isotheaspirane (Isomer 1) 1263 C13H22O 194

1795 Isotheaspirane (Isomer 1) 1279 C13H22O 194

1796 Chiloscyphone 1576 C15H22O 218

1797 2-Hydroxy-3,5-dimethoxy-9,10- 2251 C16H16O3 256

dihydrophenanthrene

1798 4,5-Dihydroxy-3-methoxy-9,10- 2330 C15H14O3 242

dihydrophenanthrene

1799 Isozierene 1556 C15H22 202

1800 Isogermacrene A 1502 C15H24 204

1801 Iso-b-elemene 1359 C15H24 204

1802 n-Decyl butanoate 1567 C14H28O2 228

1803 g-Palmitolactone 2081 C16H30O2 254

1804 n-Octyl butanoate 1371 C12H24O2 200

1805 Benzyl butanoate 1313 C11H14O2 178

1806 n-Butyl butyrate 970 C8H16O2 144

1807 n-Heptyl butanoate 1270 C11H22O2 186

1808 2-Phenylethyl butyrate 1412 C12H16O2 192

1809 Ethyl 2-phenylhexanoate 1617 C14H20O2 220

1810 Methyl 4-hydroxybenzoate 1414 C8H8O3 152

1811 n-Propyl 4-hydroxybenzoate 1584 C10H12O3 180

1812 n-Octyl hexanoate 1567 C14H28O2 228

1813 11-b-Hydroxykauren-15-a-yl acetate 2459 C22H34O3 346

1814 a-Campholenic acid 1304 C10H16O2 168

1815 5-Acetoxybornan-2-one 1399 C12H18O3 210

1816 n-Heptadecanal 1908 C17H34O 254

1817 Ventricos-7(13)-ene 1357 C15H24 204

1818 Helminthogermacrene 1503 C15H24 204

1819 allo-Aromadendra-4(15),10(14)- 1457 C15H22 202

diene

1820 Methyl 3-phenylpropanoate 1242 C10H12O2 164

1821 Nepetalactone (Isomer 1) 1331 C10H14O2 166

1822 (all-E)-Geranylcitronellol 2160 C20H36O 292

1823 Cyclooctatetraene 837 C8H8 104

1824 4-(4-Hydroxyphenyl)-butan-2-ol 1518 C10H14O2 166

1825 Lowry's phenol 1684 C12H16O4 224

1826 Platyphyllol 1588 C12H16O4 224

1827 Eugenitine 1944 C12H12O4 220

1828 Isoeugenitine 1963 C12H12O4 220

1829 Dihydrocolumellarine 1889 C15H22O2 234

1830 Myltaylenol 1727 C15H24O 220

1831 a-Gorgonene 1490 C15H24 204

1832 Aromadendra-4(15),10(14)dien-1- 1579 C15H22O 218

ol

1833 10-epi-Dihydroagarofuran 1520 C15H26O 222

1834 3,7-Dimethyl-3,7-dihydroxyoct-1- 1198 C10H20O2 172

ene

1835 Agarospirol 1635 C15H26O 222

1836 10a-Hydroxy-12-prenylguai-11-ene 2111 C20H34O 290

1837 5-Formyl-2-hydroxy-(3- 1617 C12H14O3 206

methylbutyro)-phenone

1838 4-Hydroxybenzaldehyde 1316 C7H6O2 122

1839 1,3,5-Trimethyl-1,3,5-triazin-2,4,6- 1327 C6H9O3N3 171

trione

1840 5-Formyl-2-hydroxy-(3-hydroxy-3- 1660 C12H14O4 222

methylbutyro)-phenone

1841 Octadecanoic acid 2182 C18H36O2 284

1842 Longipinanol, high temp. 1563 C15H26O 222

1843 Artemiseol 970 C10H16O 152

1844 a-Cyclocitral 1103 C10H16O 152

1845 (3E,5Z)-Undeca-1,3,5-triene (Isomer 1133 C11H18 150

2)

1846 Undeca-1,3,5-triene (Isomer 1) 1117 C11H18 150

1847 4-(4-Methoxyphenyl)-butan-2-one 1453 C11H14O2 178

1848 Atranol 1511 C8H8O3 152

1849 Chloroatranol 1466 C8H703Cl 186

1850 Myrtenyl methyl ether 1145 C11H18O 166

1851 8,14-Cedrane oxide 1536 C15H24O 220

1852 Camphene hydrate 1143 C10H18O 154

1853 6-Camphenone 1082 C10H14O 150

1854 Desmethoxyencecalin 1617 C13H14O2 202

1855 Bisabola-1,3,5,7-tetraene 1554 C15H22 202

1856 Myltayl-4-ene 1383 C15H24 204

1857 Gorgon-11-en-4-ol 1617 C15H26O 222

1858 a-Taylorione 1586 C15H22O 218

1859 Taylocyclan 1477 C15H22O 218

1860 Taynudol 1709 C15H22O 218

1861 Taylofuran 1635 C15H24O2 236

1862 3-Acetoxytaylorione 1918 C17H24O3 276

1863 Copalol 2265 C20H34O 290

1864 3a-Acetoxybicyclogermacrene 1769 C17H26O2 262

1865 Plagiooxide 1420 C15H26O 222

1866 Gymnomitr-3(15)-en-5b-ol 1653 C15H24O 220

1867 5b-Acetoxy-gymnomitr-3(15)-ene 1758 C17H26O2 262

1868 4b,5b-Diacetoxygymnomitr-3(15)- 1943 C19H28O4 320

ene

1869 15-Acetoxygymnomitr-3-ene 1797 C17H26O2 262

1870 3,15-b-Epoxy-4b- 1875 C17H26O3 278

acetoxygymnomitrane

1871 3,15-a-Epoxy-4b- 1887 C17H26O3 278

acetoxygymnomitrane

1872 Iso-a-humulene 1474 C15H24 204

1873 cis-Anethol 1230 C10H12O 148

1874 Cadina-4,11-dien-15-al 1704 C15H22O 218

1875 Cadina-4,11-dien-15-ol 1713 C15H26O 222

1876 a-Barbatenal 1659 C15H22O 218

1877 15-Nor-3-gymnomitrone 1609 C14H22O 206

1878 Bergaptene 2023 C12H8O4 216

1879 Peucedanin 2243 C15H14O4 258

1880 syn-Copalol 2165 C20H34O 290

1881 Melanene 1455 C15H24 204

1882 Panaxene 1312 C15H24 204

1883 Panaginsene 1336 C15H24 204

1884 Iso-g-bisabolene 1523 C15H24 204

1885 Viscida-4,9,14-triene 1862 C20H32 272

1886 Trichodiene 1523 C15H24 204

1887 2-Methyl-3-(4-methoxyphenyl)- 1324 C11H14O 162

prop-2-ene

1888 Gymnomitr-3(15)-en-12-oic acid 1790 C15H22O2 234

1889 12-Acetoxygymnomitr-3(15)-ene 1795 C17H26O2 262

1890 Gymnomitr-3(15)-en-12-al 1627 C15H22O 218

1891 Scapanol 1586 C15H26O 222

1892 Hydroxycitronellal 1263 C10H20O2 172

1893 2-(2-Ethoxyethoxy)-ethanol 985 C6H14O3 134

1894 Di-(2-hydroxypropyl)-ether 1003 C6H14O3 134

1895 Benzyl propionate 1231 C10H12O2 164

1896 2-Methyl-3-(4-isopropylphenyl)- 1433 C13H18O 190

propanal

1897 (Z)-b-Curcumen-12-ol 1732 C15H24O 120

1898 (Z)-b-Phenylethyl cinnamate 2006 C17H16O2 152

1899 (E)-b-Phenylethyl cinnamate 1123 C17H16O2 252

1900 Phenylethyl benzoate 1815 C15H14O2 126

1901 Phenyl ethyl phenylacetate 1868 C16H16O2 240

1902 Phenyl ethyl propionate 1468 C11H14O2 178

1903 2-(4-Methoxyphenyl)-5-methoxy- 2237 C16H16O3 256

2,3-dihydrobenzo[b]furan

1904 (Z)-Coriandrin 1234 C12H15ONS2 153

1905 (Z)-Coridrin 1708 C10H9ONS 191

1906 (E)-Coridrin 1784 C10H9ONS 191

1907 2-Methylene-6,6-dimethylcyclohex- 1092 C10H14O 150

3-ene-1-carbaldehyde

1908 1-p-Menthan-8-thiol 1196 C10H20S 172

1909 1-p-Menthen-8-thiol 1279 C10H18S 170

1910 5,5-Dimethylcyclohex-2-en-1,4- 1002 C8H10O2 138

dione

1911 Neoisomenthol 1176 C10H20O 156

1912 Menth-2-en-1,4-diol 1269 C10H18O2 170

1913 Carvone hydrate 1388 C10H16O2 168

1914 Carvone hydrate acetate 1528 C12H18O3 210

1915 8-Hydroxylinalyl isobutyrate 1588 C14H24O3 240

1916 Lyral 1637 C13H22O2 210

1917 Lyral (Isomer) 1625 C13H22O2 210

1918 2-(4-tert-butylbenzyl)-propione 1501 C14H20O 204

aldehyde

1919 Methyl 2-octynoate 1177 C9H14O2 154

1920 Caparapidiol 1686 C15H28O2 240

1921 Jaeschkeanadiol 1754 C15H26O2 238

1922 2,8-Epithio-cis-p-menthane 1242 C10H18S 170

1923 Gorgona-1,4(15),11-triene 1426 C15H22 202

1924 Aromadendra-1(10),3-diene 1509 C15H22 202

1925 8-Hydroxylinalyl 2-methylbutyrate 1688 C15H26O3 254

1926 trans-Pinane 951 C10H18 138

1927 4b-Acetoxygymnomitr-3(15)-ene 1739 C17H26O2 262

1928 1,8-Dimethyl-3-ethyl-2,9- 1344 C11H16O3 196

dioxabicyclo[3.3.1]non-7-en-6-one

1929 2,6-Diethyl-2,3-dihydro-4H-pyran- 1221 C9H14O2 154

4-one

1930 Frontaline 907 C8H14O2 142

1931 endo-Brevicomin 1039 C9H16O2 156

1932 cis-Pinane 963 C10H18 138

1933 Chalcograne (Isomer 1) 1051 C9H16O 140

1934 Chalcograne (Isomer 2) 1055 C9H16O 140

1935 Lineatine 1102 C10H16O2 168

1936 Methyl n-propyl trisufide 1121 C4H10S3 154

1937 (E)n-Propyl 1-propenyl disulfide 1063 C6H12S2 148

1938 Di-n-propyl trisulfide 1302 C6H14S3 182

1939 Methyl n-propyl disulfide 900 C4H10S2 122

1940 Di-n-propyl disulfide 1081 C6H14S2 150

1941 Di-n-propyl tetrasulfide 1558 C6H14S4 214

1942 5-Pentyl-3,4,5-trimethyl-5H-furan-2- 1474 C12H20O2 196

one

1943 Plagiochilline T 1665 C15H20O 216

1944 Plagiochilline U 1625 C15H22O 218

1945 5-Methylcyclohex-2-en-1-one 935 C7H10O 110

1946 3-Ethylcyclohexanone 1020 C8H14O 126

1947 Methyl 3-ethyl-4-methylpentanoate 1021 C9H18O2 158

1948 2,4-Diethyloct-1-ene 1106 C12H24 168

1949 Methyl trans-Dihydrojasmonate 1623 C13H22O3 226

1950 cis-Methyl dihydrojasmonate 1651 C13H22O3 226

1951 1,7-Dioxaspiro[5.5]undecane 1108 C9H16O2 156

1952 (2Z,4E)-Methyl abscisate 2076 C16H22O4 278

1953 (2Z,4E)-Methyl phaseate 2141 C16H22O5 294

1954 (2E,4E)-Methyl abscisate 2164 C16H22O4 278

1955 Pityol 945 C8H16O2 144

1956 6-Ethyl-2-methyl-2,3-dihydro-4H- 1117 C8H12O2 140

pyran-2-one

1957 n-Nonyl acetate 1283 C11H22O2 186

1958 4-epi-Maaliol 1549 C15H26O 222

1959 Plagiochiline H 1807 C17H24O3 276

1960 5-Methyloctahydrofuro [3,2- 1028 C9H16O2 156

b]oxepine

1961 Methyl 2-hydroxyhexanoate 993 C7H14O3 146

1962 Methyl 2-hydroxytetradecanoate 1838 C15H30O3 258

1963 Seudenol 941 C7H12O 112

1964 2,8-Dimethyl-1,7- 1121 C11H20O2 184

dioxaspiro[5.5]undecane (Isomer 1)

1965 2,8-Dimethyl-1,7- 1189 C11H20O2 184

dioxaspiro[5.5]undecane (Isomer 2)

1966 4-Methyl-2-buten-4-olide 869 C5H6O2 98

1967 Methyl 2-methyltetradecanoate 1758 C16H32O2 256

1968 Methyl 3-methylpentanoate 840 C7H14O2 130

1969 Methyl 2-methylundecanoate 1509 C13H26O2 214

1970 Methyl 2-methyldodecanoate 1550 C14H28O2 228

1971 Methyl 2-hydroxyisopentanoate 845 C6H12O3 132

1972 Methyl 2-hydroxypentanoate 894 C6H12O3 132

1973 4a-Methyloctahydronaphthalen-2- 1369 C11H18O 166

one

1974 Methyl madelate 1245 C9H10O3 166

1975 Methyl 2-hydroxydodecanoate 1627 C13H26O3 230

1976 1-Phenylethanol 1037 C8H10O 122

1977 2,3,5-Trimethylvalerolactone 1158 C8H14O2 142

1978 10-Methyldecalin-2,7-dione 1520 C11H16O2 180

1979 6-Hexyl-5,6-dihydropyran-2-one 1551 C11H18O2 182

1980 Methyl 2-methylpentadecanoate 2195 C17H34O2 270

1981 2,3-Epoxycinnamyl alcohol 1309 C9H10O2 150

1982 Methyl 2-methylhexadecanoate 1972 C18H36O2 284

An exemplary therapeutic compound conforming with any of the disclosed embodiments may comprise for instance a compound including at least two of delta-9-tetrahydrocannabinol or tetrahydrocannabinolic acid, and cannabidiol and optionally at least one of the listed terpenes Still further an exemplary therapeutic compound conforming with any of the disclosed embodiments may comprise for instance a compound including 20 mg of delta-9-tetrahydrocannabinol and 10 mg of cannabidiol preferably administered every δ-8 hours as needed. Still further an exemplary therapeutic compound conforming with any of the disclosed embodiments may comprise for instance a compound including 10 mg of delta-9-tetrahydrocannabinol and 5 mg of cannabidiol preferably administered every δ-8 hours as needed. Still further an exemplary therapeutic compound conforming with any of the disclosed embodiments may comprise for instance a compound including 20 mg of delta-9-tetrahydrocannabinol and 20 mg of cannabidiol preferably administered every δ-8 hours as needed. Still further an exemplary therapeutic compound conforming with any of the disclosed embodiments may comprise for instance a compound including 10 mg of delta-9-tetrahydrocannabinol and 10 mg of cannabidiol preferably administered every δ-8 hours as needed. Still further an exemplary therapeutic compound conforming with any of the disclosed embodiments may comprise for instance a compound including 15 mg of delta-9-tetrahydrocannabinol and 10 mg of cannabidiol preferably administered every δ-8 hours as needed.

Further, enumerated embodiments are described below.

•

• Embodiment 1. A pharmaceutical composition comprising: (a) tetrahydrocannabinol (THC) and cannabidiol (CBD) in a THC:CBD ratio of from 1:1.5 to 3:1 by weight; and (b) one or more terpenes listed in Table 1. • Embodiment 2. The pharmaceutical composition of embodiment 1, wherein the THC:CBD ratio is about: 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2:1, 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, or 3:1. • Embodiment 3. The pharmaceutical composition of embodiment 1, wherein the THC:CBD ratio is from 1.5:1 to 2:1. • Embodiment 4. The pharmaceutical composition of embodiment 1, wherein the THC:CBD ratio is about 1.5:1. • Embodiment 5. The pharmaceutical composition of any one of embodiments 1-4, wherein the pharmaceutical composition comprises: 1-50 mg, 5-40 mg, 7.5-30 mg, 10-20 mg, or 12.5-17.5 mg tetrahydrocannabinol (THC) per dose. • Embodiment 6. The pharmaceutical composition of any one of embodiments 1-4, wherein the pharmaceutical composition comprises about: 1 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg tetrahydrocannabinol (THC) per dose. • Embodiment 7. The pharmaceutical composition of any one of embodiments 1-4, wherein the pharmaceutical composition comprises about 10-20 mg tetrahydrocannabinol (THC) per dose. • Embodiment 8. The pharmaceutical composition of any one of embodiments 1-4, wherein the pharmaceutical composition comprises about 15-20 mg tetrahydrocannabinol (THC) per dose. • Embodiment 9. The pharmaceutical composition of any one of embodiments 1-8, wherein the pharmaceutical composition comprises: 1-35 mg, 2.5-30 mg, 5-25 mg, δ-14 mg, 10-12 mg cannabidiol (CBD) per dose. • Embodiment 10. The pharmaceutical composition of any one of embodiments 1-8, wherein the pharmaceutical composition comprises about: 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, or 30 mg cannabidiol (CBD) per dose. • Embodiment 11. The pharmaceutical composition of any one of embodiments 1-8, wherein the pharmaceutical composition comprises δ-14 mg cannabidiol (CBD). • Embodiment 12. The pharmaceutical composition of any one of embodiments 1-8, wherein the pharmaceutical composition comprises 10-12 mg cannabidiol (CBD). • Embodiment 13. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, α-humulene, linalool, p-cymene, camphene, cis-nerolidol, terpinolene, isopulegol, caryophyllene oxide, δ-limonene, geraniol, guaiol, α-bisabolol, 3-carene, β-pinene, γ-terpinene, or a combination thereof. • Embodiment 14. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, α-humulene, linalool, p-cymene, and camphene. • Embodiment 15. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, and α-humulene. • Embodiment 16. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, ocimene, cis-nerolidol, terpinolene, isopulegol, caryophyllene oxide, δ-limonene, geraniol, guaiol, and α-bisabolol. • Embodiment 17. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, ocimene, cis-nerolidol, terpinolene, isopulegol, caryophyllene oxide, δ-limonene, geraniol, guaiol, α-bisabolol, and 3-carene. • Embodiment 18. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-humulene, linalool, p-cymene, camphene, 3-carene, R-pinene, and γ-terpinene. • Embodiment 19. The pharmaceutical composition of any one of embodiments 1-12, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, α-humulene, linalool, ρ-cymene, camphene, 3-carene, β-pinene, and γ-terpinene. • Embodiment 20. The pharmaceutical composition of any one of embodiments 1-19, wherein the one or more terpenes comprise β-myrcene, and wherein the pharmaceutical composition comprises 1-100 mg, 20-80 mg, 30-60 mg, 40-50 mg, 1-10 mg, 1.5-7.5 mg, or 2-5 mg of β-myrcene per dose. • Embodiment 21. The pharmaceutical composition of any one of embodiments 1-19, wherein the one or more terpenes comprise β-myrcene, and wherein the pharmaceutical composition comprises about: 1 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg, 3 mg, 3.1 mg, 3.2 mg, 3.3 mg, 3.4 mg, 3.5 mg, 3.6 mg, 3.7 mg, 3.8 mg, 3.9 mg, 4 mg, 4.5 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of β-myrcene per dose. • Embodiment 22. The pharmaceutical composition of any one of embodiments 1-19, wherein the one or more terpenes comprise β-myrcene, and wherein the pharmaceutical composition comprises about: 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, or 60 mg of β-myrcene per dose. • Embodiment 23. The pharmaceutical composition of any one of embodiments 1-19, wherein the one or more terpenes comprise β-myrcene, and wherein the pharmaceutical composition comprises 1.5-7.5 mg of β-myrcene per dose. • Embodiment 24. The pharmaceutical composition of any one of embodiments 1-19, wherein the one or more terpenes comprise β-myrcene, and wherein the pharmaceutical composition comprises 30-60 mg of β-myrcene per dose. • Embodiment 25. The pharmaceutical composition of any one of embodiments 1-24, wherein the one or more terpenes comprise β-caryophyllene, and wherein the pharmaceutical composition comprises 1-20 mg, 2-10 mg, 2.5-5 mg, or 3-8 mg of β-caryophyllene per dose. • Embodiment 26. The pharmaceutical composition of any one of embodiments 1-24, wherein the one or more terpenes comprise β-caryophyllene, and wherein the pharmaceutical composition comprises about 1 mg, 1.5 mg, 2 mg, 2.25 mg, 2.5 mg, 2.75 mg, 3 mg, 3.1 mg, 3.2 mg, 3.3 mg, 3.4 mg, 3.5 mg, 3.6 mg, 3.7 mg, 3.8 mg, 3.9 mg, 4 mg, 4.25 mg, 4.5 mg, 4.75 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 7.6 mg, 8 mg, 9 mg, 10 mg, 12.5 mg, 15 mg, or 20 mg of β-caryophyllene per dose. • Embodiment 27. The pharmaceutical composition of any one of embodiments 1-24, wherein the one or more terpenes comprise β-caryophyllene, and wherein the pharmaceutical composition comprises 2.5-5 mg of β-caryophyllene per dose. • Embodiment 28. The pharmaceutical composition of any one of embodiments 1-27, wherein the one or more terpenes comprise ocimene, and wherein the pharmaceutical composition comprises 1-20 mg, 2-10 mg, 2.3-4.7 mg, or 3-8 mg of ocimene per dose. • Embodiment 29. The pharmaceutical composition of any one of embodiments 1-27, wherein the one or more terpenes comprise ocimene, and wherein the pharmaceutical composition comprises about 1 mg, 1.1 mg, 1.5 mg, 2 mg, 2.1 mg, 2.3 mg, 2.5 mg, 2.75 mg, 3 mg, 3.1 mg, 3.2 mg, 3.3 mg, 3.4 mg, 3.5 mg, 3.6 mg, 3.7 mg, 3.8 mg, 3.9 mg, 4 mg, 4.2 mg, 4.5 mg, 4.7 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 7.6 mg, 8 mg, 9 mg, 10 mg, 12.5 mg, 15 mg, or 20 mg of ocimene per dose. • Embodiment 30. The pharmaceutical composition of any one of embodiments 1-27, wherein the one or more terpenes comprise ocimene, and wherein the pharmaceutical composition comprises 2.3-4.7 mg of ocimene per dose. • Embodiment 31. The pharmaceutical composition of any one of embodiments 1-30, wherein the one or more terpenes comprise α-pinene, and wherein the pharmaceutical composition comprises 0.1-10 mg, 0.5-5 mg, or 1.1-2.1 mg of α-pinene per dose. • Embodiment 32. The pharmaceutical composition of any one of embodiments 1-30, wherein the one or more terpenes comprise α-pinene, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.75 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 7.5 mg, or 10 mg of α-pinene per dose. • Embodiment 33. The pharmaceutical composition of any one of embodiments 1-30, wherein the one or more terpenes comprise α-pinene, and wherein the pharmaceutical composition comprises 1.1-2.1 mg of α-pinene per dose. • Embodiment 34. The pharmaceutical composition of any one of embodiments 1-33, wherein the one or more terpenes comprise α-humulene, and wherein the pharmaceutical composition comprises 0.1-5 mg, 0.5-3.5 mg, or 0.8-1.6 mg of α-humulene per dose. • Embodiment 35. The pharmaceutical composition of any one of embodiments 1-33, wherein the one or more terpenes comprise α-humulene, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg, 3 mg, 3.1 mg, 3.2 mg, 3.5 mg, 4 mg, 4.5 mg, or 5 mg of α-humulene per dose. • Embodiment 36. The pharmaceutical composition of any one of embodiments 1-33, wherein the one or more terpenes comprise α-humulene, and wherein the pharmaceutical composition comprises 0.8-1.6 mg of α-humulene per dose. • Embodiment 37. The pharmaceutical composition of any one of embodiments 1-36, wherein the one or more terpenes comprise linalool, and wherein the pharmaceutical composition comprises 0.1-2 mg, 0.2-1.5 mg, or 0.3-0.9 mg of linalool per dose. • Embodiment 38. The pharmaceutical composition of any one of embodiments 1-36, wherein the one or more terpenes comprise linalool, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, or 2 mg of linalool per dose. • Embodiment 39. The pharmaceutical composition of any one of embodiments 1-36, wherein the one or more terpenes comprise linalool, and wherein the pharmaceutical composition comprises 0.3-0.9 mg of linalool per dose. • Embodiment 40. The pharmaceutical composition of any one of embodiments 1-39, wherein the one or more terpenes comprise p-cymene, and wherein the pharmaceutical composition comprises 0.1-20 mg, 0.25-10 mg, 5-10 mg, or 0.5-0.9 mg of p-cymene per dose. • Embodiment 41. The pharmaceutical composition of any one of embodiments 1-39, wherein the one or more terpenes comprise p-cymene, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 6.75 mg, 7 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 8 mg, 9 mg, 10 mg, 12.5 mg, 15 mg or 20 mg of p-cymene per dose. • Embodiment 42. The pharmaceutical composition of any one of embodiments 1-39, wherein the one or more terpenes comprise p-cymene, and wherein the pharmaceutical composition comprises 0.5-0.9 mg of p-cymene per dose. • Embodiment 43. The pharmaceutical composition of any one of embodiments 1-42, wherein the one or more terpenes comprise camphene, and wherein the pharmaceutical composition comprises 0.01-2 mg, 0.02-1 mg, 0.03-0.5 mg, or 0.05 to 0.15 mg of camphene per dose. • Embodiment 44. The pharmaceutical composition of any one of embodiments 1-42, wherein the one or more terpenes comprise camphene, and wherein the pharmaceutical composition comprises about 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 1.25 mg, 1.5 mg, 1.75 mg, or 2 mg of camphene per dose. • Embodiment 45. The pharmaceutical composition of any one of embodiments 1-42, wherein the one or more terpenes comprise camphene, and wherein the pharmaceutical composition comprises 0.05-0.15 mg of camphene per dose. • Embodiment 46. The pharmaceutical composition of any one of embodiments 1-45, wherein the one or more terpenes comprise cis-nerolidol, and wherein the pharmaceutical composition comprises 0.5-20 mg, 1-10 mg, or 1.5 to 5 mg of cis-nerolidol per dose. • Embodiment 47. The pharmaceutical composition of any one of embodiments 1-45, wherein the one or more terpenes comprise cis-nerolidol, and wherein the pharmaceutical composition comprises about 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.25 mg, 2.5 mg, 3 mg, 4 mg, 4.5 mg, 4.8 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg 10 mg, 15 mg, or 20 mg of cis-nerolidol per dose. • Embodiment 48. The pharmaceutical composition of any one of embodiments 1-45, wherein the one or more terpenes comprise cis-nerolidol, and wherein the pharmaceutical composition comprises 1.5-5 mg of cis-nerolidol per dose. • Embodiment 49. The pharmaceutical composition of any one of embodiments 1-48, wherein the one or more terpenes comprise terpinolene, and wherein the pharmaceutical composition comprises 0.5-10 mg, 1-5 mg, or 1.2 to 3 mg of terpinolene per dose. • Embodiment 50. The pharmaceutical composition of any one of embodiments 1-48, wherein the one or more terpenes comprise terpinolene, and wherein the pharmaceutical composition comprises about 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.25 mg, 2.5 mg, 3 mg, 4 mg, 4.5 mg, 4.8 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg 10 mg, 15 mg, or 20 mg of terpinolene per dose. • Embodiment 51. The pharmaceutical composition of any one of embodiments 1-48, wherein the one or more terpenes comprise terpinolene, and wherein the pharmaceutical composition comprises 1.2-3 mg of terpinolene per dose. • Embodiment 52. The pharmaceutical composition of any one of embodiments 1-51, wherein the one or more terpenes comprise isopulegol, and wherein the pharmaceutical composition comprises 0.1-5 mg, 0.5-3.5 mg, or 0.8 to 2.3 mg of isopulegol per dose. • Embodiment 53. The pharmaceutical composition of any one of embodiments 1-51, wherein the one or more terpenes comprise isopulegol, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.3 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 4.8 mg, or 5 mg of isopulegol per dose. • Embodiment 54. The pharmaceutical composition of any one of embodiments 1-51, wherein the one or more terpenes comprise isopulegol, and wherein the pharmaceutical composition comprises 0.8-2.3 mg of isopulegol per dose. • Embodiment 55. The pharmaceutical composition of any one of embodiments 1-54, wherein the one or more terpenes comprise caryophyllene oxide, and wherein the pharmaceutical composition comprises 0.1-5 mg, 0.5-3.5 mg, or 0.8 to 2.2 mg of caryophyllene oxide per dose. • Embodiment 56. The pharmaceutical composition of any one of embodiments 1-54, wherein the one or more terpenes comprise caryophyllene oxide, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 4.8 mg, or 5 mg of caryophyllene oxide per dose. • Embodiment 57. The pharmaceutical composition of any one of embodiments 1-54, wherein the one or more terpenes comprise caryophyllene oxide, and wherein the pharmaceutical composition comprises 0.8-2.2 mg of caryophyllene oxide per dose. • Embodiment 58. The pharmaceutical composition of any one of embodiments 1-57, wherein the one or more terpenes comprise δ-limonene, and wherein the pharmaceutical composition comprises 0.1-5 mg, 0.5-3.5 mg, or 0.8 to 1.6 mg of δ-limonene oxide per dose. • Embodiment 59. The pharmaceutical composition of any one of embodiments 1-57, wherein the one or more terpenes comprise δ-limonene, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 4.8 mg, or 5 mg of δ-limonene per dose. • Embodiment 60. The pharmaceutical composition of any one of embodiments 1-57, wherein the one or more terpenes comprise δ-limonene, and wherein the pharmaceutical composition comprises 0.8-1.6 mg of δ-limonene per dose. • Embodiment 61. The pharmaceutical composition of any one of embodiments 1-60, wherein the one or more terpenes comprise geraniol, and wherein the pharmaceutical composition comprises 0.1-3 mg, 0.2-1.5 mg, or 0.4 to 0.9 mg of geraniol per dose. • Embodiment 62. The pharmaceutical composition of any one of embodiments 1-60, wherein the one or more terpenes comprise geraniol, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.5 mg, or 3 mg of geraniol per dose. • Embodiment 63. The pharmaceutical composition of any one of embodiments 1-60, wherein the one or more terpenes comprise geraniol, and wherein the pharmaceutical composition comprises 0.4-0.9 mg of geraniol per dose. • Embodiment 64. The pharmaceutical composition of any one of embodiments 1-63, wherein the one or more terpenes comprise guaiol, and wherein the pharmaceutical composition comprises 0.1-5 mg, 0.2-3.5 mg, or 0.4 to 3.2 mg of guaiol per dose. • Embodiment 65. The pharmaceutical composition of any one of embodiments 1-63, wherein the one or more terpenes comprise guaiol, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.4, 2.5 mg, 2.75, 3 mg, 3.2 mg, 3.5 mg, 4 mg, 4.5 mg, or 5 mg of guaiol per dose. • Embodiment 66. The pharmaceutical composition of any one of embodiments 1-63, wherein the one or more terpenes comprise guaiol, and wherein the pharmaceutical composition comprises 0.4-3.2 mg of guaiol per dose. • Embodiment 67. The pharmaceutical composition of any one of embodiments 1-66, wherein the one or more terpenes comprise α-bisobolol, and wherein the pharmaceutical composition comprises 0.1-3 mg, 0.2-1.5 mg, or 0.3 to 0.7 mg of α-bisobolol per dose. • Embodiment 68. The pharmaceutical composition of any one of embodiments 1-66, wherein the one or more terpenes comprise α-bisobolol, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.5 mg, or 3 mg of α-bisobolol per dose. • Embodiment 69. The pharmaceutical composition of any one of embodiments 1-66, wherein the one or more terpenes comprise α-bisobolol, and wherein the pharmaceutical composition comprises 0.3-0.7 mg of α-bisobolol per dose. • Embodiment 70. The pharmaceutical composition of any one of embodiments 1-69, wherein the one or more terpenes comprise 3-carene, and wherein the pharmaceutical composition comprises 0.1-3 mg, 0.2-1.5 mg, or 0.4 to 0.9 mg of 3-carene per dose. • Embodiment 71. The pharmaceutical composition of any one of embodiments 1-69, wherein the one or more terpenes comprise 3-carene, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.5 mg, or 3 mg of 3-carene per dose. • Embodiment 72. The pharmaceutical composition of any one of embodiments 1-69, wherein the one or more terpenes comprise 3-carene, and wherein the pharmaceutical composition comprises 0.4-0.9 mg of 3-carene per dose. • Embodiment 73. The pharmaceutical composition of any one of embodiments 1-72, wherein the one or more terpenes comprise β-pinene, and wherein the pharmaceutical composition comprises 0.1-5 mg, 0.3-3 mg, or 0.6 to 2.0 mg of β-pinene per dose. • Embodiment 74. The pharmaceutical composition of any one of embodiments 1-72, wherein the one or more terpenes comprise β-pinene, and wherein the pharmaceutical composition comprises about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.2 mg, 2.4, 2.5 mg, 2.75, 3 mg, 3.2 mg, 3.5 mg, 4 mg, 4.5 mg, or 5 mg of β-pinene per dose. • Embodiment 75. The pharmaceutical composition of any one of embodiments 1-72, wherein the one or more terpenes comprise β-pinene, and wherein the pharmaceutical composition comprises 0.6-2.0 mg of β-pinene per dose. • Embodiment 76. The pharmaceutical composition of any one of embodiments 1-75, wherein the one or more terpenes comprise γ-terpinene, and wherein the pharmaceutical composition comprises 0.05-1.6 mg, 0.1-0.8 mg, or 0.2 to 0.4 mg of γ-terpinene per dose. • Embodiment 77. The pharmaceutical composition of any one of embodiments 1-75, wherein the one or more terpenes comprise γ-terpinene, and wherein the pharmaceutical composition comprises about 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.11 mg, 0.12 mg, 0.13 mg, 0.14 mg, 0.15 mg, 0.16 mg, 0.17 mg, 0.18 mg, 0.19 mg, 0.20 mg, 0.21 mg, 0.22 mg, 0.23 mg, 0.24 mg, 0.25 mg, 0.26 mg, 0.27 mg, 0.28 mg, 0.29 mg, 0.3 mg, 0.31 mg, 0.32 mg, 0.33 mg, 0.34 mg, 0.35 mg, 0.36 mg, 0.37 mg, 0.38 mg, 0.39 mg, 0.4 mg, 0.45 mg, 0.5 mg, 0.55 mg, 0.6 mg, 0.75 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, or 1.6 mg of γ-terpinene per dose. • Embodiment 78. The pharmaceutical composition of any one of embodiments 1-75, wherein the one or more terpenes comprise γ-terpinene, and wherein the pharmaceutical composition comprises 0.2-0.4 mg of γ-terpinene per dose. • Embodiment 79. The pharmaceutical composition of any one of embodiments 1-78, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, α-humulene, or a combination thereof, and wherein the pharmaceutical composition comprises about 30-60 mg of the β-mycene, about 2.5-5 mg of the β-caryophyllene, about 2.3-4.7 mg of the ocimene, about 1.1-2.1 mg of the α-pinene, about 0.8-1.6 mg of the α-humulene, or a combination thereof per dose. • Embodiment 80. The pharmaceutical composition of any one of embodiments 1-78, wherein the one or more terpenes comprise β-myrcene, β-caryophyllene, ocimene, α-pinene, and α-humulene; and wherein the pharmaceutical composition comprises about 30-60 mg of the β-mycene, about 2.5-5 mg of the β-caryophyllene, about 2.3-4.7 mg of the ocimene, about 1.1-2.1 mg of the α-pinene, and about 0.8-1.6 mg of the α-humulene per dose. • Embodiment 81. The pharmaceutical composition of any one of embodiments 1-80, wherein the pharmaceutical composition is formulated as a liquid, a pill, a gel capsule, a vaporizable liquid, a vaporizable solid, a transdermal ointment or salve, or a transdermal patch. • Embodiment 82. The pharmaceutical composition of any one of embodiments 1-80, wherein the pharmaceutical composition is formulated as a liquid. • Embodiment 83. The pharmaceutical composition of embodiment 82, wherein the liquid comprises citric acid, blue agave, glycerine, one or more lorann oils, food coloring, or a combination thereof. • Embodiment 84. The pharmaceutical composition of embodiment 82, wherein the liquid comprises: (a) about 1% to 7% w/w citric acid; (b) about 40% to 49% w/w blue agave; (c) about 40% to 49% w/w glycerin; (d) about 0.1% to 1.5% w/w lorann oils; (e) about 0.01 to 0.4% food coloring; (f) or a combination thereof. • Embodiment 85. The pharmaceutical composition of embodiment 82, wherein the liquid comprises: (a) about 1% to 7% w/w citric acid; (b) about 40% to 49% w/w blue agave; (c) about 40% to 49% w/w glycerin; (d) about 0.1% to 1.5% w/w lorann oils; and (e) about 0.01 to 0.4% food coloring. • Embodiment 86. The pharmaceutical composition of embodiment 82, wherein the liquid comprises: (a) about 3-5% w/w citric acid; (b) about 45-49% w/w blue agave; (c) about 45-49% w/w glycerin; (d) about 0.7-0.9% w/w lorann oils; and (e) about 0.1-0.3% food coloring. • Embodiment 87. The pharmaceutical composition of any one of embodiments 1-86, for use in the treatment of opioid addiction. • Embodiment 88. The pharmaceutical composition of any one of embodiments 1-86, for use in the treatment of pain. • Embodiment 89. The pharmaceutical composition of any one of embodiments 1-86, for use in the treatment of chemotherapy-induced nausea and vomiting. • Embodiment 90. A method of treating opioid addition, the method comprising administering an effective amount of a pharmaceutical composition comprising one or more cannabinoids to a subject in need thereof. • Embodiment 91. The method of embodiment 90, wherein the pharmaceutical composition is the pharmaceutical composition of any one of embodiments 1-86. • Embodiment 92. The method of embodiment 90 or 91, wherein the pharmaceutical composition is administered every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours. • Embodiment 93. The method of embodiment 90 or 91, wherein the pharmaceutical composition is administered every 6, 8 or 12 hours. • Embodiment 94. The method of any one of embodiment 90-93, wherein the subjects opioid use decreases by at least 50% within 5 weeks of beginning treatment as determined by morphine equivalency of opioids used.

Example 1 —Exemplary Formulation Preparation

This example details the production of an exemplary cannabinoid formulation that can be used in the methods disclosed herein.

Briefly, 400 g citric acid, 5000 g blue agave, and 5000 g glycerin are mixed and heated to 150° C. Separately, 300 g ethanol is heated and mixed with THC oil and CBD isolate until complete dissolution. Then, both mixtures are combined, flavoring (80 g Lorann Oils, e.g., watermellon, cherry) and coloring (20 g food coloring) are added, and the resulting mixture is sonicated until ingredients are thoroughly incorporated.

The final product is aliquoted to bottles, each containing about 5.5 oz. A single dose is about 12 mL.

The final product can contain, for example, about 15-20 mg THC and about 10-12 mg CBD per dose. The final product can also contain terpenes; for example, 30-60 mg 0-myrcene (e.g., about 45 mg), 2.5-5 mg β-caryophyllene (e.g., about 3.7 mg), 2.3-4.7 mg ocimene (e.g., about 3.5), 1.1-2.1 mg α-pinene (e.g., about 1.6), 0.8-1.6 mg α-humulene (e.g, about 1.2 mg), or a combination thereof. Table 2 contains an exemplary recipe.

TABLE 2

Exemplary formulation recipe

Batch Size: 10,000 g

16 g formulation = 12 mL volume = 1 dose

Percent

Amount by

Component Added Weight mg/g mg/dose

Carriers/Excipients

Citric Acid 393.27 g 3.933%

Blue Agave 4729.13 g 47.291%

Glycerine 4729.13 g 47.291%

Flavor: Lorann 78.65 g 0.787%

Oils

Food Coloring 19.66 g 0.197%

Cannabinoids

THC 9.38 g 0.094% 0.9375 mg/g 15 mg/dose

CBD 6.25 g 0.063% 0.625 mg/g 10 mg/dose

Terpenes

β-myrcene 28.13 g 0.281% 2.8125 mg/g 45 mg/dose

β- 2.31 g 0.023% 0.23125 mg/g 3.7 mg/dose

Caryophyllene

Ocimene 2.19 g 0.022% 0.21875 mg/g 3.5 mg/dose

α-pinene 1.00 g 0.010% 0.1 mg/g 1.6 mg/dose

α-humulene 0.75 g 0.008% 0.075 mg/g 1.2 mg/dose

Example 2

Over the last 150 years the perceived and reported medicinal effects or benefits associated with the consumption of products derived from the cannabis plant have fluctuated as much as the most volatile stock market period in history. Periodically, the benefits have been held out to be Olympian in nature, virtually a cure all for all conditions while at other times use of the cannabis has been associated with “reefer madness”; including suicidal ideation, sexual promiscuity, and in general uncontrolled impulses. The truth, as usual lies somewhere in between. Add in a dose of world politics and posturing; difficulty in conducting trials; an error in taxonomy; the radically different effect ascribed to the two main components of the plant, Delta-9 tetrahydrocannabinol (THC) and Cannabidiol (CBD) consumed in a variety of ways; a less than clear understanding of the metabolism of the compounds and the endocannabinoid system; and the inability to link a specific plant profile to a specific outcome have all made it even more difficult in separating the flower from the trim, as it pertains to cannabis Sativa and its medicinal effects.

For the purposes of this forum the historic marketing of cannabis and its by-products will be left to an excellent reference as will references to reefer madness type publications. Regarding world and US politics, our present-day situation, for the most part, is governed nationally by the Nixon administration ignoring the recommendations of the National Commission of Marihuana and Drug Abuse (The Schafer Commission) and its appendix both published in 1972, which overall called for decriminalization of personal possession and use of cannabis . Even this report was not without controversy. To paraphrase a report issued by the Committee on Public Health of the New York Academy of Medicine, it recommended that a government agency investigate the feasibility of control and distribution of marihuana through a government agency, while a New England Journal editorial suggested that legalization offered the best promise for effective control of marihuana. Nahas and Greenwood published a detailed rebuttal to the Shafer Commission report and ultimately the administration ignored the Commission's recommendations. Currently 28 states, the District of Columbia and a few of the over 500 recognized Indian tribal nations have passed laws regulating the sale of cannabis either for medical or both medical and recreational use and the laws enacted by each of these government(s) or their legislation are at odds with federal statute. The recent rescinding of the Cole memorandum by Attorney General Sessions has added fuel to the fires of confusion which unfortunately will not be solved here but all should be left with the warning of “buyer beware”.

Now onto the science. Like staging systems for each cancer, we can all argue the merits of the specifics defining each stage, but none would argue against the need for uniformity. For without it, discussion of results and therefore evaluation of new treatments would be rendered impossible. Cannabis , was taxonomically divided into three species in the 1970s; C. indica, C. sativa , and C. ruderalis . Adding to the confusion, yet ultimately clarifying was the work of McPartland wherein he proved on a genetic basis that these were all the same species, just different subspecies. More importantly he found that C. sativa originated in India and should have been classified as C. indica; C. indica originated in Afghanistan and should have been identified as C. afghanica ; and C. ruderalis is most properly classified as C. sativa . Until this nomenclature is standardized comparing research results will be near impossible.

Since Mechooulam's group identified and synthesized both cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC) the psychoactive component in the cannabis plant there have been over 60 phytocannabinoids the identified in addition to approximately 400 other components of the cannabis plant including a large number of terpenes that account for the associated aroma and may contribute to the entourage effects of cannabis . Research efforts have logically been based upon our understanding of the cannabinoid receptors so far identified throughout the body, but particularly in the brain and metabolism via the cytochrome P450 pathways. Left to further study is the molecular basis for the therapeutic effect of associated with cannabidiol (CBD) as it has little affinity for the CB1 and CB2 receptors. Of most importance at this time has been the identification of CBD acting as a negative allosteric modulator thereby changing the shape of the CB1 receptor and thus dampens the psychoactive effect associated with the consumption of THC when taken in combination with CBD.

Much of our collective knowledge regarding the clinical effects of cannibinoids arises from case reports and observational and retrospective studies. There are few prospective randomized trials reported. Many that pertain to clinical oncology involve the use of dronabinol for the relief of chemotherapy-induced nausea and vomiting and pain. May and Giode have thoroughly reviewed much of this literature. Dronabinol has offered little relief over available anti-emetic regimens. Additional prospective studies have been conducted using oromucosal nabiximols (THC:CBD of 1:1) for intractable spasticity in patients with multiple sclerosis (MS) and those results led to the FDA ultimately granting GW Pharmaceuticals (London UK, Carlsbad CA) approval for this indication. Trials using the same product, designed to determine its effectiveness in cancer-associated pain, was not found to be better than placebo. Maccarrone et al have reviewed results of trials involving oromucosal nabiximols. Russo similarly has provided an excellent review on the matter of trial design and other controversies associated with research in this area, including issues involving clinical trial approval and design. Highlighted by Russo are the difficulties encountered when attempting to undertake research involving cannabis , in particular the need to either use cannabis provided exclusively by the University of Mississippi or apply to cultivate and supply your study drug.

In Nevada, efforts to conduct federally-approved research undertaken with the intent of filing a new drug application a has been thwarted as the Institutional Review Board (IRB) at the University Medical Center (UMC) requires DEA assurance before considering any protocol containing cannabis in a treatment arm, yet to obtain federal permission one needs IRB approval of the study of concern.

Addressing the opiate crisis in this country has led to a number of studies being conducted using cannabis -based therapy as an alternative means of managing chronic and cancer-related pain. Despite Nabiximols not appearing to be statistically superior when compared to placebo in controlling pain in cancer patients, there are other randomized placebo controlled trials demonstrating the efficacy of using cannabis for pain control. There is also significant evidence that a cannabis -opioid interaction exists that results in improved pain control. All of the studies to date have either used pain scales or patient interview results to determine the success or failure of the cannabis intervention. Given the increasing availability of legal cannabis , there will be fewer opportunities to study a cannabis naïve population use as it is clear from the work of Bachhuber et al. that patients are self-treating with cannabis in order to reduce if not eliminate their dependence on narcotics. This is reflected by the 24% reduction in opiate-related deaths in states with legalized medical marijuana programs as compared to those without.

We, a group of physicians in Nevada, are licensed to cultivate, produce and sell cannabis -related products and have recently undertaken a randomized, placebo controlled study using a guava-based syrup with a THC:CBD ratio of about 2:1 and a placebo containing only the flavored guava-based syrup. As a proof of concept 25 patients with a history of at least 3 years of chronic opiate use were enrolled in a single arm study with the endpoint being a 30% reduction of opiate intake determined by weekly pill count.

The population of subjects in this study included 14 women and 11 men. The average age of participants was about 55 years old, with the youngest being 21 and the oldest being 77. The median age was about 58 years old. According to their medical histories, 4 participants had a history of gynecologic or breast cancer; 11 participants have had spine surgery; 5 participants have had a hysterectomy; 4 participants reported hypertension; 2 participants reported coronary artery disease, 2 participants had diabetes; 11 participants used tobacco; 6 participants used alcohol; and 3 participants reported drug abuse.

A morphine equivalent calculation was adopted for this study to account for the varying opiates used by the study participants. Hydrocodone alone was used by 9 participants; hydrocodone plus morphine sulfate was used by 1 participant; hydromorphone alone was used by 2 participants; hydromorphone plus methadone was used by 1 participant; oxycodone alone was used by 6 participants; oxycodone plus methadone was used by 1 participant; oxycodone plus morphine sulfate was used by 2 participants; and Percocet was used by 3 participants.

23 of the 25 patients reduced their opiate intake by greater than 50%. The average weekly pill count is charted in FIG. 1 a with regression analysis shown in FIG. 1 b . The average weekly pill counts after conversion to morphine equivalents is shown in FIG. 2 a with regression analysis shown in FIG. 2 b . These results provide an objective basis to evaluate the potential of cannabis to replace to reduce the opiate consumption across the US. We have also opened a trial to evaluate the effectiveness of this syrup with some slight modifications in the terpene profile, in controlling chemotherapy-induced nausea and vomiting (CINV).

References, each of which is incorporated by reference in its entirety:

• Mills M. Moguls and Mexicans: The American history of cannabis legalization. The New Econom Mar. 27, 2015. theneweconomy.com. • National Commission on Marihuana and Drug Abuse: Marihuana: A Signal of Misunderstanding: First Report of the National Commission on Marihuana and Drug Abuse. Washington D.C., Govt. Print. Off. 1972. • National Commission on Marihuana and Drug Abuse: Marihuana: A Signal of Misunderstanding: Technical papers, Appendix, vols. 1 and 2. Washington D.C., Govt. Print. Off. 1972. • Wechsler H. Marihuana, alcohol and public policy. New Eng. J. Med. 287:516-17, 1972 • Nahas G G, Greenwood A. The first report of the National Commission on marihuana (1972): signal of misunderstanding or exercise in ambiguity. Bull N Y Acad Med. 1974 Jan; 50(1):55-75. • McPartland J M. “ Cannabis sativa and Cannabis indica versus “ Sativa ” and “Indica”.” In Cannabis sativa L.—Botany and Biotechnology, edited by Chandra S, Lata H and ElSohly M A, pp 101-121. Switzerland: Springer International Publishing, 2017. • Micholaum R and Shvo Y. Hasish. I. The structure of cannabidiol.Tetrahedron. 1963 Dec; 19(12): 2073-8 • Gaoni Y and Micholaum R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish.J. Am. Chem. Soc., 1964, 86 (8), pp 1646-1647. • Howlett A C1, Barth F, Bonner T I, Cabral G, Casellas P, Devane W A, Felder C C, Herkenham M, Mackie K, Martin B R, Mechoulam R, Pertwee R G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002 Jun; 54(2):161-202. • Breivogel C S1, Childers S R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 1998 December; 5(6 Pt B):417-31 • Russo E B. Taming THC; potential cannabis synergy and phytocannabinoid=terpenoid entourage effects. Br J Pharmacol. 2011 August; 163 (7):1344-1364.

• Lapairie R B, Bagher, A M, Kelly, M E Denovan-Wright, E M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015 October; 172(20): 4790-4805. • May M B and Glode A E. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to anti-emetics. Cancer Manag Res. 2016; 8: 49-55.

• Maccarrone M, Maldanado R, Casas M, Henze T, and Centonze D. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Review of Clinical Pharmacology. 2017; 10: 443-55. • Russo E B. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Front Pharmacol. 2016; 7: 309-339. • Lichtman A H, Lux E A, McQuade R, Rossetti s, Sanchez R, Sun W. Wright S, Kornyeyeva E, Fallon M T. Results of a double-blind, randomized, placebo-controlled study of Nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain.nJ Pain Symptom Manage. 2018; 55: 179-188. • Abrams D I, Couey P, Shader S B, Kelly M E, Benowitz N I. Cannabinoid-opioid Interaction in chronic pain. Clin. Pharmacol. Ther. 2011; 90; 844-851.

• Miller G. Pot and Pain. Hints are emerging that cannabis could be an alternative to opioid painkillers. Science. 2016: 354; 566-568 • Whiting P F, Wolff R E, Deshpande S, Di Niso M, Duffy S, Hemandez A V, Keurentjes J C, Lang S, Misso K, Rider s, Schmidkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A systematic review and meta-analysis. JAMA. 2015; 313; 2456-2473. • Bachhuber M A, Saloner B, Cunningham C O, Barry C L. Medicinal cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern. Med. 2014 174; 1668-1673.

EXAMPLE 3 a Phase III Double-Blind, Randomized, Placebo Controlled (with Crossover) Trial of Medical Marijuana Versus Placebo for the Reduction of Opiate Consumption in Patients with Chronic Pain

Arm I: Placebo Arm II: THC/CBD (strain specific)

If no improvement If no improvement

↓ ↓

Double the Dose Double the Dose

↓ ↓

If no improvement, Cross-over to If no improvement, Cross-over to

Arm II Arm I

Objectives

Primary Objective: To determine if the number of patients consuming opiates for chronic pain treate d with medicinal cannabis (15-20 mg THC/10-12 mg CBD-strain specific) in an agave-based syrup that are able to eliminate their opiate consumption is not reduced by 300% when compared to an identical agave-based syrup without cannabis.

Secondary Objective: To determine the incidence of adverse events associated with both regimens. Common Terminology for Adverse Events (CTAE ver. 4) will be used to scale adverse events.

Background and Rationale

The available literature on the medicinal effects of cannabis is sparse and for the most part lacks critical aspects of study design including prospective design and randomization. The reasons for this are varied, but primarily they are based on the fact that cannabis remains a schedule 1 drug and its production and ingestion are against federal law. Most studies have evaluated synthetics, nabilone or dronabinol, with few evaluating THC derived from plant. Internationally, over 30 countries have approved its use either recreationally or medicinally. Some countries such as Paraguay and Chile have legalized cultivation and production of cannabis products. Over half of the states and the District of Columbia have legalized the use of cannabis medicinally and some have approved its use recreationally. In the last few years, research into the underlying neurophysiology associated with cannabis has led to an increased understanding of the different active components and the biochemical pathways responsible for the associated therapeutic effects. The constituents seemingly responsible for the claimed medicinal effects of the cannabis plant can include delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

The purported beneficial medicinal effects associated with cannabis ingestion are quite diverse. Of the claims made, the most studied are in patients with multiple sclerosis, where a beneficial effect on muscle spasticity and pain are well-documented, but not necessarily as consistently as one might like. Cannabis can also be effective in treating seizures, anorexia, chronic pain, and nausea and vomiting that is associated with chemotherapy. Cannabidiols may also have a therapeutic effect of inflammation, diabetes, cancer, and neurodegenerative diseases. On the other hand THC ingestion has been associated with less than desirable side effects such as agitation; panic disorder; depression and even psychosis.

Perhaps as importantly, the political landscape is changing as rapidly as is the understanding of the underlying mechanisms of action associated with cannabis . Indications of this are the increasing number of states that have legalized the medicinal use of cannabis and the call by some states, such as Nevada, to undertake research to evaluate the clinical benefits associated with the use of cannabis.

The opiate epidemic continues to be associated with over 100 deaths daily in the United States. Couple this with the estimated total annual cost of pain-related health of approximately $600 billion and perhaps this figure is even higher for the nations in European Union (EU) and therein is born the impetus to evaluate virtually any therapy that may thwart these related problems. This estimate includes the actual costs related to the medical care as well as the economic losses which contribute to approximately one-half of these costs. Economic losses include claimed disability, loss of productivity and lost wages. Medical care including physician time, hospitalization, surgical procedures, diagnostic testing and prescription drugs all contribute to the costs associated with the treatment of pain, as well the costs associated with the adverse effects associated with their utilization. Unfortunately, one of the adverse effects associated with prescription painkillers is death. Overdose deaths secondary to prescription opioids were five times higher in 2016 than 2000 and sales of these prescription drugs have quadrupled. That being said, the number of deaths dues to prescription opioids has remained relative stable at approximately 14,000 to 16,000 deaths per year. Much of the increase in mortality related to opioid consumption is due the rapid rise in those associated with the use of synthetic opioids. Of importance is the fact that in state with either medical marijuana or both medical and retail marijuana programs in place there was a 24.8% lower mean annual opiod overdose mortality rate (95% CI, −37.5% to −9.5%: P=0.003) compared with states without medical marijuana laws.

Addressing the opiate crisis in this country has led to a number of studies being conducted using cannabis -based therapy as an alternative means of managing chronic and cancer-related pain. Despite Nabiximols not appearing to be superior when compared to placebo in controlling pain in cancer patients, cannabis may have efficacy for pain control. A cannabis -opioid interaction may also result in improved pain control.

Cannabis contains at least 63 cannabinoids but two are best understood studied. The first, delta-9 tetrahydrocannabinol (THC), is thought to be responsible for the psychoactive effects that are widely associated with cannabis . The other main active component, cannabidiol (CBD), has no known psychoactive effect associated with its consumption but is thought to possibly provide anti-neoplastic, analgesic and antineuroleptic effects. Even though both cannabinoids are present in every plant, the interactions with the cerebral endocannabinoid receptor system are quite different. CBD binds as an antagonist to the cannabinoid receptor CB1 but the bond between THC and the same receptor is at least 100 times stronger. CBD also antagonizes the action on the cannabinoid G protein-coupled receptor GPR55, which is thought to be responsible the different neuromodulatory actions as the CB1 receptor. Claims of the subjective effects associated with cannabis ingestion include improvement in mood; relaxation; and increased sensitivity. On the other hand THC ingestion has been associated with less than desirable adverse effects such as agitation; panic disorder; depression and even psychosis.

Cannabinoids can have an effect on serotonergic systems, including increasing cerebral production of 5-hydroxytryptamine (5-HT), serotonin while decreasing its uptake at the synapse level. THC may also have dopaminergic antagonistic actions which may contribute to its beneficial profile regarding pain control.

Other phytocannabinoids such as cannabichromene (CBC), cannabigerol (CBG) as well as a number of terpenoids may contribute its analgesic effect. CBD, cannabinol (CBN),CBC and CBG can have anti-inflammatory and analgesic effects over and beyond that associated with THC. B-caryophyllene may be a selective CB2 agonist and other terpenes such as linalool and α-Pinene may have analgesic and anti-inflamatory effects respectively. Myrcene on the other hand may have analgesic effects mediated through an opioid-like action. This may lead to another avenue as to how cannabis and it component parts may prevent opiate withdrawal and allow for the use of lesser amounts of opioids while preventing the development of tolerance. Used in combination with opioid pain medications, cannabis can lower opioid side effects, cravings, and withdrawal severity, as well as enhance the analgesic effects of opioids, thereby allowing for lower doses and less risk of overdose.

All of the studies to date have either used pain scales or patient interview results to determine the success or failure of the cannabis intervention.

We have recently undertaken a phase II feasibility trial using a guava-based syrup with a THC:CBD ratio of 1.5: 1 to 2:1 derived from a specific cannabis plant with a unique profile of other phytocannabinoids such as CBC, CBN, and CBG as well as a number of terpenoids which likely contribute to its analgesic effect. Each dose of syrup contained 15-20 mg of THC and 10-12 mg of CBD as well as a unique profile associated with one specifically bred cannabis plant. A proof of concept trial of 25 patients with a history of at least 3 years of chronic opiate use were enrolled in a single arm study with the target for success being a 30% reduction of opiate intake determined by weekly pill count. Using a morphine equivalent conversion of all of the various opiates consumed by the study population it was determined that there was a reduction in opiate consumption of approximately 75% and 8/25 patients (40%) were able to replace their prescription opiates with the agave-based THC-CBD syrup. This provides an objective basis to evaluate the potential of cannabis to reduce if not eliminate a significant amount of the opiate consumption across the US. As explained above the actions of THC, CBD, and associated terpenes are potentially complementary and the recent feasibility trial provides substantial evidence of potential benefit of using them together for patients with chronic pain.

That being said another important consideration in administering cannabis to patients is the potential drug-to-drug interactions and adverse effects associated with its use and potential withdrawal. THC is metabolized via the Cytochrome P450 pathway and more specifically it is thought that the CYP2C9 enzyme is responsible for the first pass metabolism of THC. The CYP3A4 enzyme may also have a role in its metabolism. Coumadin effect on prothrombin time (PT) is significantly enhanced by the use of THC/CBD. Theophylline levels may be adversely affected. There have been reported adverse events when cannabis is used with sildenafil, including a myocardial infarction. Since THC is a CNS depressant its use with alcohol, barbiturates, antihistamines, narcotics, and BZD, theoretically could amplify the effects of both drugs. It should be noted there has not been any clinical trial documenting these interactions. Similarly, adverse events need to be carefully documented. In this context cannabinoid receptors are not located in the brainstem as are opioid receptors and therefore do not have the associated risk of respiratory depression and death. Adverse effects including, but not limited to tachycardia and hypotension, anxiety and nervousness, hyperactivity, muscle relaxation, decreased bowel motility, and bronchodilatation have been documented.

The addictive potential of cannabinoids is thought to be lower than opiates and its derivatives as well as other frequently abused substances. Interestingly, as cannabinoids are stored in adipose, excretion takes place over a relatively long-time thus preventing precipitous declines in the plasma concentration and potentially explaining the lack of acute withdrawal symptoms associated with the cessation of cannabis use. Nevertheless, there have been documented symptoms associated with withdrawal including, but not limited to, nausea and vomiting, increased activity, nervousness, irritability, insomnia, and vasomotor symptoms.

This overall safety profile of the cannabinoids made them an excellent candidate to be studied as an opiate substitute. A recently completed pilot study demonstrated in 25 patients, a 75% reduction in opiate ingestion over a 4-5 week period, with 8/25 patients completely discontinuing their opiate use. The same formulation used in that study will be studied here.

Inclusion of Women and Minorities

No potential subject will be excluded from participating in this or any study solely on the basis of ethnic origin or socioeconomic status. Every attempt will be made to enter all eligible patients into this protocol and therefore address the study objectives in a patient population representative of the entire population currently consuming opiates for over three years.

PATIENT ELIGIBILITY AND EXCLUSIONS

Eligible Patients Criteria

•

• 1) Patients currently consuming opiates chronically for a minimum of 3 years. • 2) Patients who can read understand and write English or have a translator available to do so. • 3) Patients who are able to complete the assessments. • 4) Patients who are able to comply with treatment regimen and be seen on a weekly basis at the study site to have their medications counted and an assessment completed. • 5) Patient must hold a valid Nevada Medical Marijuana Card or be qualified by reciprocity as defined by Nevada Statute. Ineligible Patients Criteria • 1) Patients who, in the opinion of their physician, have any condition that may contradict potential withdrawal symptoms associated potential reduction of opiate ingestion. • 2) Patients known to have had a hypersensitivity reaction to any of the drugs to be received as part of this trial. • 3) Patients currently taking warfarin or similar products. • 4) Patients taking Tadalafil (Cialis T M), Sildenafil (Viagra), or Theophylline. • 5) Pregnant patients or patients on oral contraceptives who are not willing to use another form of back up birth control in addition to the pill. • 6) Patients who have used cannabis within the last one month. Study Modalities

Tetrahydrocannabinol: Cannabidiol (THC:CBD) agave based syrup (20 mg THC/10 mg CBD) vs control agave-based syrup.

Each bottle will contain either 150-200 mg:100-120 mg (THC:CBD) in an agave based syrup with reconstituted terpene profile or the agave-based syrup alone. The emulsification process renders the material virtually odorless allowing for the patient to be blinded.

Storage and Stability: store vials at 2-8° C. (36-46° F.).

Preparation: emulsified solution.

How Supplied: in glass jars with increments and doses labeled on each bottle.

Administration: both are to be administered on a q6 to q8 hour basis (e.g., every 6 to 8 hours) by either direct administration or the syrup is to be mixed with 7-up with care being taken to chew the ice. If ineffective, the patient will double the dose. If there is no improvement then the patient will be crossed-over.

Adverse Events: THC ingestion has been associated with adverse effects such as agitation; panic disorder; depression and even psychosis and all adverse events will be chronicled based on version 4.

Cannabis

DESCRIPTION

Tetrahydrocannabinol: Cannabidiol (THC:CBD) agave based syrup (15-20 mg THC/10-12 mg CBD) with reconstituted terpene profile versus control agave-based syrup.

Cannabis is intended for use as a psychoactive drug or as a medicine. The main psychoactive part of cannabis is tetrahydrocannabinol (THC); it is one of at least 421 known compounds in the plant, including at least 61 other cannabinoids, such as cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabivarin (THCV).

Researchers have subsequently confirmed that THC exerts its most prominent effects via its actions on two types of cannabinoid receptors, the CB1 receptor and the CB2 receptor, both of which are G-protein coupled receptors. The CB1 receptor is found primarily in the brain as well as in some peripheral tissues, and the CB2 receptor is found primarily in peripheral tissues, but is also expressed in neuroglial cells THC appears to alter mood and cognition through its agonist actions on the CB1 receptors, which inhibit a secondary messenger system (adenylate cyclase) in a dose dependent manner. These actions can be blocked by the selective CBlreceptor antagonist SR141716A (rimonabant), which has been shown in clinical trials to be an effective treatment for smoking cessation, weight loss, and as a means of controlling or reducing metabolic syndrome risk factors. However, due to the dysphoric effect of CB1 antagonists, this drug is often discontinued due to these side effects. Via CB1 activation, THC indirectly increases dopamine release and produces psychotropic effects. Cannabidiol also acts as an allosteric modulator of the mu and delta opioid receptors. THC also potentiates the effects of the glycine receptors. The role of these interactions in the “marijuana high” remains elusive.

The high lipid-solubility of cannabinoids results in their persisting in the body for long periods of time. Even after a single administration of THC, detectable levels of THC can be found in the body for weeks or longer (depending on the amount administered and the sensitivity of the assessment method). A number of investigators have suggested that this is an important factor in marijuana's effects, perhaps because cannabinoids may accumulate in the body, particularly in the lipid membranes of neurons.

In comparison to smoking and inhalation, after oral ingestion, systemic absorption is relatively slow resulting in maximum A9-THC plasma concentration within 1-2 hours which could be delayed by few hours in certain cases. In some subjects, more than one plasma peak was observed. Extensive liver metabolism probably reduces the oral bioavailability of A9-THC by 4-12%. After oral administration, maximum A9-THC plasma concentration was 4.4-11 ng/mL for 20 mg and 2.7-6.3 ng/mL for 15 mg. Much higher concentration of 11-OH THC was produced after ingestion than inhalation. Following assimilation via the blood, A9-THC rapidly penetrates in to fat tissues and highly vascularized tissues including brain and muscle resulting in rapid decrease in plasma concentration. This tissue distribution is followed by slow redistribution of it from the deep fat deposits back into the blood stream. It should be noted that the residual A9-THC levels are maintained in the body for a long time following abuse. The half-life of it for an infrequent user is 1.3 days and for frequent users 5-13 days. After smoking a cigarette containing 16-34 mg of A9-THC, THC—COOH is detectable in plasma for 2-7 days. A clinical study carried out among 52 volunteers showed that THC—COOH was detectable in serum from 3.5 to 74.3 hours. Initial concentration was between 14-49 ng/mL. This was considerably less than the THC—COOH detection time of 25 days in a single chronic user.

A9-THC is metabolized in the liver by microsomal hydroxylation and oxidation catalyzed by enzymes of cytochrome P450 (CYP) complex. The average plasma clearance rates have been reported to be 11.8±3 L/hour for women and 14.9±3.7 L/hour for men. Others have determined approximately 36 L/hour for naïve cannabis users and 60 L/hour for regular cannabis users. More than 65% of cannabis is excreted in the feces and approximately 20% is excreted in urine. Most of the cannabis (80-90%) is excreted within 5 days as hydroxylated and carboxylated metabolites. There are eighteen acidic metabolites of cannabis identified in urine and most of these metabolites form a conjugate with glucuronic acid, which increases its water solubility. Among the major metabolites (A9-THC,11-OH-THC, and THCCOOH), THCCOOH is the primary glucuronide conjugate in urine, while 11-OH-THC is the predominant form in feces. Since A9-THC is extremely soluble in lipids, it results in tubular re-absorption, leading to low renal excretion of unchanged drug. Urinary excretion half-life of THCCOOH was observed to be approximately 30 hours after seven days and 44-60 hours after twelve days of monitoring. After smoking approximately 27 mg of A9-THC in a cigarette, 11-OH-THC peak concentration was observed in the urine within two hours in the range of 3.2-53.3 ng/mL, peaking at 77.0±329.7 ng/mL after 3 hours and THCCOOH peaking at 179.4 ng/mL±146.9 after 4 hours.

Stability and Storage

Store at room temperature in a colored bottle to avoid decomposition of the THC.

Preparation

The syrup is prepared using CO2 extracted THC which is then decarboxylated. The syrup is composed of agave syrup, glycerin, citric acid, lecithin, THC/CBD oil, coloring and flavoring. Each bottle, marked on the sides in 12 millimeter increments, will contain a total of 150-200 mg of THC and approximately 100-120 mg of CBD and will provide ten doses of medicine. The placebo will be the identical mixture without the addition of THC/CBD oil.

Administration

The patient will ingest 12 ml of either placebo or medicinal cannabis containing approximately 15-20 mg of THC and 10-12 mg CBD with the plant-specific terpenes reconsituted on a QID basis. The patients will be allowed to double the dose if symptoms to do not resolve.

Adverse Events

Short-term adverse effects include alterations in short-term memory, sense of time, sensory perception, attention span, problem solving, verbal fluency, reaction time, and psychomotor control. Some users report positive feelings such as mild euphoria and relaxation, while others, particularly naïve users, report anxiety, paranoia, and panic reactions. Depression and anxiety have also been reported as short-term adverse events. The short-term effects of marijuana last approximately 1-4 hours, depending on potency of the marijuana, the route of administration, and the tolerance of the user. Furthermore, there have been reports of adverse cardiac events including arrhythmias associated with a prolonged Q-T interval; hypertension and hypotension; tachycardia; and myocardial infarction. It is much more difficult to assess long-term adverse effects that may be attributable to the consumption of medicinal cannabis . While there is no question that marijuana causes short-term impairments in brain function, the degree to which these impairments are reversible with chronic use is less clear. Some studies have shown that brain function recovers over time, while others demonstrate persistence of subtle, but important, impairments. There is some suggestion that schizophrenia may be associated with long-term usage of cannabis . Lastly, there are the general concerns of smoking associated with cannabis use although that is not of concern as it relates to this study as the cannabis will be ingested and not inhaled.

Drug Interactions

A 9-THC is metabolized in the liver by microsomal hydroxylation and oxidation catalyzed by enzymes of cytochrome P450 (CYP) complex. As a result any drug that is similarly metabolized may be affected. Particular attention must be given to warfarin or similar products; tadalafil or similar products; and anti-depressants.

Treatment Plan and Entry

IRB Approval and IRB-Approved Informed Consent

Patient Entry and Registration

Treatment Plan

This is a double-blind phase III prospective randomized two-arm study which will be conducted in patients with chronic pain with a history of at least 3 years use of opiates for analgesia. Patients will be randomized using a computer based randomization program off-site and overseen by the independent observer. Patients will start the study within 2 days of filling their opiate prescription and verification through the Nevada State Prescription Monitoring Program that the patient is receiving narcotics from only a single source. The total morphine milligram equivalents (MME) used weekly by the subject will be calculated based on the CDC conversion table. Subjects will be given a diary to record time and amount of study medication used on a daily basis in addition to recording any adverse events. Diaries will be collected weekly. Patients will be given physician phone number in order to report any adverse event.

Week 1. Patients are to use syrup (A or B) as directed on a q 6 hour basis and use their opiates only for breakthrough pain. The patient will be seen at the end of each week and a pill count will be done to determine the quantity of opiate (MME) consumed by the subject and recorded.

Weeks 2-7. At the end of week 2 if there has been no improvement as determined by at least a 20% reduction in total MME used compared to the baseline, the patient will crossed over and continued on the new syrup for a minimum of two additional weeks and if no reduction of at least 20% in total MME study treatment will be discontinued. If the patient's consumption of MME decreases by more than 20% within the first two weeks after initial drug assignment or after two weeks after being crossed-over, the patient will continue on the study drug for at least 4 additional weeks. The patient will be followed through the end of the study with collection of all study data.

Treatment Modifications

Before cross-over has taken place if there is no improvement from the patient's baseline assessment the dose of either the placebo or THC/CBD will be doubled. Within two weeks after cross-over should the total MME used not decrease by at least 20% the subject will be recorded as a failure of study treatment.

Study Parameters

Observations and Tests

The following observations and tests are to be performed and recorded on the

Baseline or Day Day Day Day Day Day Days 8, 15, 22,

PARAMETER Day 1 2 3 4 5 6 7 29, 36, 43

History & Physical 1

Medication diary X** X X X X X X 2

Pill count and MME calculation X** X X X X X X 2

Gen Chemistry Panel: Electrolytes: 1 3

CBC c diff: PT/INR

Toxicity Diary & Assessment X X X X X X X 2

•

• 1. The baseline History and Physical done will be used if performed within 30 days of entry. • 2. Patients will return the Medication Diary weekly. The toxicity assessment will be completed daily by the patient and tabulated weekly unless grade 3 or greater toxicity occurs. • 3. Additional blood work will be ordered by the treating physician as needed. Evaluation Criteria

The MME calculated at study entry, weekly and then at completion will be used to determine treatment course as well as the success or failure of the study drug.

The patients will complete a daily medication and toxicity diary and will be assessed weekly.

Parameters of Response

Amount of opiate consumed by pill count and MME will be recorded in the medication diary and by the physicians conducting the study. The primary outcome is the complete elimination of opiate used to control the subject's symptoms.

Secondary outcome is the percentage reduction of opiate used to control the subject's symptoms as measured by pill count and MME.

Adverse events will be documented by the study subjects and verified by the physicians conducting the study

Duration of Study

The duration of the study will be 4 weeks at a minimum unless subject withdraws voluntarily or is caused to withdraw secondary to an adverse event deemed severe enough either by the patient or treating physician to warrant the subject's withdrawal from the protocol prescribed treatment plan.

Study Monitoring and Reporting Procedures

Adverse Event Reporting For A Commercial Agent

Definition of Adverse Events (AE)

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that occurs in a patient administered a medical treatment, whether the event is considered related or unrelated to the medical treatment. The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting. All appropriate treatment areas should have access to a copy of the CTCAE version 4.0.

Definition of Serious Adverse Event (SAE)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose:

•

• 1. Results in death • 2. Is life threatening (i.e., the subject was, in the opinion of the investigator, at immediate risk of death from the event as it occurred); it does not refer to an event which hypothetically might have caused death if it were more severe • 3. Requires or prolongs inpatient hospitalization • 4. Results in persistent or significant disability/incapacity (i.e., the event causes a substantial disruption of a person's ability to conduct normal life functions) • 5. Results in a congenital anomaly/birth defect • 6. Requires intervention to prevent permanent impairment or damage • 7. Is an important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the patient/subject or may require intervention to prevent one of the other outcomes listed above. Reporting Expedited Adverse Events

An AE report may need to reach multiple destinations. All expedited AEs will be reported to the IRB or the supervising body overseeing this study. Reporting will be modeled after AdEERS submissions. All adverse reactions will be immediately directed to the Study Chair for further action.

Note: All deaths on study require both routine and expedited reporting regardless of causality. Attribution to treatment or other cause must be provided.

Expedited AE reporting timelines defined:

“24 hours; 3 calendar days”—The investigator must initially report the AE within 24 hours of learning of the event followed by a complete report within 3 calendar days of the initial 24-hour report.

“7 calendar days”—A complete report on the AE must be submitted within 7 calendar days of the investigator learning of the event. Any medical event equivalent to CTCAE grade 3, 4, or 5 that hospitalization (or prolongation of existing hospitalization) must be reported regardless of attribution and designation as expected or unexpected with the exception ofany events identified as protocol-specific expedited adverse event reporting exclusions.

AEs should be reported by the investigator.

Pilot Trials Utilizing a Commercial Agent: AdEERS Expedited Reporting Requirements for Adverse Events That Occur Within 30 Days of the Last Dose of Any Study Agent

Reporting Requirements for Adverse Events that occur within 30 Days of the Last Dose of the Commercial Agent on Pilot Trials—GUIDELINES TO BE FOLLOWED regarding reporting of AEs to the Principal Investigator and the IRB

Grade 3 Grade 3

Grade 1 Unexpected With Expected

Unexpected Hospitalization With Hospitalization Grades Grades

and Grade 2 Grade 2 Without Without 4 & 5 2 4 & 5 2

Expected Unexpected Expected Hospitalization Hospitalization Unexpected Expected

Unrelated Not Not Not 7 Not 7 Not 7 7

Unlikely Required Required Required Calendar Required Calendar Required Calendar Calendar

Days Days Days Days

Possible Not 7 Not 7 7 7 Not 24-Hrs; 3 7

Probable Required Calendar Required Calendar Calendar Calendar Required Calendar Calendar

Definite Days Days Days Days Days Days

1 Adverse events with attribution of possible, probable, or definite that occur greater than 30 days after the last dose of treatment with a commercial agent require reporting as follows: AdEERS 24-hour notification followed by complete report within 3 calendar days for: Grade 4 and Grade 5unexpected events AdEERS 7 calendar day report:. Grade 3 unexpected events with hospitalization or prolongation of hospitalization and Grade 5 expected events

2 Although an AdEERS 24-hour notification is not required for death clearly related to progressive disease, a full report is required as outlined in the table. Please see exceptions below under the section entitled, “Additional Instructions or Exceptions to AdEERS Expedited Reporting Requirements for Pilot Trials Utilizing a Commercial Agent.” March 2005

Any event that results in persistent or significant disabilities/incapacities, congenital anomalies, or birth defects must be reported to the Study Chair if the event occurs following treatment with a commercial agent.

Additional Instructions or Exceptions to AdEERS Expedited Reporting Requirements for Pilot Trials Utilizing a Commercial Agent will be applied to this study:

In rare cases, pregnancy might occur in clinical trials. Any pregnancy occurring in association with the use of the study medication and the pregnancy outcome must be reported within five days of first awareness.

The event of overdose of aprepitant is considered an SAE by the manufacturer. In the event that there is an overdose of aprepitant, report the overdose and any clinical consequences that occur in association with an overdose.

Procedures for Expedited Adverse Event Reporting:

Expedited Reports: Expedited reports are to be submitted to the study Chair and the IRB using reports similar to the AdEERS.

Data Management Forms

The following forms must be completed for all patients and must be received in the study office in accordance with the schedule below.

Due within

Form ± Weeks Event Copies* Comments

History and Physical 1 4 Registration 1

Consent 4 Registratiom 1 Submit to study co-ordinator

Patient Symptom Diary 4 weekly 1 Submit to study co-ordinator

Pill count and MME log 2 weekly 1 Submit to study co-ordinator

T (Toxicity) Form 2 weekly 1 Submit to study co-ordinator

AE report See protocol 1 Submit to study co-ordinator

Form R 2 Registration 1 Submit to study co-ordinator

1 The History and Physical It is not necessary to repeat for this study. Statistical Considerations

Study Design

This is a randomized, 2-arm, double-blind, placebo-controlled phase III clinical trial evaluating THC/CBD as an aid to stopping opioid patients who are taking opioids due to chronic pain.

The overall objective of this study is to evaluate the probability of stopping opioid use within 5 weeks for patients diagnosed with chronic pain and treated with THC/CBD compared to those receiving placebo.

Treatment allocation and Emergency Unblinding

The subjects enrolled into this study will receive either daily THC/CBD or a placebo. The study treatments will be sequentially allocated from predetermined lists consisting of randomly permuted study treatments within blocks. This allocation procedure will tend to allocate each of the study regimens to nearly an equal number of the enrollees. Other than blocking the treatments, the randomization procedure will not be otherwise constrained to provide an equal number of subjects in each treatment group. The randomized treatment for each individual will remain concealed unless there arises a need for emergency unblinding. Emergency unblinding occurs when the appropriate clinical care of the subject requires knowledge of her study treatment. The study's Principle Investigator will be responsible for reviewing and approving requests for emergency unblinding. An independent statistician will be responsible for revealing the study treatment.

Measures of Efficacy and Safety

The principal observation for evaluating the therapeutic efficacy and safety of the study regimens are:

Primary Endpoints:

Primary efficacy endpoint: cessation of opioids for at least 7 days as determined by the treating physician.

Primary safety endpoint: Common Terminology Criteria for Adverse Events (CTCAE)—version 4.0.

Secondary Endpoints:

Weekly morphine equivalency does (MED).

Pain Numeric Score (PNS)

Enrollment and Target Sample Size

The target enrollment for this study is 64 subjects. The estimated accrual rate is 6 subjects per month. At this rate the enrollment period for this study is expected to require at most 1 year.

In order to account for the loss in power due to non-compliance, the target sample size will be increased by 2 subjects for each subject who withdraws from the study prior to completing at least 4 weeks of treatment or cannot be adequately evaluated for opioid usage.

Study Hypotheses

Null Hypotheses for Primary Efficacy Endpoint:

Ho: THC/CBD does not increase the probability of stopping opioids within 5 weeks of starting THC/CBD compared to placebo.

Type I Error Allocation

The type I error for the primary efficacy hypothesis will be 0.025 for a one-tail test.

Analytic Procedures for Testing Hypothesis (HO)

Primary Analysis:

For the primary analysis subjects will be group according to their randomly assigned treatment and they will be included in the analysis, regardless of their compliance with their assigned treatment plan. Individuals who withdraw early from the study without stopping opioids will be classified in the analysis of the primary endpoint as treatment failures (i.e., not stopping opioids).

Inferences regarding the clinical significance of THC/CBD will be made based on a Fisher's exact test of the primary study hypothesis.

Secondary and Exploratory analyses:

A logistic model will be used to assess whether the subject's initial morphine equivalency dose (MED), age or other clinical or demographic factors are treatment effect modifiers.

A linear mixed model will be used to model the patients' weekly morphine equivalency dose over time for women randomized to placebo vs those randomized to THC.

Statistical Power

With 32 subjects treated on each of the study regimens, this design provides 82% chance of rejecting the primary null hypothesis for efficacy when the true probabilities of stopping opioids within 5 weeks are 5% and 35% for placebo and active, respectively.

Interim Analyses

An interim futility analysis will be performed when there are at least 16 subjects treated and evaluated in each of the randomized treatment groups. If the proportion of the subjects randomly assigned to placebo who stopped all opioid usage within 5 weeks is greater than or equal to the proportion of subjects on THC/CBD, then consideration will be given to stopping the study. Otherwise, the study will continue to accrue until the target enrollment has been attained. If the study is stopped early due to this stopping boundary, then the conclusion of the study will be that it is unlikely that THC/CBD increases the probability of stopping opioid use in patients with chronic pelvic pain

If the true probability stopping opioids on THC/CBD is equal to placebo, then there is a 64% chance that this stopping boundary will recommend stopping the study early. On the other hand, if the true probabilities for stopping opioids are 5% and 35% on placebo and THC/CBD, respectively, then this stopping boundary decreases the statistical power of the study by less than 0.5%.

Interim and final reports will include an accounting of all subjects registered onto the study, regardless of their eligibility status or compliance to their assigned treatment.

The Data Monitoring Committee (DMC) is responsible for reviewing the results of interim analyses. The decision to terminate accrual to the study or to release study results early includes consideration of adverse events, treatment compliance, as well as results from external studies.

REFERENCES, EACH OF WHICH IS INCORPORATED BY REFERENCE IN ITS ENTIRETY

• May M B and Glode A E. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to anti-emetics. Cancer Manag Res. 2016; 8: 49-55. • Maccarrone M, Maldanado R, Casas M, Henze T, and Centonze D. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Review of Clinical Pharmacology. 2017; 10: 443-55. • Russo E B. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Front Pharmacol. 2016; 7: 309-339. • Lichtman A H, Lux E A, McQuade R, Rossetti s, Sanchez R, Sun W. Wright S, Kornyeyeva E, Fallon M T. Results of a double-blind, randomized, placebo-controlled study of Nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain.nJ Pain Symptom Manage. 2018; 55: 179-188. • Svendsen K B, jensen T S, Bach F W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized doubleblind placebocontrolled crossover trial. BMJmj. 2004: 329; 253. • Vermersch P. Sativex® (tetrahydrocannabinol+cannabidiol) and endocannabinoid system modulator: basic features and main clinical data. Expert Rev Neurother. 2011; 114 (Supp): 15-19. • Ware M A, Wang T, Shapiro S, Collet Jpand the COMPASS study team. Cannabis for the management of pain: Asessment of safety study (COMPASS). J Pain; 2015 Dec 16 (12): 1233-1242. • Perron Be, Bohnert K, Perone A K, Bonn-Miller M O and Ilgen M. Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs. 2015; 76(3); 406-13. • Lucas P and Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017; 42:30-35. • de Vrol ies M, van Rickevorsel D C M, Vissers K C P, Wilder-Smith O H G, van Goor H, Pain and Nociception Neuroscience Research Group. Clin Gastroenterol Hepatol. 2017; 15(7): 1079-1086. • Boehnke K F, Litinas E and Clauw D J. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016; 17 (6): 739-44. • Mills M. Moguls and Mexicans: The American history of cannabis legalization. The New Econom Mar. 27, 2015. theneweconomy.com. • Micholaum R and Shvo Y. Hasish. I. The structure of cannabidiol.Tetrahedron. 1963 Dec; 19(12): 2073-8. • Gaoni Y and Micholaum R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish.J. Am. Chem. Soc., 1964, 86 (8), pp 1646-1647. • Howlett AC1, Barth F, Bonner T I, Cabral G, Casellas P, Devane W A, Felder C C, Herkenham M, Mackie K, Martin B R, Mechoulam R, Pertwee R G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002 Jun; 54(2):161-202. • Breivogel CS1, Childers S R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 1998 December; 5(6 Pt B):417-31. • Whiting P F, Wolff R E, Deshpande S, Di Niso M, Duffy S, Hemandez A V, Keurentjes J C, Lang S, Misso K, Rider s, Schmidkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A systematic review and meta-analysis. JAMA. 2015; 313; 2456-2473. • Abrams D I, Couey P, Shader S B, Kelly M E, Benowitz N I. Cannabinoid-opioid Interaction in chronic pain. Clin. Pharmacol. Ther. 2011; 90; 844-851.

• Miller G. Pot and Pain. Hints are emerging that cannabis could be an alternative to opioid painkillers. Science. 2016: 354; 566-568. • Gaskin D J. Richard P. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research.Washington, DC: The National Academies Press; 2011. Appendix C: The economic costs of pain in the United States; pp. 301-37. • Gaskin D J. Richard P. The Economic Costs of Pain in the United States. Journal of Pain. 2012; 13(8):715-24. • Whiting P F, Wolff R F, Deshpande S, Di Nisio M, Duffy S, Hemandez A V, Keurenjtes J C, Lang S, Misso K, Ryder S, Schmidkofer S, Westwood M, and Kleijnen J. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015; 313(24):2456-2473. • Rudd R A1, Aleshire N, Zibbell J E, Gladden R M. Increases in Drug and Opioid Overdose Deaths—United States, 2000-2014.MMWR Morb Mortal Wkly Rep. 2016 Jan. 1; 64(50-51):1378-82. • Bachhuber M A, Saloner B, Cunningham C O, Barry C L. Medicinal cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern. Med. 2014 174; 1668-1673. • Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure trive. Br J Pahrmacol. 2005: 146:913-15. • Appendino G, Chianese G, Taglialatela-Scafati O. Cannabinoids: occurrence and medicinal chemistry. Curr Med Chem. 2011; 18:1085-1099. • Mackie K. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol. 2006; 46:101-22. • Price M R, Baille G L, Thomas A, Stevenson L A, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley P, Christopoulos A, Pertwee R G, and Ross R A. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68: 1484-1495. • Gorzalka B B, Hill M N and Hillard C J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurisci Biobehav Rev. 2008; 32: 1152-1160. • Izzo A A, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30:515-527. • Maione S, Costa B, Di Marzo V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. 2013; 154:S87-S93. • Costa B, Trovato A E, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007; 556:75-83. • Evans F. Cannabinoids:the separation of central from peripheral effects on a structural basis. Planta Med. 1991; 57:S60-S67. • Qin N, Neeper M P, Liu Y, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008; 28:6231-6238 • Wirth P W, Watson E S, ElSohly M, et al. Anti-inflammatory properties of cannabichromene. Life Sci. 1980; 26:1991-1995. • Izzo A A, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa , on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012; 166:1444-1460. • Maldonado R, Banos J E, Cabanero D. The endocannabinoid system and neuropathic pain. Pain. 2016; 157:S23-S32 • La Porta C, Bura S A, Llorente-Onaindia J, et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain. 2015; 156:2001-2012. • Paula-Freire L I G, Andersen M L, Molska G R, and Kohn D O. Evaluation of the Antinociceptive Activity of Ocimum gratissimumL. (Lamiaceae) Essential Oil and its isolated Active Principles in Mice. Phytother Res. 2013; 27:1220-1224. • Lemberger L, Silberstein S D, Axelrod J and Kopin I J. Marihuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science. 2014; 170:1320-22 • Yamamoto I, Watanabe K Narimatsu S, and Yoshimura H. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol. 1995; 27: 741-746. • Bellnier T, Brown G W, Ortega T R. Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis . Ment Health Clin [Internet]. 2018; 8(3):110-5. • Rong C, Carmona N E, Lee Y L, Ragguett R M, Pan Z, Rosenblat J D, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, Mansur R, Ho R C, McIntyre R S. Drug-drug interactions as a result of co-administering A9-THC and CBD with other psychotropic agents. Expert Opin Drug Saf. 2018 January; 17(1):51-54. • Nicholson A N, Turner C, Stone B M, and Robson P J. Effect of delta-9 tetrahydrocannabinol and cannabidiol on nocturnal sleep and early morning behavior in young adults. J Clin Psychopharmacol. 2004; 24: 305-323. • Russo R B. Current therapeutic cannabis controversies and clinical trial design issues. (Review) Frontiers in Pharmacology. 2016; 7: 1-30. • Jones R T, Benowitz N, and Bachman J. Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci. 1976; 282: 221-239. • Nutt D, King L A, Saulsbury W, and Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369: 1047-1053. • Adams I B, Martin B R. Cannabis : pharmacology and toxicology in animals and humans. Addiction. 1996; 91; 1585-614. • Grotenhermen F, Russo E. eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Binghampton, N Y: The Haeworth Press, 2002. • Sutton I R, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol. 2006; 4 (10):531-5. • Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003; 3(10):745-55. • Sink K, Segovia K, Sink J, et al. Potential anxiogenic effects of cannabinoid CB1 receptor anagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharm. 2010; 20:112-122. • Christensen R, Kristensen P K, Bartels E M et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet. 2007; 370: 1706-13. • Hudson B D, Hebert T E, M Kelly M E. Ligand and Heterodimer-Directed Signaling of the CB1 Cannabinoid Receptor. Molecular Pharmacology 2010; 77: 1-9. • McHugh D, Hu S S J, Rimmerman N et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration trough GPR18, the putative abnormal cannabidiol receptor. Bmc Neuroscience 2010; 11:11-44. • Huestis M A. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005: 657-90. • Hollister L E, Gillespie H K, Ohlsson A et al. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 198; 21: 171-1775. • Lemberger L, Axelrod J, Kopin I J. Metabolism and disposition of delta-9-tetrahydrocannabinol in man. Pharmacol Rev 1971; 23: 371-80. • Law B, Mason P A, Moffat A C et al. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol. 1984; 36: 289-94. • Karschner E L, Schwilke E W lowe R H et al. Implications of plasma delta-9-tetrahydrocannabinol, 11-hydroxy-THC and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol. 2009; 33: 469-77. • Owen S M, McBAy A J, Reisner H M, et al. 1251 radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method. Clin Chem. 1981; 27: 619-24. • Chiarotti M, Costamagna L. Analysis of 11-nor-9-carboxy-delta (9)-tetrahydrocannabinol in biological samples by gas chromatography tandem mass spectrometry (GC/MS-MS). Forensic Scilnt. 2000; 114:1-6. • Kogan N M, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007; 9: 413-30. • Haggerty G C, Deskin R, Kurtz P J et al. The pharmacological activity of the fatty acid conjugate 11 palmitoyxy-delta 9-tetrahydrocannabinol. Toxicol Appl Pharmacol. 1986; 84: 599-606. • Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999; 23: 323-332. • Huestis M A, Henningfield J E, Cone E J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992; 16: 276-82. • Reiter A, Hake J, Meissner C et al. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a “low-step” detoxification ward. Forensic SciInt. 2001; 119: 248-253. • Lowe R H, Abraham T T, Darwin W D et al. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009; 105:24-32. • Goulle J P, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr. 2008; 66:232-244. • Halldin M M, Andersson L K, widman M et al. Further urinary metabolites of deltal-tetrahydrocannabinol in man. Arzneimittelforschung 1982; 32: 1135-1138. • Huestis M A, Cone E J. Urinary excretion half-life of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans. Ther Drug Monit. 1998; 20: 570-576. • Kelly P, Jones R T. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992; 16: 228-235. • Johanson E K, Hollister L E, Halldin M M. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res Monogr. 1989; 95: 457-458. • Manno J E, Manno B R, Kemp P M et al. Temporal indications of marijuana use can be estimated from plasma and urine concentrations of delta-9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol. 2001; 25: 538-549. • Iverson L., Cannabis and the brain. Brain. 2003; 126: 1252-70. • Hall W. and Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009; 374: 1383-91. • Solowij N, Stephens R S, Roffman R A et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAM. 2002; 287: 1123-31. Erratum in JAMA 2002; 287: 1651. • National Governors Association Policy Academy Drug Abuse Prevention. “State of Nevada Plan to Reduce Prescription Drug Abuse”. Nevada 2017. (pp 3-56) • Centers for Disease Control and Prevention, National Center for Injury and Prevention Control, Division of Unintentional Injury Prevention. Atlanta, Georgia. U.S. Department of Health and Human Services. “Calculating Total Daily Doses of Opioids for Safer Dosage”. www.cdc.gov/drugoverdose/prescribing/guideline.html. Atlanta, Georgia 2017. (pp1-2) • National Cancer Institute: Common Terminology Criteria for adverse Events (CTCAE), Version 4.0 Bethesda, Md. U.S. Department of Health and Human Services, National Institutes of Health, 2010.

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.